Investigating Potentially Arrhythmogenic Atrial Substrate using Computational Simulations and Explainable Machine Learning

Savannah Bifulco

A dissertation

submitted in partial fulfillment of the

requirements for the degree of

Doctor of Philosophy

University of Washington

2023

Reading Committee:

Dr. Patrick Boyle, Chair

Dr. Nazem Akoum

Dr. Herbert Sauro

Program Authorized to Offer Degree: Bioengineering

University of Washington

Abstract

Investigating Potentially Arrhythmogenic Atrial Substrate using Computational Simulations and Explainable Machine Learning

Savannah Bifulco

Chair of the Supervisory Committee:

Patrick Boyle

Department of Bioengineering

This dissertation discusses applications of computational simulations and explainable machine learning (xML) on the mechanistic understanding of arrhythmogenic atrial substrate. We review the current understanding of atrial arrhythmia mechanisms in Chapter 1. Then, we explore how computational simulations, in highly detailed patient-specific atrial models derived from late gadolinium enhanced (LGE) magnetic resonance imaging (MRI) scans, and machine learning give rise to new frontiers of clinical treatment in Chapter 2. In Chapter 3, we aim to understand the absence of arrhythmia in patients who suffered an embolic stroke of undetermined source (ESUS) despite the presence of putatively pro-arrhythmic fibrosis. We reconstructed patient-specific atrial models from ESUS and atrial fibrillation (AFib) patients then assessed the arrhythmogenic capacity of the fibrotic substrate. Analyzing the reentrant drivers in each subpopulation revealed that the intrinsic pro-arrhythmic substrate properties of fibrosis were indistinguishable between ESUS and AFib patients. In our second aim, we investigate the synergy between ablation-induced scar and native fibrosis in atrial models of persistent AFib patients. We reconstructed pre- and post-ablation models to assess AFib inducibility. We classified simulated arrhythmia episodes and determined that pre-ablation models were more likely to harbor rotor-like activity, while post-ablation models were more likely to harbor

anchored reentry around ablation lesions, veins, or valves. We then developed an xML algorithm to predict and quantify the spatial properties of arrhythmogenic scar regions (Chapter 4). Our third aim is to use xML techniques to distinguish populations of patients at risk for recurrent arrhythmias from those who will remain arrhythmia free following ablation. We identified the key population-level and patient-specific level risk factors for post-ablation recurrence. The explainable aspect of our approach allowed us to understand why a particular patient can have large prediction weights for some risk factors without tipping the balance towards an incorrect prediction. We thus present a comprehensive clinical tool to explain patient recurrence risk by combining patient-specific clinical profiles and left atrial pre/post-ablation substrate patterns via an explainable classifier (Chapter 5). In conclusion, this dissertation showcases the potential of computational simulations and xML in advancing our understanding of arrhythmogenic atrial substrate and its implications for clinical practice. The findings highlight the importance of patient-specific modeling, the role of fibrosis in arrhythmia susceptibility, the impact of ablation on arrhythmia inducibility, and the predictive capabilities of xML techniques in assessing catheter ablation outcomes. By integrating these approaches, this research offers valuable insights for risk assessment, personalized treatment strategies, and the development of comprehensive clinical tools for the management of atrial arrhythmias.

Table of Contents

Investigating Potentially Arrhythmogenic Atrial Substrate using Computational Simulations and Explainable Machine Learning 1

List of Figures 7

List of Tables 8

Chapter 1. Current Understanding of Atrial Arrhythmia Mechanisms **9**

1.1. Brief summary 9

1.2. Introduction 9

1.2 Arrhythmias 9

1.3 Proposed Mechanisms of AFib 10

1.4 Role of Fibrosis 15

1.5 Therapies for patients with AFib 17

Chapter 2. Modeling and Simulation **21**

2.1 Brief Summary 21

2.2 Introduction 21

2.3 Cell-Scale Modeling of Cardiac Electrophysiology 22

2.4 Tissue-Scale Modeling of Cardiac Electrophysiology 26

2.5 Organ-Scale Modeling 27

2.6 Applications of Computational Modeling for the Heart 30

2.7 Machine Learning 33

Chapter 3. Computational Modeling Identifies Embolic Stroke of Undetermined Source Patients with Potential Arrhythmic Substrate **38**

3.1 Abstract 38

3.2 Introduction 38

3.3 ESUS and AFib Patient Characteristics and Model Architecture 40

3.4 Induction of Arrhythmia and Fibrosis Quantification in Patient-Derived Models 42

3.5 Arrhythmia Dynamics 46

3.6 Properties of RD Localization 47

3.7 Properties of pro-RD fibrosis 49

3.8 Further Discussion 50

3.8.1 Inducibility of reentry and fibrosis quantification in patient derived atrial models 50

3.8.2 RD localization dynamics and morphology in patient-derived atrial models 52

3.8.3 Insights from analysis of RD inducibility and localization by LA region 53

3.9 Limitations 55

3.10 Conclusions 56
3.11 Methods and Data Availability 57
Chapter 4. Explainable Machine Learning to Predict Anchored Reentry Substrate Created by Persistent Atrial Fibrillation Ablation in Computational Models 63
4.1 Abstract 63
4.2 Introduction 64
4.3 Persistent AFib Patient Characteristics 66
4.4 Arrhythmia Induction and Substrate Quantification 67
4.5 Explainable prediction of scar capable of sustaining reentrant arrhythmia drivers 70
4.6 Further Discussion 78
4.4.1 Relationship between PsAF substrate characteristics and model inducibility 78
4.4.2 Machine learning to identify pro-arrhythmic post-ablation substrate 80
4.4.3 Analysis of potentially arrhythmogenic non-conductive tissue regions 81
4.7 Clinical Perspective 82
4.8 Limitations 82
4.9 Conclusions 83
4.10 Methods and Data Availability 84
Chapter 5. Explainable Machine Learning for Cardiac Catheter Ablations: Identifying Risk Factors and Predicting Post-Ablation Recurrence 91
5.1 Abstract 91
5.2 Introduction 92
5.3 Results 94
5.4 Discussion 108
5.4.1 Population-based risk factors 109
5.4.2 Patient-specific risk-factors 111
5.4.3 Application of Model on New Clinical Data 112
5.5 Clinical Applications 112
5.6 Limitations 113
5.7 Conclusion 114
5.8 Methods and Data Availability 114
Chapter 6. Conclusion and Future Directions 121
Acknowledgements 123
References 126

List of Figures

Chapter	Figure	Page
1	Figure 1.1 Summary of potential cell-scale mechanisms of AFib.	12
	Figure 1.2 Examples of reentrant drivers	14
2	Figure 2.1 Schematic representation of ionic model	25
	Figure 2.2 Overview of modeling workflow for atrial and ventricular simulations	29-30
3	Figure 3.1. Model Architecture Overview	41
	Figure 3.2 LA Subdivision Scheme	41
	Figure 3.3 Fibrosis Quantification Overview	42
	Figure 3.4 Summary of RD characteristics between ESUS and AFib models	45-46
	Figure 3.5 Maps of fibrotic tissue distribution and activation time for ESUS and AFib models in which pacing succeeded or failed to induce RD-driven arrhythmia	47
	Figure 3.6 Summary of IdS and RD localization characteristics	48-49
	Figure 3.7 Summary of the region-by-region extent of tissue with a spatial fibrosis pattern (as characterized by local density and entropy) associated with RD localization (i.e., pro-RD tissue)	49-50
4	Graphical Abstract	64
	Figure 4.1 Pre-ablation and post-ablation models with examples of FR- and AR-perpetuated simulated arrhythmia.	68
	Figure 4.2 Analysis of the effect of substrate burden on model inducibility	69
	Figure 4.3 Summary of pre- and post-ablation simulation outcomes	70
	Figure 4.4 Overview of additional simulation sets	71
	Figure 4.5 Summary of non-conductive tissue arrhythmogenicity RdF prediction algorithm	72
	Figure 4.6 Explainability analysis of RdF for predicting arrhythmogenicity from scar spatial attributes	74
	Figure 4.7 Dependence plots of SHAP importance value vs. raw feature value	76
	Figure 4.8 Scar patterns with and without post-ablation simulated recurrence sites	77
	Figure 4.9. Edge cases for classification of simulated reentrant arrhythmias	87
	Figure 4.10. Example of flattened pulmonary vein ostia and mitral valve for area of non-conductive tissue calculation.	89

5	Graphical Abstract	92
	Figure 5.1 ROC curve including simulation data	97
	Figure 5.2 Feature selection process	98-99
	Figure 5.3 Summarization of random forest prediction algorithm effectiveness in testing sets across five folds	99
	Figure 5.4 Summary of feature importance	101
	Figure 5.5 Dependence plots of SHAP importance vs. raw feature value	102
	Figure 5.6 Dependence plots for all features	103
	Figure 5.7 Explanation of individual patient prediction scores	105
	Figure 5.8 Summary of model performance on internal validation cohort	107

List of Tables

Chapter	Table	Page
3	Table 3.1. Patient Characteristics in ESUS and AFib groups.	40
4	Table 4.1 List of clinical and spatial features proposed as inputs for a machine learning algorithm.	66-67
5	Table 5.1 Patient characteristics in training and validation cohort	94
	Table 5.2 List of all features prior to feature selection process	95-96
	Table 5.3 List of simulation features excluded from study	96-97
	Table 5.4 Patient characteristics in training/validation cohort and internal testing cohort	106

Chapter 1. Current Understanding of Atrial Arrhythmia Mechanisms

1.1. Brief summary

The first chapter of this dissertation provides an overview of arrhythmias, a broad spectrum of disorders characterized by irregular heart and rhythm. Atrial arrhythmias are associated with high morbidity risks, yet their underlying mechanisms remain poorly understood. This chapter discusses the current understanding of arrhythmia mechanisms through the lens of experimental and computational work and current therapy options for patients. By delving into these aspects, this chapter sets the foundation for further investigation into the complexities of arrhythmia and potential advancements in treatment strategies.

1.2. Introduction

Currently, arrhythmias are associated with substantial morbidity and economic costs. Atrial fibrillation (AFib) alone affects an estimated 46.3 million people worldwide (1). Current research supports the hypothesis that initiation and maintenance of AFib require pathophysiological remodeling of the atria. This pathophysiological remodeling of AFib encompasses various aspects, including alterations in cellular electrophysiology, tissue heterogeneity, and disease-associated remodeling of the cell and tissue. These components contribute to creating an AFib-prone substrate which is able to generate unique electrical phenomena including a rapidly firing focus and/or complex re-entrant circuits/rotors. Finally, we discuss AFib therapy, including pharmacotherapy and surgical interventions.

1.2 Arrhythmias

Arrhythmia, at its most simplistic definition, is an abnormal rhythm of the heart. In a healthy heart, an impulse (i.e., an action potential) is generated from specialized cells in the right atrium in the sinoatrial node, called pacemaker cells. These initiate an action potential that results in an

electrical impulse that travels through the atria. Subsequently, it reaches the atrioventricular node where conduction is temporarily delayed before passing through the bundle of His and eventually through the Purkinje fibers. Any deviation from this conduction pattern is considered an arrhythmia.

Arrhythmias can be sub-classified into tachyarrhythmias or bradyarrhythmias. Bradyarrhythmias are defined as heart rates below 60 beats per minute and can include atrioventricular block, sinus node dysfunction, or sinus bradycardia (2). Tachyarrhythmias, on the other hand, are characterized by heart rates above the normal range and can be categorized based on their origin. Ventricular tachycardias originate below the atrioventricular node and include ventricular fibrillation, premature ventricular beats and sustained/non-sustained ventricular tachycardia (3). Supraventricular tachycardias, on the other hand, originate above the atrioventricular node and include atrioventricular re-entrant tachycardia, atrioventricular nodal re-entrant tachycardia, atrial premature complexes, atrioventricular junctional extrasystoles, atrial tachycardia, atrial flutter (AFL), and AFib (4). Of these arrhythmias, this dissertation discusses primarily AFL and AFib.

Each arrhythmia listed above can be diagnosed via an electrocardiogram (ECG), with most arrhythmias having a unique discernible ECG signature. AFL presents as a rapid but regular beat with a saw-tooth appearance of the P-wave, a part of the ECG signature associated with atrial activation. AFib on the other hand, presents as an irregular pattern of rapid beating with no discernible P-wave. Management of these two arrhythmias is similar, yet the goal of therapy for AFL is primarily rate-control centric (see 1.5 Therapies for patients with AFib).

1.3 Proposed Mechanisms of AFib

The action potential, discussed previously as the electrical stimulation originating in the sinoatrial node, is determined by the opening and closing of various transmembrane proteins,

including ion channels and transporters. In general, the cardiac action potential is divided into five distinct phases: fast depolarization (Phase 0), a transient repolarization (Phase 1), long-lasting plateau (Phase 2), large repolarization toward the diastolic potential (Phase 3), and return to resting membrane potential (Phase 4) (**Figure 1.1A**). Phase 0 is generated by an abrupt increase in sodium influx through I_{Na} channels into the cell, causing resting membrane potential to rapidly increase from the negative resting membrane potential to positive voltage values (approximately +30 to +40mV). Following this depolarization, a short repolarization occurs as a result of I_{to}, often referred to as a notch. The plateau-phase (Phase 2) is characterized by simultaneous calcium influx (Ca_L) and potassium efflux (I_{Ks}). The repolarization phase is largely driven by increased potassium efflux (including the I_{Ks}, I_{Kr}, and I_{K1} currents). During phases 1, 2 and 3, the cell exists in a state of refractoriness, where the cell is unable to be re-excited, a phenomenon primarily driven by the inactivation of I_{Na} channels. Finally, the cell returns to resting membrane potential, mainly defined by inwardly rectifying potassium channels (**Figure 1.1A**). The resting membrane potential can be estimated by the Nernst equation

$$E_{ion} = \frac{RT}{nF}\ln(\frac{[Iion]_o}{[Iion]_i}) \qquad \textit{Equation 1}$$

Where R is the universal gas constant (8.314 J/(mol*K)), T is temperature in K, n is ion valence, F is the Faraday constant (96480 C/mol), I_{ion} is the concentration of the ion inside and outside of the cell.

While the exact etiology of AFib is unknown, disturbances in action potential generation and/or conduction play a central role. Current evidence demonstrates that AFib typically requires a trigger for initiation (i.e., a rapidly firing ectopic foci) and a vulnerable electrophysiological and/or anatomical substrate for maintenance, thought to be driven by reentrant drivers (RDs) (5).



Figure 1.1 Summary of potential cell-scale mechanisms of AFib. (A) Description of active ion channels during each phase of the action potential and action potential morphology changes during atrial fibrillation (dashed line). (B) Schematic of cardiomyocytes couples by gap junctions as determinants of conduction velocity. *Reproduced from (6) with permission.*

Electrical foci play a pivotal role in AFib and are often characterized by deep venous origin and rapid, unpredictable firing. While ectopic beats are commonly confined to the pulmonary veins, there is evidence that triggered activity can exist in other regions of the left and right atrium (7). Largely, ectopic foci are believed to play a primary role in the initiation of AFib, providing a proverbial “spark” to a susceptible substrate (i.e. the “tinder”). However, there is evidence that these paroxysms initiated by discharges from one or multiple sources produce progressive pathologic changes in the atrial substrate that lead to self-perpetuation of AFib (8). From a clinical standpoint, this signifies the transition from paroxysmal atrial fibrillation (PxAF), characterized by intermittent episodes sustained primarily by ectopic foci, to persistent atrial fibrillation (PsAF), a more persistent disease state believed to be sustained by reentrant drivers (RDs).

The simplest form of an RD is described by the 'leading circle model', described by Allessie et al. in 1977 (9). In this model, shown in **Figure 1.2B**, a wavefront circles around refractory tissue that is maintained by constantly emanating centripetal wavelets from the primary wavefront. Recent research has suggested that spiral waves, which are a specific type of functional reentry may be critical in understanding AFib maintenance. Unlike the leading circle model, spiral waves exhibit variable wavefront velocity due to complex current source-sink mismatch at the core, also known as the phase singularity. This tissue core becomes effectively inexcitable, forming an area of functional block similar to the center of the 'leading circle' model. A spiral wave has the ability to move through space and under certain circumstances can meander in various complex forms (10, 11).

RDs can form when a wavefront interacts with some form of barrier, either due to a structural obstacle such as a scar or functional myocardial electrical inhomogeneity or anisotropy. This idea has been explored both theoretically (12) and experimentally (13). As a wavefront passes through a barrier it can bend and break into daughter wavelets, which can induce multiple disorganized waves leading to the chaotic atrial activation associated with AFib (14). Tissue anisotropy is also likely to be a critical determinant of rotor formation, similarly causing wavefronts to bend and initiate spiral wave reentry around a functionally inexcitable core. Thus, rotor formation requires areas of non-uniformity due to tissue heterogeneity or delivery of premature stimuli in the form of ectopic foci. In this dissertation, RDs are defined as one or several patient-specific localized sources of fast, repetitive activity from which activation propagates and breaks down into fibrillatory conduction in the rest of the atria.

It is still intensely debated whether the sustaining mechanism of AFib is localized AFib drivers (i.e., reentrant drivers) or if it involves self-replicating wavelets traversing across the entire atrial myocardium (15). Due to the transmural complexity of the atrial wall, it is difficult to observe reentries in a patient using current technology. Nevertheless, it is widely believed reentrant

drivers can exist on many spatial scales around a site of anatomical or functional block. In other words, reentry can exist anywhere from a macro-scale (i.e., around a non-conductive vein, valve or scar) to a micro-scale reentrant (i.e., localized reentry) circuit (16) with a refractory or slow-conducting core (**Figure 1.2**). Overall, recent computational and experimental data support the idea that reentrant drivers are critical to sustaining AFib (17).



Figure 1.2. Examples of reentrant drivers. (A) Schematic of a re-entrant driver around an anatomic barrier (i.e., ablation-delivered scar, valve, or vein ostia), where the wavelength (black) is shorter than the pathlength, allowing for an excitable gap (white). (B) A reentrant driver based on leading reentry with a functionally refractory core, due to continuous feeding of electrical activation toward the center. (C) A schematic of a spiral wave with a phase singularity at the point where the wavefront and the wavetail meet. *Partially reproduced from (10) with permission.*

Complex fractionated atrial electrograms (CFAEs) are considered possible drivers of AFib. CFAEs may arise from a variety of factors, including the presence of multiple wavelets, slow conduction, local reentry, autonomic innervation, sites of fibrillatory conduction, or most likely a combination of these factors (18). However recent research suggests that mapping and ablation of complex fractionated atrial electrograms might be becoming obsolete due to poor outcomes in favor of better AFib-promoting region identification (19).

Broadly, ectopic-triggered activity and rotors/RDs are generally thought to arise from structural, electrical, and autonomic remodeling. Electrical remodeling occurring in myocytes is a highly

characterized mechanism of AFib. Altered ionic currents, primarily L-type Ca^{2+} and inward rectified K^+, play a significant role as they can drastically alter action potential morphology. Gap junction function, specifically connexins 40 and 43, which can affect conduction velocity and conduction heterogeneity have also been linked to AFib (20). Additionally, altered calcium handling can lead to delayed afterdepolarizations, which in turn contribute to formation of ectopic foci and thus initiation of AFib (21). Increased K^+ currents which alter the resting potential can also lead to reduced atrial refractoriness and wavelength (22, 23). Autonomic dysfunction in AFib is characterized by increased sympathetic activity and autonomic changes. It has been suggested that the increased sympathetic activity leads to heterogeneous changes in atrial refractoriness which in turn favor reentrant waves (24). Finally, aspects of structural remodeling, such as atrial size, the cellular ultrastructure, and changes in tissue properties (i.e., fibrosis), predispose the atria to defects in conduction primarily leading to reentry formation and perpetuation. Increased atrial size has been known to promote AFib via additional area available for rotor formation (25) or by indirectly affecting tissue properties such as atrial stretch (26). Fibrosis is a salient feature of a majority of computational models of AFib and has been a focus in recent research surrounding AFib, including this dissertation.

1.4 Role of Fibrosis

Atrial fibrosis can result from various factors including aging, myocardial infarction, volume overload, endurance training, or a variety of other potential sources. It has been independently associated with the likelihood of recurrent arrhythmias, suggesting an empirical link between AFib and fibrosis (27). Late gadolinium enhanced (LGE)-MRI is a widely used method for assessing the degree of fibrosis in the left atrium (LA), allowing for visualization of gadolinium contrast accumulation in tissues with increased extracellular space. LGE-MRI serves as a standard of reference for evaluation of myocardial fibrosis. The degree of left atrial (LA) fibrosis, as estimated by LGE-MRI, can predict the success of catheter ablation (see 1.5 Therapies for

patients with AFib) at up to 5 years post-procedure. As such, fibrosis is increasingly recognized as a key determiner of disease severity.

Several specific profibrotic signaling molecules are associated with atrial fibrosis and by extension AFib, including Angiotensin II (28), aldosterone (29), and TGF-β1 (30). Angiotensin II and aldosterone stimulate fibroblast proliferation and collagen synthesis, contributing to the development of fibrosis (31). TGF- β1 is also a potent stimulator of collagen-producing cardiac fibroblasts (32).

Fibrotic tissue acts as a promoter for AFib through various mechanisms. In general, the impact of fibrosis in arrhythmogenesis is governed by the extent of disruption in electrical connections between cardiomyocytes (33). This disruption involves the loss or partial redistribution of gap junctions at the intercalated discs at the ends of myocytes (34). This reduced coupling leads to areas of slowed conduction or conduction block, thus acting as prime substrate for RDs. In addition, when gap junction conductance becomes too low, propagation can no longer be mediated by the sodium current, which inactivates before sufficient charge can flow into adjacent unexcited myocytes to bring them to their activation threshold (35). In this case, the more slowly inactivating L-type Ca current mediates propagation, but with a dramatically slower conduction velocity. Fibrosis is also suspected to promote ectopic activity by disrupting electrical connections, enabling aberrant cells to overcome source-sink mismatch and propagate ectopic signals into the surrounding healthy myocardium (36). Fibrosis is also intricately linked to inflammatory processes, as chronic inflammation triggered by oxidative stress, cytokines, and immune cell infiltration initiates and perpetuates fibrotic pathways in atrial tissue (37). In addition to disrupting electrical conduction, fibrosis can lead to reduced mechanical function in the atria. Fibrotic tissue is less compliant and exhibits impaired contractility (38), which may contribute to complications associated with AFib, such as stroke (39).

The relationship between AFib and fibrosis can be explored using patient-specific models, such as those based on LGE-MRI. These models have provided additional evidence supporting the connection between fibrosis and AFib, demonstrating that individuals with significant remodeling exhibit re-entrant drivers that persist at boundaries between fibrotic and non-fibrotic tissue, contributing to the perpetuation of AFib (40). Re-entrant drivers observed in modeling studies agree reasonably well with those observed by intracardiac mapping (41) and body surface mapping (42). In the past few years, the understanding of the role of fibrosis in maintaining persistent AFib has led to several computational studies aimed at elucidating how the remodeled atrial structure defines AFib dynamics (40, 43, 44).

1.5 Therapies for patients with AFib

The management of AFib encompasses various therapies aimed at restoring and maintaining normal heart rhythm, controlling heart rate and preventing stroke. These strategies pay a crucial role in improving the quality of life for individuals with AFib.

First-line treatment involves addressing reversible risk factors such as hyperthyroidism or alcohol consumption, if applicable, and initiating anti-arrhythmic drug therapy. There are three major arms of drug treatment in AFib: rhythm control, rate control, and stroke prevention. Rhythm control aims to restore sinus rhythm using class I or class III anti-arrhythmic drugs. Class I drugs exert their effects primarily by blocking sodium channels to reduce the rate of the rise of the action potential and reduce overall excitation, while class III blocks potassium channels by prolonging the action potential duration to delay conduction (45). On the other hand, rate control therapy is aimed at lowering the heart rate. β-blockers are the preferred agents, also referred to as class II anti-arrhythmic drugs. Class IV anti-arrhythmics, or non-dihydropyridine calcium channel blockers can also be used, depending on the individual's characteristics or preferences. Finally, stroke prevention in patients with AFib is critical as these individuals are approximately five times more likely to have a stroke compared to healthy

individuals (46). Anticoagulant therapy is highly recommended in preventing strokes for most AFib patients, but the decision can be aided by risk assessment schemes such as the CHA2DS2-VASc score. Further information on the relationship between stroke and AFib can be found in Chapter 3. Computational Modeling Identifies Embolic Stroke of Undetermined Source Patients with Potential Arrhythmic Substrate.

In addition to drug-based therapy, direct current cardioversion can be used to quickly convert a patient from AFib with rapid ventricular response to sinus rhythm. This intervention has been found to be more effective in patients with less than 60 days of persistent AFib (47).

Catheter ablation is a therapeutic procedure that can be performed using either radiofrequency (RF) or cryoballoon ablation techniques. It is designed to eliminate abnormal electrical activity, specifically ectopic foci, within the pulmonary vein region by creating non-conductive scar. This procedure is commonly referred to as pulmonary vein isolation (PVI). RF ablation involves the use of a catheter that emits high-frequency electrical energy, generating heat to create scar tissue. In contrast, cryoballoon ablation utilizes a balloon catheter to freeze the surrounding tissue. In long-term follow-up studies, the rate of freedom from atrial arrhythmias with a single procedure is 54.1% in paroxysmal AFib patients and 41.8% in patients with persistent AFib. (48, 49). Despite modest success rates, catheter ablation remains as a cornerstone of treatment for AFib. Recent research points to pro-arrhythmic post-ablation substrate as a potential mechanism of AFib recurrence following catheter ablation (50), which is explored further in Chapter 4. Explainable Machine Learning to Predict Anchored Reentry Substrate Created by Persistent Atrial Fibrillation Ablation Furthermore, Chapter 5. Explainable Machine Learning for Cardiac Catheter Ablations: Identifying Risk Factors and Predicting Post-Ablation Recurrencedelves into the use of patient-specific healthcare data and computational models to predict recurrent arrhythmia after ablation, providing further insights.

Regarding the therapeutic targeting of drivers rather than ectopic foci in the pulmonary veins (i.e., PVI) is a newly researched topic with numerous associated clinical trials. A more comprehensive discussion of computationally-derived clinical trials is provided in 2.6 Applications of Computational Modeling for the Heart. Targeting of RDs real-time in patients is a technically challenging problem, requiring electroanatomical mapping (EAM) or similar approaches. EAM involves the integration of electrical signals recorded from multiple points on the heart surface with the anatomical structure of the heart, enabling the identification of abnormal electrical pathways or arrhythmogenic sites. However, EAM is limited by physical challenges regarding catheter splines or electrodes having varied contact with atrial tissue, resulting in low-resolution maps. Furthermore, there are potential artifacts from far-field signals and proprietary mapping software packages are plagued by heavy signal processing and interpolation. As a result of these limitations or other confounding sources, clinical trials have shown no significant difference between rotor ablation and conventional therapy (51). On the other hand, there has been some promise with other systems and techniques, such as pulsed field ablation, wide-band dielectric-based mapping, and non-contact acquisition of intracardiac voltage signals reviewed here (52).

Scientific interest has also shifted into targeting the electrophysiological defects “upstream”, which include directly targeting structural and electrical remodeling. The major prevention targets of these therapies are left atrial dilation, fibrosis, oxidative stress, inflammation, sympathetic nerve activity, and ion channel function. Although, data from clinical trials using angiotensin-converting enzyme inhibitors and angiotensin receptor blockers to intercept the progression of targets listed above has had mixed results in terms of secondary prevention of AFib (53). Nevertheless, a significant amount of ongoing research continues to investigate this area. A better understanding of underlying mechanisms of these strategies is needed and future

avenues are highly focused on targeting fibrosis via inhibition of TGF-β1 and decreasing gap junction uncoupling as more highly targeted approached (54).

Chapter 2. Modeling and Simulation

With text from Heart. 2020 Dec 10:heartjnl-2020-316854 (55)

2.1 Brief Summary

A major challenge for the rational design of AFib models is integrating multiscale characteristics in a way that is effective and computationally feasible. At the cell-scale, models for cardiac cellular electrophysiology and ion dynamics have been through cycles of development and retroactive extension (56-59). At the tissue-scale, characteristics of electrical activation in the myocardium (i.e., conduction velocity, effective refractory period, conduction velocity restitution, and action potential duration restitution) are known to modulate impulse propagation. In turn, this determines arrhythmia dynamics and stability. While cell scale and tissue scale models have significantly contributed to our knowledge of atrial arrhythmias, the complexity of AFib demands the integration of multiscale models. 3D models have evolved from simplistic geometries with limited anatomical detail (60) and progressed through realistic geometries with regional heterogeneity (61). Additionally, the application of machine learning is gaining prominence in AFib research, enabling the analysis of complex data and the development of clinically relevant insights. Here, we review key aspects for models as a foundation for developing model-based treatment.

2.2 Introduction

A model can be described as a simplified representation of a complex system or phenomenon. Models are essential tools that allow us to test hypothesis and gain insights that may be infeasible or impractical to obtain via experimental methods. Modern cardiac models incorporate an extraordinary amount of structural and biophysical detail, including anatomical structures of the heart, ion channel kinetics, cellular electrophysiology, tissue-level propagation, and the effects of drugs or interventions. Significant effort is devoted to producing models that

realistically represent effects of cardiac fibrosis, considered a key element in both atrial (62) and ventricular arrhythmias (63). Generally, the objective of these models is to facilitate simulations that can be used to study the likelihood, timing, frequency, and location of focal sources and RDs, as discussed in Chapter 1. Current Understanding of Atrial Arrhythmia Mechanisms (64-66). Although new physiological findings have given rise to increased model complexity, concomitant advances in computing technology have made it possible to conduct simulation studies in larger numbers of patients, giving rise to studies that use larger virtual cohorts to systematically assess treatment optimization in AFib research. Furthermore, these computational platforms can enhance our mechanistic understanding of the complex arrhythmia pathophysiology and reveal links between the effects of genetic mutations, physiological regulations, and drugs on cellular, tissue and organ function or clinical phenotypes. Machine learning can also leverage these computational models in combination with clinical data (i.e., ECGs, electronic health record data) to open up new possibilities in for enhanced arrhythmia management and personalized care.

2.3 Cell-Scale Modeling of Cardiac Electrophysiology

At the cellular scale, ordinary differential equations are solved to represent cell membrane dynamics such as ion channel gating kinetics and other intrinsic processes that contribute to action potential dynamics. Models describing contraction, which focus on myofibril, sarcomere, and myofilament dynamics also exist, but are explored elsewhere (67). There are a variety of different electrophysiological cell-scale models, many of which are documented at CellML (https://www.cellml.org/). These models describe many different cell types, including ventricular (68), atrial (56, 58) and stem cell-derived cardiomyocytes (69, 70) with varying degrees of mathematical and physiological complexity. For the entirety of this dissertation, the Courtemanche model for the human atrial action potential (56) was implemented at the cell-

scale. This model provides a balance of physiological complexity with computational efficiency needed in highly detailed organ-scale models.

A schematic representation of the currents, pumps, exchangers, and compartments in the Courtemanche model is given in **Figure 2.1.** The cell membrane is modeled as a capacitor connected in parallel with variable resistances and batteries representing the ionic channels and driving forces, where the time derivative of the membrane potential (V) is given by

$$\frac{dV}{dt} = \frac{-(I_{ion}+I_{st})}{C_m} \qquad \textit{Equation 2}$$

where I_{st} is the total stimulus current flowing across the membrane and C_m is the membrane capacitance (mF mm^{-2}) and where I_{ion}, the total ionic current flowing across the membrane is given by

$$I_{ion} = I_{Na} + I_{K1} + I_{to} + I_{Kur} + I_{Kr} + I_{Ks} + I_{CaL} + I_{p,Ca} + I_{NaK} + I_{NaCa} + I_{b,Na} + I_{b,Ca} \qquad \textit{Equation 3}$$

Each additional membrane current given in *Equation 3* is defined in Equations 4-15

$$I_{Na} = g_{Na} m^3 hj(V - E_{Na}), g_{Na} = 7.8 \quad \textit{Equation 4}$$

$$I_{K1} = \frac{g_{K1}(V-E_K)}{1+exp[0.07(V+80)]}, g_{K1} = 0.09 \qquad \textit{Equation 5}$$

$$I_{to} = g_{to} o_a^3 o_i (V - E_K), g_{to} = 0.1652 \quad \textit{Equation 6}$$

$$I_{Kur} = g_{Kur} u_a^3 u_i (V - E_K), g_{Kur} = 0.005 + \frac{0.05}{1+exp[\frac{(V-15)}{-13}]} \qquad \textit{Equation 7}$$

$$I_{Kr} = \frac{g_{Kr} x_r (V-E_K)}{1+exp(\frac{V+15}{22.4})}, g_{Kr} = 0.0294 \qquad \textit{Equation 8}$$

$$I_{Ks} = g_{Ks} x_s^2 (V - E_K), g_{Ks} = 0.129 \qquad \textit{Equation 9}$$

$$I_{CaL} = g_{CaL} d\, f\, f_{Ca} (V - 65.0), g_{CaL} = 0.1238 \quad \textit{Equation 10}$$

$$I_{NaK} = I_{NaK(max)} f_{NaK} \frac{1}{1+\left\{{}^{K_{m,Na(i)}}/_{[Na^+]_i}\right\}^{1.5}} \cdot \frac{[K^+]_o}{[K^+]_o + K_{Km.K(o)}}, I_{NaK(max)} = 0.6 \qquad \textit{Equation 11}$$

$$I_{NaCa} = \frac{I_{NaCa(max)}(exp\left[\frac{\gamma VF}{RT}\right][Na^+]_i^3[Ca2+]_o - exp\left[\frac{(\gamma-1)VF}{RT}\right][Na^+]_o^3[Ca^{2+}]i)}{(K_{m,Na}^3+[Na^+]_o^3)(K_{m,Ca}+[Ca^{2+}]_o)\cdot(1+k_{sat}exp\left[\frac{(\gamma-1)VF}{RT}\right])}, I_{NaCa(max)} = 1600.0 \quad \textit{Equation 12}$$

$$I_{p,Ca} = I_{p,Ca(\max)}\frac{[Ca^{2+}]_i}{0.0005+[Ca^{2+}]_i}, I_{p,Ca(max)} = 0.275 \quad \textit{Equation 13}$$

$$I_{b,Ca} = g_{b,Ca}(V - E_{Ca}), g_{b,Ca} = 0.00113 \quad \textit{Equation 14}$$

$$I_{b,Na} = g_{b,Na}(V - E_{Na}), g_{b,Na} = 0.000674 \quad \textit{Equation 15}$$

Handling of intracellular Ca^{2+} concentration by the sarcoplasmic reticulum uptake and release is implemented using a two-compartment model (68). Intracellular calcium is taken into the sarcoplasmic reticulum uptake compartment (network sarcoplasmic reticulum) coupled to a release compartment (junctional sarcoplasmic reticulum). The main currents (in mM/ms) are given by

$$I_{rel} = k_{rel}u^2vw([Ca^{2+}]_{rel} - [Ca^{2+}]_i), k_{rel} = 30 \quad \textit{Equation 16}$$

$$I_{tr} = \frac{[Ca^{2+}]_{up}-[Ca^{2+}]_{rel}}{\tau_{tr}}, \tau_{tr} = 180 \quad \textit{Equation 17}$$

$$I_{up} = \frac{I_{up(max)}}{1+(K_{up}/[Ca^{2+}]_i)}, I_{up(max)} = 0.005 \quad \textit{Equation 18}$$

$$I_{leak} = \frac{[Ca^{2+}]_{up}}{[Ca^{2+}]_{up(max)}}I_{up(max)} \quad \textit{Equation 19}$$

Unless otherwise noted, physical units are as follows: time (t) is in milliseconds (ms), V is in millivolts, C_m is in picofarads, current density is in picoamperes per picofarad, conductance is in nanosiemens per picofarad, and concentrations are in millimoles per liter. Detailed equations for gating variables associated with *Equations 3-18* can be found in Courtemanche et. al (56). Furthermore, a list of cell-model initial state variables can be found in Niederer et al. 2011 (71).



Figure 2.1 Schematic representation of ionic model. Includes 3 intracellular components: myoplasm, sarcoplasmic reticulum release compartment, and sarcoplasmic reticulum uptake compartment. *Reproduced from (56) with permission.*

As part of the model calibration process, these electrical parameters are routinely adjusted to match emergent properties (e.g., action potential duration) in different types of cardiac tissue (e.g., affected by disease-related remodeling and/or fibrosis). These properties are particularly important for realistically representing reentrant drivers in organ-scale models (72, 73). In 3.11 Methods and Data Availability, 4.10 Methods and Data Availability, and 5.8 Methods and Data Availability these aforementioned electrical parameter changes are outlined explicitly with respect to the above formulations. Currently, primarily generalized electrophysiological parameters are included in patient-specific models (i.e., these parameters are not changed based on a patient's specific electrophysiological data; **Figure 2.2**). Alterations in cell-scale models on a patient-specific basis can be used to investigate the effects of genetic mutations, drugs, and therapeutic strategies (see 2.6 Applications of Computational Modeling for the Heart).

2.4 Tissue-Scale Modeling of Cardiac Electrophysiology

Electrical impulse propagation in the heart is commonly modelled using either the bidomain equation (74) or the monodomain equation (75). The monodomain model is a reduction of the bidomain model which assumes that the intra- and extracellular domains have equal anisotropy ratios. For many applications of cardiac electrophysiology, including those outlined in this dissertation, the monodomain model provides the most optimal balance between computational efficiency and mathematical complexity.

The monodomain equation is given by

$$\chi(C_m \frac{\partial V}{\partial t} + I_{ion}(V)) = \nabla \cdot \sigma \nabla V \qquad \textit{Equation 20}$$

where V is the membrane voltage (mV), σ is the conductivity tensor (mS mm^{-1}), I_{ion} is the current due to the flow of ions through channels in the cell membrane (Equation 2; μA mm^{-2}), and χ is the surface area to volume ratio. As described in section 2.3 Cell-Scale Modeling of Cardiac Electrophysiology, I_{ion} is described by a system of ODEs, where the current is a function of the voltage (V), channel gating states, and other state variables. Throughout this dissertation we used openCARP (76) to solve Equation 20 using the finite element method. More information regarding the verification of simulations of cardiac tissue electrophysiology, including parameterization, ordinary differential equation and partial differential equation solvers, and solution methods can be found elsewhere (71).

At the tissue-scale, alterations in conduction velocity and spatially heterogeneous anisotropic conduction arise from fibrotic remodeling (usually obtained via LGE-MRI, discussed previously) as well as local cardiac fiber orientations. Cardiac fiber orientations play an important role in cardiac electrophysiology as they dictate the primary direction of electrical conduction within the heart. Accurately incorporating accurate fiber orientations into computational models enables more realistic simulations of electrical activity. However, fiber orientations are difficult to obtain

from *in vivo* imaging given current technology, yet they retain a relatively preserved pattern throughout the population. This calls for techniques to diffeomorphically map fiber orientations from anatomically based human atlas models or *ex vivo* diffusion tensor MRI data sets. To represent the fiber microstructure, an anisotropic conductivity tensor can be introduced into the model with its principal axed aligned with a fiber orientation domain. Minimal approaches, like that used by Hoermann et al., (77) use image registration and reorientation methods based on an atlas atrium with fibers predefined from detailed histological observations. In contrast, Roney et al. (78) used rule-based approaches, which generate mathematical descriptions based on histological observations. They established a universal atrial coordinate system and defined fibers derived from diffusion-tensor MRI relative to user-defined anatomical structures.

An emerging area of research focuses on incorporating tissue-scale patient-specific electrophysiological parameters obtained from catheter measurements into computational models. These models allow for prediction of personalized atrial activation times, with correlations ranging from 0.65 to 0.96 (79). Model calibration, parameter selection, and efforts to gauge uncertainty in these measurements have been previously reviewed (80). In general, in order to parameterize models, experimental data are obtained and then an optimization problem is solved. This ongoing and iterative process of parameter optimization can help ensure that computational models accurately reflect the individual patient's conduction velocity and conduction pattern.

2.5 Organ-Scale Modeling

At the organ scale, realistic atrial and ventricular geometry obtained from MRI, computed tomography scans, or electroanatomical mapping is the norm for patient-specific computational modeling (**Figure 2.2**) (44, 81). Segmentation of these images defines the cardiac anatomy, and subsequent finite element representation provides a computer-readable description of the heart’s geometry. However, the process of image segmentation, whether manually or

automatically (82), can cause anatomical variation in the model due to imaging resolution, contrast, or artefacts. By developing a framework to quantify “left atrial uncertainty”, Corrado et al. showed that variation in shape affects simulations of LA activation times (83). As such, accurate and reliable segmentation of cardiac anatomy from medical imaging data is essential to ensure that the computational models faithfully represent the heart’s true anatomical structure.

Clinical MRI scans with a contrast agent (e.g., LGE-MRI) can reveal each individual’s unique pattern of disease-related remodeling. Since the first validations with histology (84, 85), LGE-MRI’s ability to distinguish areas of myocardial infarction on a patient-specific basis has gained broad traction especially in pre-procedural assessment of arrhythmogenic substrate (27) and visualization of radiofrequency-induced ablation lesions (86). Via incorporation of this substrate-based imaging data, patient-specific models of increasing complexity can be achieved.



Figure 2.2 Overview of modeling workflow for atrial and ventricular simulations. Data defining the cardiac geometry and fibrosis distribution is obtained from imaging modalities such as LGE-MRI or computed tomography. Tissue- and cell-scale information, including action potential morphology, and conduction velocity in fibrotic, non-fibrotic, and border-zone regions are found from literature sources. Fiber orientations are obtained from human atlas geometries and subsequently mapped to patient-specific geometries. These data formulate an organ-scale model typically consisting of fibrotic and non-fibrotic regions for atrial models and fibrotic, non-fibrotic, and border-zone regions for ventricular models. Electrical stimuli can be applied to any area within the model and can elicit either (1) a reentrant driver, (2) macro-reentry around any non-conductive surface (e.g. around the left inferior pulmonary vein as shown here) or (3) termination of wavefronts indicating a return to sinus rhythm. Simulations have a range

of applications from mechanistic (e.g. elucidating mechanisms of reentry or anti-arrhythmic drugs) to therapeutic (e.g. ablation planning procedures or arrhythmia risk stratification). *Figure reprinted from (55)with permission.*

In addition to electrophysiological modeling, both hemodynamic and mechanical modeling are important considerations for atrial organ scale modeling. By incorporating hemodynamic and mechanical aspects, comprehensive multi-physics models can provide a more holistic understanding of cardiac function and its relationship to arrhythmias. Electromechanical simulations in ventricles have investigated stretch-activated channels as potential pro-arrhythmic substrate (87). Such simulations also have important implications in understanding feedback mechanisms (88), the effect of transmural heterogeneity (89), and impaired atrial contraction as a result of electrical remodeling (90). Recent multi-physics models which incorporate electrical activation, passive and active myocardial mechanics, as well as blood hemodynamics can be used to assess the performance of left-ventricular assist devices (91). These models have also been proposed to investigate the relationship between arrhythmias, fibrosis, and stroke (39). Through the integration of hemodynamic and mechanical factors, these multi-physics models offer valuable tools for advancing our understanding of cardiac function and developing novel therapeutic strategies, although at the cost of significant computational power.

2.6 Applications of Computational Modeling for the Heart

Precision medicine, defined as a form of medicine that is tailored to the individual, is emerging as a potential future for cardiac electrophysiology, with computational models of the heart providing an invaluable tool at the forefront of the movement. Tailoring the treatment path to an individual's pathology, whether at the genetic, pharmacologic, substrate or ablation planning levels using computational modeling or machine learning is a promising avenue for this platform.

Multi-scale models can represent effects of pro-arrhythmic mutations and elucidate potential mechanistic drug targets by modulating ion channel expression levels at the cell/protein scale. While genetic and drug effects are not explored thoroughly in this dissertation, they are important applications of our work. For example, paired-like homeodomain transcription factor 2 (Pitx2) is a key regulator in the establishment of left-right cardiac asymmetry, and insufficiency has been strongly associated with AFib in a recent genome-wide association study (92). Using a multi-scale model that incorporated recent experimental data on Pitx2 electrical and structural remodeling established by loss-of-function mouse models, Bai et al. showed that shortened action potential duration (APD), slow conduction, and an increase in susceptibility to triggered activity occur by means of elevated calcium transport ATPase functionality increasing sarcoplasmic reticulum Ca^{2+} concentration (93). Furthermore, a common anti-arrhythmic drug for patients with AFib is amiodarone, but it is known to impair sinoatrial node function in some cases. In a sino-atrial node model, amiodarone caused bradycardia by partially inhibiting the funny current, L-type calcium channel, and beta-adrenergic receptors, indicating that amiodarone ought to be used with caution in patients that have sino-atrial node dysfunction associated with AFib. (94). These findings highlight the capability of cardiac models to generate hypotheses and explore mechanisms related to genetic factors and drug effects.

In a bilayer model of the atria, endo-epicardial decoupling exacerbated the effects of longer fibrotic obstacles (i.e., stringy fibrosis), including prolonged activation times, increased anisotropy, and local activation fluctuations (95). This decoupling is known to increase AFib stability and influence breakthrough rate (96). The simulated effects of increasing epicardial fibrosis have also been compared with electroanatomical mapping of long-standing persistent AFib patients. Increasing epicardial fibrosis in the models was correlated with higher rates of breakthrough and endo-epicardial dissociation (97). Overall, the aforementioned work shows how computational models can be used to highlight the importance of accurate modeling of the

endocardial and epicardial walls as surface-level conduction patterns may not necessarily reflect the overall nature of electrical activity.

One of the most tantalizing applications of cardiac modeling is personalized ablation, designed specifically to neutralize the pro-arrhythmic capacity of each patient's unique electro-anatomic substrate. Current ablation strategies, including the most widely used technique of electrically isolating the pulmonary veins, are only successful about 50% of the time (98). Pulmonary vein isolation (PVI) is one of the most prevalent strategies, as patient-specific susceptibility to AFib initiation and perpetuation has been attributed to both electrophysiological properties and fibrosis levels in the pulmonary vein region (43). Recent studies have revealed that high susceptibility of *in silico* pulmonary vein RD localization suggests high likelihood of PVI success. In cases of failure, however, recurrent AFib after PVI has been attributed to both preserved fibrotic tissue accountable for RDs missed during the ablation procedure and the emergence of new RDs following ablation (99).

One of the earliest studies in simulation-driven methods for catheter ablation treatment planning found that the most effective strategy for terminating persistent AFib *in silico* was applying >4 ablation lines, with localization of ablation lesions to regions of high *in silico* RD propensity (100). More recently, the notion of directly personalizing a treatment plan based on computational findings was explored in a prospective clinical study of ten persistent AFib patients (101). The method, called “OPTIMA" (OPtimal Target Identification via Modeling of Arrhythmogenesis), consisted of iterative personalized target identification and ablation followed by arrhythmia simulation until AFib could not be re-induced despite aggressive virtual pacing (Fig. 3). The study reported no incidence of recurrent AFib, and only one patient had post-ablation atrial flutter by the end of follow-up (101). A randomized clinical trial comparing OPTIMA to traditional pulmonary vein isolation is currently underway (identifier: NCT04101539). The clinical usefulness of virtual ablation of AFib (“CUVIA-AF1”; identifier: NCT02171364) is

also noteworthy (102). Patients in this study were randomly divided into two groups: empirical ablation or model-guided ablation. In the latter, five standardized ablation templates were assessed *in silico* prior to clinical treatment. The lesion set that terminated arrhythmia most rapidly was carried out in the clinical procedure. After a 31-month follow-up, patients in the model-guided ablation group saw a significantly lower recurrence rate (20.8% N=53) compared to those in the empirical ablation group (40%; N=55).

Machine learning has been used to bolster the results from personalized simulations and has predicted whether patients are likely to experience AFib recurrence following PVI (103). In this study, electrical features derived from simulations have been found to be more predictive than features derived from LGE-MRI alone. This might be because the models derived from LGE-MRI used in the simulations retained many of the key imaging features while adding important information about the substrate's interaction with electrical stimuli. A similar study accurately predicted long-term atrial fibrillation recurrence in individual patients by combining outcome data with patient-specific acute simulation response (104). Machine learning techniques in conjunction with simulation studies have significant potential in the field of atrial fibrillation research, and future work outlined in this dissertation aims to satisfy that need.

2.7 Machine Learning

Artificial intelligence (AI) and machine learning (ML) have emerged as rapidly evolving fields in medicine, driving intense exploration. AI refers to machine-based data processing to classify complex patterns and decode data beyond direct human interpretation. ML is a sub-discipline of AI and is able to identify higher-order interactions between variables that are beyond the reach of modern statistical capability. With the rise of extensive electronic databases, AI tools have demonstrated promise in interpreting this wealth of data, aiding in disease diagnosis, and enhancing the prediction of disease prognosis.

Deep learning, a powerful AI tool, uses techniques such as convolutional neural networks and is well-suited for interpreting complex raw data. In cardiac electrophysiology, deep learning has been successfully applied to predict left ventricular dysfunction from electrocardiograms (105) and to automatically segment the left atria in late-gadolinium enhanced magnetic resonance images (82). On the other hand, supervised ML (e.g., logistic regression, support vector machines, and random forest learning) takes engineered features and trains (i.e., optimizes a model's parameters) a model to find linear or non-linear relationships between features and known outcomes of interest. There are many unique advantages and disadvantages to each of these systems, reviewed here (106). Often one of the biggest challenges with traditional ML is proper feature selection (i.e., deciding which features to use in a model) and feature engineering (i.e., processing these features for optimization) to represent the input data in an ideal manner. The data is partitioned to ensure that the testing set, which is used to evaluate the model, is distinct and not included in the training process. Model performance is commonly assessed by calculating the area under the receiver operating characteristic curve (AUC), which indicates the classifier's ability to differentiate between two classes.

Some common issues with AI/ML include imbalanced class proportions (107), overfitting (108), and high-dimensional feature spaces (109). A method for reducing overfitting and preventing high-dimensionality is least absolute shrinkage selection operator (LASSO) regularization, or a form of weighted L1 regularization, described below and implemented in Chapter 5. Explainable Machine Learning for Cardiac Catheter Ablations: Identifying Risk Factors and Predicting Post-Ablation Recurrence.

$$Cost = \sum_{i=1}^{M}(y_i - \sum_{j=0}^{p} x_{ij} w_j)^2 + \alpha \sum_{j=0}^{p} |w_j| \quad \textit{Equation 21}$$

where M is the number of outcomes in a model, p is the number of features, y is the outcome variable, x is the feature, w is the fit coefficient, and α is the penalty terms that regularizes the

coefficients. Thoughtful consideration of bias is also warranted during the study design process (110).

Recent advances in ML and AI have recently seen a surge in performance, often achieved by increasing model complexity (111). These systems are now synonymous with “black box” approaches where models are plagued by uncertainty in methodology and ultimately in the way that they come to decisions. This ambiguity has made it problematic for ML systems to be adopted in sensitive yet critical clinical domains. As a result, xML/xAI has been increasingly studied in recent years. A recent review by Adadi and Berrada (112) highlighted trends in the community to explore explainability and stressed the need for more formalism in definition of xML/xAI. Upon identification of this lack of formality, recent research has introduced preliminary frameworks for assessing interpretability in predictive modeling (113).

First introduced by Ribeiro et al. at the International Conference on Knowledge Discovery and Data Mining, the local interpretable model-agnostic explanations (LIME) is one of the most popular interpretability methods. Briefly, the method works by generating simulated, randomly sampled, perturbed subsets of input data and subsequently assessing the accuracy of the output. If the prediction is correct, then the perturbed subset of input data within that iteration is weighted positively with respect to how close the sampled data is to the true data. LIME is a powerful and straightforward method, but there are drawbacks wherein poor choices in parameterization for generating the subsets of input data can lead to LIME missing out on important features (114). The LIME model was updated to DLIME (deterministic LIME) where random perturbation was replaced with hierarchal clustering (115).

Shapley Additive explanations (SHAP) is a game-theory inspired method that attempts to enhance interpretability by computing importance values for each feature on an individual-prediction basis (116). The basic idea behind SHAP is to consider all possible combinations of features and measure their influence on the prediction, which is performed mathematically by

summing the average marginal contribution of a feature across all possible feature combinations. The marginal contribution of a feature is the difference in prediction when the feature is included in a set compared to when it is not included in that same set (i.e., if we have three players one marginal contribution for player 3 is defined by {1,2,3} – {1,2}). This value is summed across all possible mutations, where order of addition to the subset of features is important. Written mathematically,

$$\phi_i = \sum_{S \subseteq F - \{i\}} \frac{|S|!(|F|-|S|-1)!}{|F|!} (v(S \cup \{i\}) - v(S)) \quad \textit{Equation 22}$$

where ϕ_i is the Shapley value of feature {i}, defined as the average contribution of {i} in all permutations of F (the full set of feature permutations). |F| denotes the number of features in set F. S denotes the set of feature permutations *without* feature {i}, hence S ⊆ F - {i}. Finally, the contribution of feature {i} to the total predictive power within each permutation is v(S ∪ {i} – v(S), where v is a characteristic function which quantifies the predictive power. Note the similarity in this mathematical formulation to the numerical example above. This Shapley value should have three properties, described as additive feature attributions (116)

1. Local Accuracy – the explanation model should match the original model
2. Missingness – requires features missing in the original input to have no impact
3. Consistency – if an input feature's contribution *increases or stays the same* regardless of the other inputs that features importance shall not *decrease*

In practice, since the number of possible feature subsets grows exponentially with the number of features, an exact calculation of Shapley values for all subsets may be infeasible. Approximation algorithms are often employed to efficiently estimate the Shapley values, including sampling-based approaches, tree-based approaches, and linear approximations. Of these, the work in this dissertation is based on Tree SHAP, an approach within the tree-based

approaches subsection. This method leverages the structure of tree-based models like random forest and recursively partitions the feature space using tree nodes and computes Shapley values within each partition (117). Within these tree-explainers, interaction indices which follow from generalizations of the original Shapley value properties are also considered. This value can allocate importance not just among each individual feature, but among all pairs of features (118).

Overall, there are major concerns about the transparency of AI/ML models in clinical practice as many modern models have little to no explanation about how a conclusion was reached. These concerns can potentially be mitigated in part by implementing an explainability algorithm like LIME or SHAP. Chapter 5. Explainable Machine Learning for Cardiac Catheter Ablations: Identifying Risk Factors and Predicting Post-Ablation Recurrence attempts to ameliorate of this clinician distrust by implementing the SHAP explainable machine learning algorithm on a random forest model to predict post-ablation recurrence following catheter ablation.

Chapter 3. Computational Modeling Identifies Embolic Stroke of Undetermined Source Patients with Potential Arrhythmic Substrate

With text from eLife. DOI: 10.7554/eLife.64213 (119)

3.1 Abstract

Cardiac MRI has revealed fibrosis in ESUS patients comparable to levels seen in AFib. We used computational modeling to understand the absence of arrhythmia in ESUS despite the presence of putatively pro-arrhythmic fibrosis. MRI-based atrial models were reconstructed for 45 ESUS and 45 AFib patients. The fibrotic substrate's arrhythmogenic capacity in each patient was assessed computationally. Reentrant drivers were induced in 24/45 (53%) ESUS and 22/45 (49%) AFib models. Inducible models had more fibrosis (16.7 ± 5.45%) than non-inducible models (11.07 ± 3.61%; $p<0.0001$); however, inducible subsets of ESUS and AFib models had similar fibrosis levels ($p=0.90$), meaning that the intrinsic pro-arrhythmic substrate properties of fibrosis in ESUS and AFib are indistinguishable. This suggests that some ESUS patients have latent pre-clinical fibrotic substrate that could be a future source of arrhythmogenicity. Thus, our work prompts the hypothesis that ESUS patients with fibrotic atria are spared from AFib due to an absence of arrhythmia triggers.

3.2 Introduction

AFib is the most common cardiac arrhythmia, affecting 1–2% of the world's population and significantly contributing to worldwide morbidity and mortality (120). The primary source of AFib-related mortality is stroke, with around 20% of all ischemic strokes occurring in AFib patients (120). Sub-clinical AFib (i.e., transient, asymptomatic AFib) is implicated as a potential cause of ESUS, and the current course of clinical care following ESUS is to look for evidence of AFib via an external monitor, an implanted loop recorder, or other forms of wearable monitoring devices

(121). If AFib is diagnosed, treatment with oral anticoagulants is started to mitigate the possibility of recurrent stroke Clinical studies have shown that AFib has been detected in only 30% of patients with long-term rhythm monitoring (122). This creates a frustrating problem for clinicians: in the wake of ESUS events, it is impossible to know which individuals should be treated as high-risk for AFib and therefore monitored accordingly.

Recent evidence from clinical studies suggests that the LA fibrosis burden measured by LGE-MRI is as high in ESUS patients as in AFib patients without stroke (123). This finding supports the hypothesis that atrial fibrosis is an element of the causal pathway for stroke, through an atrial cardiopathy, and independent of AFib. The absence of AFib despite the presence of a fibrotic substrate is intriguing and one potential explanation is that ESUS patients have pro-arrhythmic fibrotic substrate but lack the triggers needed to initiate arrhythmia. Another potential explanation is that the fibrosis present in ESUS patients is not pro-arrhythmic. Patient-derived computational modeling of atrial arrhythmias is uniquely poised to test these hypotheses. Previously, personalized atrial models have been used to assess arrhythmogenic propensity of fibrotic substrate and predict AFib ablation targets (101, 124). Applying the same approach, we can use computational models to predict if, in the presence of appropriate triggers, fibrotic remodeling in ESUS has the fundamental capacity to harbor reentrant arrhythmic activity.

Thus, we present a large-scale computational study to ascertain whether the fibrotic substrate with the potential to perpetuate AFib-sustaining reentrant drivers (RDs) exists in ESUS. Our hypothesis is that a pre-clinical AFib substrate, attributed to a pattern of fibrotic atrial remodeling that is conducive to RD perpetuation, exists in ESUS patients. By conducting simulations in models derived from LGE-MRI, we can begin to understand potential pro-arrhythmic properties of atrial fibrosis in ESUS patients. The study thus provides insights on the role of atrial fibrosis as a pathophysiological nexus between AFib and stroke.

3.3 ESUS and AFib Patient Characteristics and Model Architecture

Ninety patient-derived models were included in our analysis: 45 post-stroke ESUS and 45 pre-ablation AFib patients. Demographic information about both patient groups is provided in **Table 3.1**. There was a significant difference in LA surface area; however, the potential importance of this feature for interpreting our findings is offset by the lack of difference in LA volume index (a more commonly used measurement of normalized LA surface area), which suggests that higher LA surface area in those with AFib is a consequence of higher body mass index (BMI). LA fibrosis burden was not significantly different between ESUS (13.6 ± 6.2%) and AFib patients (14.2 ± 4.5%) (p=0.91), consistent with previous findings (123).

	ESUS (N=45)	**AFib (N=45)**	**P value**
Age, y	60±16	62±12	0.504
Female, %	44.0%	32.8%	0.275
BMI, kg/m^2	27.6±4.3	29.5±5.9	0.08
CHA_2DVASc score	2.0	1.9	0.345
CHF, n	14.3%	18.4%	0.599
Hypertension, n	68.5%	61.2%	0.468
Diabetes mellitus, n	20.4%	12.2%	0.292
CAD, n	18.4%	18.4%	1.000
Smoking, n	32%	28%	0.679
LA fibrosis, %	13.6±6.2%	14.2±4.5%	0.91
LA surface area, cm^2	109±26	134±40	0.0007
LA volume index, mL/m^2	60±29	57±26	0.607

Table 3.1. Patient Characteristics in ESUS and AFib

Personalized LA bilayer models were generated for all ESUS and AFib patients. Examples of physiological detail incorporated in models can be seen in **Figure 3.1**, including patient-specific patterns of fibrotic remodeling, realistic atrial fiber orientations, and locations of electric pacing sites. The LA subdivision scheme derived from universal atrial coordinates is further outlined in **Figure 3.2**



Figure 3.1. Model Architecture Overview (**A**) Reconstruction of LA geometry with anatomical features labeled (RIPV/RSPV/LIPV/LSPV, right/left inferior/superior pulmonary veins; LAA, LA appendage). The LA is modeled as a bilayer comprising nested endocardial and epicardial shells linked in both fibrotic and non-fibrotic regions by 1D linear elements. (**B**) LA fiber orientations for the endocardium and epicardium, mapped from human atlas geometry as described in Materials and methods. (**C**) AFib trigger sites as pacing sites (posterior/anterior LIPV, LSPV, RSPV, RIPV, LAA base, mitral valve annulus, and posterior wall). (**D**) Regions of the LA generated as described in methods and **Figure 3.2**: atrial floor, anterior wall and LAA, posterior wall, left PVs, and right PVs. *Figure reprinted from eLife. 2021 May 4:10.7554/eLife.64213*



Figure 3.2. LA subdivision scheme. (**A**) Alpha coordinate from universal atrial coordinate (UAC) system mapped on to a representative LA model. (**B**) Beta coordinate from UAC mapped on to a representative LA model. (**C**) 2D representation of UAC with pulmonary vein locations labeled. Dashed lines represent edges of the five atrial regions. (**D**) Segmented LA mapped onto a 3D mesh with numbered regions corresponding to regions in (**C**). (**E**) Final division scheme after edge expansion of the LPVs and RPVs to generate regions 3 and 4, respectively.

3.4 Induction of Arrhythmia and Fibrosis Quantification in Patient-Derived Models

Rapid electric stimulation caused RD-sustained arrhythmia in 22 of 45 AFib models (48.8%) and 24 of 45 ESUS models (53.3%). Thus, the capability of the fibrotic substrate to sustain RDs was not significantly different between the two groups (p=0.83, **Figure 3.3A**). ESUS and AFib models were then sorted by amount of global LA fibrosis and arranged into quartiles. For five models (21.7%) in the first quartile (fibrosis < 9.75%), six models (28.5%) in the second quartile (fibrosis < 12.6%), 15 (62.5%) models in the third quartile (fibrosis < 17. 5%), and 20 (91.0%) models in the top quartile, simulations revealed at least one pacing site for which stimulation produced an episode of RD-sustained arrhythmia (**Figure 3.3B**).



Figure 3.3 Fibrosis Quantification Overview (A) Histogram of AFib (22/45) and ESUS (24/45) inducible patients. Inducibility was not significantly different by χ^2 test. (**B**) Patients with ESUS and AFib arranged by percentage of LA fibrosis. Dotted lines indicate the quartiles of fibrosis observed for all 90 patient-derived models. Circles are indicative of stable reentry observed in the model from at least one pacing site after in silico pacing protocol. Triangles indicate no RDs after pacing from all 15 pacing sites independently. Cases that lacked RDs despite high fibrosis (inset I) or were inducible despite low fibrosis (inset II) are highlighted. *Figure reprinted from eLife. 2021 May 4:10.7554/eLife.64213*

Source data for this figure can be downloaded at this address. Columns information as follows: ESUS and AFib patient ID numbers; inducibility status (i.e., whether RD-sustained arrhythmia was observed in the corresponding patient-specific LA model); and LA volumetric fibrosis burden (%) extracted directly from clinical report.

To explore potential pro-arrhythmic substrate properties in ESUS and AFib, we analyzed fibrosis burden in the sub-groups of each cohort in which RD-sustained arrhythmias were inducible and non-inducible. Fibrosis burden was not significantly different between inducible ESUS and AFib models with (**Figure 3.4A**; p=0.90, confidence interval; CI: [−3.4, 4.1]) or without induced reentry (**Figure 3.4A**; p=1, CI: [−2.1, 2.4]). However, when fibrosis burdens for inducible and non-inducible models were aggregated across ESUS and AFib groups, a significant difference was evident (**Figure 3.4A**; 16.7 ± 5.46% vs. 11.07 ± 3.61%; p<0.0001, CI: [3.4, 7.6]).

We also investigated potential differences in the number of unique RDs and the number of AFib triggers that induced reentry in each patient-derived model. In all 46 inducible models, the median number of unique RDs was one for both AFib and ESUS models (AFib range: 1–5; ESUS range: 1–8). There was no significant difference in the number of unique reentrant morphologies per model between the two groups (**Figure 3.4B**; p=0.83, CI: [-7.7×10^{-5}, 8.8×10^{-5}]). The number of unique RDs was positively correlated with atrial fibrosis burden (**Figure 3.4C**; R = 0.63, p<0.0001). For all RD-inducible cases, the median number of stimulation sites from which rapid pacing led to RD formation was three for AFib and two for ESUS models (range for both groups: 1–9). No significant difference was found in the number of pacing sites that induced reentry per model between AFib and ESUS (**Figure 3.4D**; p=0.79, CI: [−2.0, 1.0]). The number of RD inducing pacing sites was also significantly correlated with fibrosis burden (**Figure 3.4E**; R = 0.62, p<0.0001).

In addition to its role as part of the substrate for reentrant arrhythmia, fibrosis may directly lead to increased AFib trigger incidence via calcium dysregulation leading to localized to regions of depolarized resting potential (125, 126). To investigate whether cohort-scale differences in this intrinsic pro-trigger property of fibrosis may explain the lack of arrhythmia in ESUS, we ran additional simulations to assess the total extent of abnormally depolarized tissue in ESUS and AFib models; notably, these values are distinct from total fibrosis burdens, since non-fibrotic

tissue can be pulled to a more positive resting potential via electrotonic coupling. We found no significant difference in these values between ESUS and AFib models (**Figure 3.4F**; p=0.32; CI: [–0.007, 0.019]); if anything, there was a trend toward *more* trigger-prone tissue in ESUS. These findings provide preliminary evidence against the notion that the lack of arrhythmia in ESUS might be due to lower rates of fibrosis-related ectopic pacemaking.


A
AFib
ESUS
****
ns
ns
Atrial fibrosis (%)
25
20
15
10
5
Yes
No
Reentry induced in model?
Number of unique reentrant drivers
B
ns
8
6
4
2
AFib
ESUS
C
R = 0.63, P = 3.1E−11
8
6
4
2
0
10
20
Atrial fibrosis (%)
Number of triggers that induced reentry
D
ns
9
6
3
0
AFib
ESUS
E
R = 0.62, P = 8.3E−11
9
6
3
0
10
20
Atrial fibrosis (%)
Tissue with resting membrane potential above −75.3 mV
F
ns
Percentage (%)
15
10
5
0
AFib
ESUS

Figure 3.4 Summary of RD characteristics between ESUS and AFib models. (**A**) Boxplot of fibrosis percentage in ESUS and AFib models where reentry was induced (ESUS: N = 24, IQR = 10.6; AFib: N = 22, IQR = 5) and where reentry was not induced (ESUS: N = 21, IQR = 5; AFib N = 23, IQR = 3.5). Across ESUS and AFib models, fibrosis burden for RD-inducible and RD non-inducible models was significantly different ($p<0.0001$). (**B**) Boxplot of number of unique reentrant morphologies elicited by all 15 pacing sites ($p=0.83$). (**C**) Correlation plot of fibrosis vs. number of RDs ($R = 0.63$, $p<0.0001$). (**D**) Boxplot of the number of pacing sites which induced reentry ($p=0.79$). (**E**) Correlation plot of fibrosis vs. number of pacing sites that induced reentry ($R = 0.62$, $p<0.0001$). (**F**) Boxplot depicting percentage of tissue with significantly depolarized tissue (>95th percentile) between ESUS and AFib models after reaching steady state. $p=0.32$; CI: [–0.007, 0.019]. *Figure reprinted from eLife. 2021 May 4:10.7554/eLife.64213*

Source data for this figure can be downloaded at this address. For each LA model used in the study: number of pacing sites that induced RD-sustained arrhythmia; number of unique RD locations; percentage of tissue significantly depolarized in quiescent state, as presented in Figure 3.3F.

3.5 Arrhythmia Dynamics

Analysis of simulated reentry episodes revealed no qualitative differences in arrhythmia dynamics between AFib and ESUS models. **Figure 3.5** shows examples of RD-perpetuated in silico arrhythmia and instances where stimulation failed to induce reentry for both groups. Of note, this figure highlights two inducible low-fibrosis ESUS models (**Figure 3.5A**: 6.9% fibrosis, RD near the LIPV; **Figure 3.5B**: 10.0% fibrosis, RD on the atrial floor) and a non-inducible high-fibrosis ESUS model (**Figure 3.5C**: 16% fibrosis). In the latter case, dense fibrosis on the posterior wall resulted in conduction block as indicated. **Figure 3.5D,E** present examples of RD-driven arrhythmia in AFib models (9.9% and 13.7% fibrosis, respectively), and **Figure 3.5F** shows an AFib model (11.6% fibrosis) in which reentry was not induced due to wavefront collision in the posterior wall region. Overall, this shows that both ESUS and AFib models exhibited activation patterns consistent with previous definitions of RD-driven arrhythmia; examples of inducible low-fibrosis and non-inducible high-fibrosis models emphasize that fibrosis burden alone is an insufficient predictor for a potential arrhythmic substrate.



Figure 3.5 Maps of fibrotic tissue distribution (left) and activation time (right) for ESUS and AFib models in which pacing succeeded (rows 1–2) or failed (row 3) to induce RD-driven arrhythmia. Black arrows indicate directions of wavefront propagation in RDs. Double lines indicate sites of conduction block. Black-shaded regions in activation maps indicate locations where activation did not occur during the analysis interval. (A) ESUS model with 6.9% fibrosis and reentry inferior to LIPV. (B) ESUS model with 10.0% fibrosis and reentry on the atrial floor. (C) ESUS model with 16% fibrosis with wavefront termination through fibrosis on posterior wall. (D) AFib model with 9.9% fibrosis and reentry observed adjacent to RIPV on posterior wall. (E) AFib model with 13.7% fibrosis and reentry observed on the anterior wall. (F) AFib model with 11.6% fibrosis with wavefront collision on posterior wall. *Figure reprinted from eLife. 2021 May 4:10.7554/eLife.64213*

3.6 Properties of RD Localization

As described in 3.11 Methods, each model was automatically subdivided into five anatomical regions (see schematic illustrations in **Figure 3.1D**, and Chapter 3) and region-wise inducibility score analysis (IdS, as described in 3.11 Methods) was used to gauge likelihood of RD induction in response to rapid electrical stimulation from different locations in the LA. While ESUS and AFib models had a statistically similar pattern of inducibility rates ($p=0.45$, by χ^2 test), stimulation from the posterior wall was approximately two times more likely to induce RDs in

AFib models than ESUS models (**Figure 3.6A**, IdS = 6 vs. IdS = 3). In other words, with all other factors held equal, our simulations suggest that triggered activity in the posterior wall may be more likely to initiate reentrant arrhythmia in AFib patients compared to ESUS patients. The same IdS values plotted in **Figure 3.6A** were mapped onto representative LA models to facilitate visual comparison of regional sensitivity to rapid pacing (**Figure 3.6B**). Next, we considered the number of unique RD localization sites in each LA region across the different model groups (i.e., AFib vs. ESUS). The LPV region was most likely to harbor RDs in the AFib cohort (**Figure 3.6C**, N = 17). In the ESUS cohort, the anterior wall was the most likely region to contain an RD (**Figure 3.6D**, N = 16). The association between the type of model (ESUS vs. AFib) and RD localization was not significant (p=0.13, χ^2 test).



Figure 3.6. Summary of IdS and RD localization characteristics. (**A**) Region-wise IdS for both ESUS and AFib LA models. (**B**) Heat map of the regions in which triggers are most likely to induce arrhythmias depicted as representative ESUS and AFib models. (**C**) Histogram of RDs across all AFib and ESUS models binned by localization to specific LA regions. (**D**) Heat map of regions in which RDs are most likely to localize depicted as representative ESUS and AFib models. *Figure reprinted from eLife. 2021 May 4:10.7554/eLife.64213*

Source data for this figure can be downloaded at this address. For each episode of RD-sustained arrhythmia induced in each patient-specific LA model, the location of the pacing associated pacing site and the LA region in which the RD ultimately anchored are provided.

3.7 Properties of pro-RD fibrosis

To further examine trends in RD inducibility and localization observed in **Figure 3.6**, we also carried out region-wise analysis of fibrosis spatial pattern. In a previous study (40), machine learning was used to quantitatively characterize the fibrosis distribution in regions that most frequently harbored RD organizing centers (i.e., high local fibrosis density *and* entropy). As described in 3.11 Methods, the distribution of pro-RD tissue regions was determined for each inducible model; these values were then subdivided in the five-region schematic (**Figure 3.7A**). This analysis revealed that the extent of pro-RD tissue in the LPV region was significantly higher in AFib compared to ESUS models (**Figure 3.7B**; p=0.01); this was consistent with our findings on regional inducibility, and RD localization as shown in **Figure 3.6**. Likewise, for regions that were associated with greater inducibility and RD localization in ESUS models (anterior wall+LAA, atrial floor), there was a trend toward a larger extent of pro-RD tissue compared to AFib models, but these did not reach the level of significance.



Figure 3.7. Summary of the region-by-region extent of tissue with a spatial fibrosis pattern (as characterized by local density and entropy) associated with RD localization (i.e., pro-RD tissue). (A) Maps of pro-RD tissue for representative AFib and ESUS cases, including boundaries between regions. (B) Region-wise extent of pro-RD tissue in inducible AFib and ESUS models, depicted as boxplots (**p<0.01, Wilcoxon rank-sum test; CI: [–0.149, –0.021]). *Figure reprinted from eLife. 2021 May 4:10.7554/eLife.64213*

Source data for this figure can be downloaded at this address. For each LA model used in the study, proportion of pro-RD tissue (as calculated by previously established machine learning-based analysis of fibrosis spatial pattern) in each LA region.

3.8 Further Discussion

This study used a novel computational modeling approach with stimulus locations chosen based on clinically observed AFib triggers to shed new light on the role of the fibrotic atrial substrate in the potential for initiation and perpetuation of reentry in ESUS patients. In models reconstructed from 45 post-stroke ESUS and 45 pre-ablation AFib patients, we showed that the AFib and ESUS groups did not differ significantly in the propensity of the fibrotic substrate to sustain RDs in response to simulated burst pacing. This is the first study to use computational modeling and simulation to assess potential pro-arrhythmic capacity of LA fibrosis in ESUS patients. Moreover, to the best of our knowledge, this is the largest cohort ever studied via computational analysis of atrial electrophysiology in models derived from LGE-MRI, exceeding the number of patient-specific models (N = 50) in the former largest study (127) by a factor of ≈1.8.

3.8.1 Inducibility of reentry and fibrosis quantification in patient derived atrial models

Experimental findings have shown that atrial fibrosis results in changes that promote reentry (128, 129), but the exact mechanism of this connection is not fully understood. Previous modeling studies have linked RD localization to specific spatial patterns of fibrotic remodeling in AFib (40, 130). Recent clinical findings indicate that atrial fibrosis burden does not differ significantly between AFib and ESUS patients, and yet (by definition) ESUS patients do not demonstrate AFib at the time of stroke or during ambulatory monitoring (123). Given the findings summarized above, a potential explanation is that, notwithstanding the fact that ESUS patients

have substantial fibrosis, the particular spatial distribution of fibrotic remodeling in their atria is not conducive to arrhythmia perpetuation. Our findings suggest that this is likely not the case. From the standpoint of computational models derived from patient LGE-MRI scans, fibrotic substrate in individuals with ESUS is indistinguishable from that in patients with AFib in terms of the fundamental capacity to sustain RDs. For inducible models from both cohorts, we found that high fibrosis models were more likely to exhibit RDs irrespective of whether they corresponded to ESUS or AFib patients. This is in agreement with prior computational studies, which found the same general association (40, 101), and is consistent with clinical understanding, wherein higher fibrosis burden is associated with poor outcomes in AFib ablation procedures (27). Notably, we did observe several cases in which models defied inducibility expectations based on fibrosis alone. Such models exhibited RDs despite low fibrosis or were non-inducible despite high fibrosis. This observation confirms that, as observed previously in analogous AFib modeling studies (40, 101), assessment of raw fibrosis burden LGE-MRI scans alone is insufficient to fully characterize arrhythmogenic capacity of potentially pro-arrhythmic substrate in ESUS.

Consistent with the goal of this research to understand the contribution of fibrotic substrate to potential RD formation in ESUS, we purposefully excluded arrhythmias perpetuated by other mechanisms from our study design (e.g., self-sustaining activity driven solely by focal sources). This allows us to study the fibrotic substrate in the absence of all other confounding factors. Additionally, our analysis of abnormal steady-state depolarization in LA models suggests the potential for fibrosis itself to serve as a source of arrhythmia triggers is no greater in AFib than in ESUS models. Potential contributions from the right atrium (RA) were also excluded, since only the LA was segmented from LGE-MRI as part of the clinical workflow. Either of these factors may explain the absence of simulated arrhythmia in 23 of 45 AFib models, many of which had very little LA fibrosis (i.e., AFib in these individuals might have been predominantly focal in

nature or sustained by RDs in the RA). This rate of inducibility is consistent with previous studies (e.g., 13 of 20 in computational models reconstructed from LGE-MRI scans of persistent AFib patients) (40), supporting the notion that LA fibrosis is associated with increased arrhythmia inducibility but fails to tell the whole story. Importantly, neither of these model constraints repudiates the central finding of our study, which suggests that there is no difference between ESUS and AFib patients in terms of the fundamental capacity of the fibrotic substrate to potentially harbor RDs.

3.8.2 RD localization dynamics and morphology in patient-derived atrial models

As discussed above, our qualitative findings suggest that ESUS patients' fibrotic substrate is no different than that of AFib patients in terms the capacity to sustain RDs per se. We performed additional analysis to assess whether specific consequences of fibrotic remodeling influenced any characteristics of RD inducibility in different ways for simulations in models corresponding to ESUS vs. AFib patients. First, we found that there was no significant difference in global fibrosis burden between inducible AFib and ESUS models. Thus, our computational modeling suggests that intrinsic pro-arrhythmic traits of ESUS and AFib fibrotic substrate are indistinguishable. Given this result, one potential alternative explanation for the lack of arrhythmia in ESUS patients is a lack of suitable triggers, despite an abundance of fibrotic substrate on par with that observed in AFib. The plausibility of this explanation is strengthened by the fact that the pacing sites from which episodes of reentry were induced in our study were based on common AFib trigger sites as identified in a recent clinical study (7); this is in contrast to previous modeling studies, which simulated triggered activity from evenly-distributed atrial sites (101). Nevertheless, the premise of this aspect of our work was not to assess an absence of triggers, but instead ask the following: if the atria of these ESUS patients were subjected to the same type of triggered activity known to occur in typical AFib patients, is it possible the result would be sustained arrhythmia? In more than half of the cohort (24/45), our analysis suggests that the

answer is yes. This new hypothesis could be validated in future studies by designing clinical protocols that systematically monitor ESUS patients with different levels of fibrosis for potential AFib triggers via electrocardiographic readouts.

Further analysis was performed to probe potential differences between ESUS and AFib simulations that went beyond consideration of RD inducibility as a binary variable. Specifically, we found no difference in the number of unique model-predicted RDs or the number of pacing sites that induced RDs between ESUS and AFib. Instead, these variables were highly correlated with LA fibrosis burden, which is consistent with the concept that high fibrosis models are more susceptible to pacing-induced RDs. This finding further substantiates our principal claim that no significant differences exist between the detected fibrotic substrate in ESUS and AFib, in that it holds true for the substrate's capacity to sustain reentry and its susceptibility to triggered activity. The general implication is that in the presence of simulated triggered activity, both of these characteristics are closely linked to global fibrosis burden.

RDs identified by non-invasive electrocardiographic imaging (ECGI) and in silico phase singularity identification have been shown to co-localize with fibrosis boundary zones identified by LGE-MRI (40, 42, 131, 132). RD localization dynamics in this study were consistent with these findings, as illustrated by representative LA fibrotic tissue distributions and corresponding RDs in **Figure 3.5**. RD morphology in this study corroborated previous findings – arrhythmias were perpetuated by one RD at a time, with activity in the periphery including conduction block, transient reentry, and wavefront collision (40, 101).

3.8.3 Insights from analysis of RD inducibility and localization by LA region

Further to the macroscopic analysis discussed above, our region-by-region analysis of RD inducibility and localization showed that spatial properties of the fibrotic substrate between AFib and ESUS models are not intrinsically different. However, this analysis yielded several noteworthy findings that suggest subtle distinctions in fibrosis pattern may exist between the two

groups. The most striking difference exists for the posterior wall region, where the IdS score was ≈2× higher in AFib compared to ESUS models. Thus, even in cases where posterior LA wall ectopic excitations occur in ESUS patients, our simulations suggest that they could be up to 50% less likely to engage the fibrotic substrate and initiate sustained reentry compared to the same activity in AFib patients. This possibility does not contradict our hypothesis that the lack of arrhythmia in ESUS is due to a dearth of triggers; rather, it is a complementary corollary that can be put to the test in future clinical and computational analysis.

While understanding of RD localization dynamics in AFib remains limited, evidence from ECGI mapping indicates that reentrant activity occurs most frequently in the PV and posterior wall regions (42, 133, 134). Our findings are consistent with these data for AFib but not ESUS models. Many (41.1%) AFib model RDs localized to the LPV region. In contrast, in the ESUS population the RD localization hotspot was the region comprising the anterior wall and LAA (37%). The importance of this finding is unclear, as tendencies toward reentrant activity in particular LA areas have not been meaningfully correlated to clinical arrhythmia properties and are potentially subject to changes in conduction velocity or action potential duration (73). However, it provides a path for future validation studies: if incident AFib in patients who previously presented with ESUS can be characterized by intracardiac mapping, the hypothesis that RDs localize preferentially to the anterior wall can be tested.

Finally, our analysis of fibrosis spatial patterns revealed that the proportion of tissue with the propensity to harbor RDs (as established via machine learning in prior work (40)) was higher in the LPV region for AFib compared to ESUS models. While we acknowledge that a more fulsome analysis will be required to draw comprehensive conclusions on this subject, we note that our results are consistent with the most prominent observed regional variabilities in RD localization and inducibility between the two model groups. In contrast, ESUS patients trended toward a higher percentage of pro-RD tissue in all anatomical areas except the LPVs. Thus,

despite some interesting and potentially consequential differences in regional distribution of potentially pro-arrhythmic fibrosis, our overarching conclusion remains unchanged: our models suggest that if the ESUS substrate were subjected to suitable triggered activity, it could sustain the same types of RDs as those that contribute to AFib perpetuation.

3.9 Limitations

In this chapter, atrial tissue is modeled as a bilayer to drastically reduce computational load. Previous studies have used this modeling framework (131, 135) to represent human atria effectively, but the framework remains a simplification compared to volumetric 3D models. Moreover, clinical-grade MRI resolution limits our ability to detect fine details in anatomical structure and spatial distribution of potentially arrhythmogenic substrate, for instance slow-conducting tracks of fibrotic atrial tissue that could underlie micro reentrant circuits (136). While these models are patient-specific in terms of LA anatomy and each individual's unique pattern of fibrotic remodeling, they do not incorporate inter-patient variability in conduction velocity (CV) and electrophysiological properties such as ion channel expression. Nevertheless, our previous analysis indicates that this representation of atrial architecture with generic 'average AFib' electrophysiology is appropriate for use in patient-derived modeling (73, 130).

As in previous studies (99, 103), our models do not differentiate between cell- or tissue-scale properties of atrial electrophysiology between patients with paroxysmal and persistent forms of AFib. Likewise, our approach to characterizing potential arrhythmia propensity in ESUS patients assumes cell- and tissue-scale remodeling based on experimental and clinical data from the AFib milieu. Although this is relevant as a limitation and must be considered when interpreting our results, this aspect of our approach is also one of the major advantages of the modeling and simulation methodology. Specifically, it allows us to assess whether there are any relevant differences in the spatial pattern of fibrotic remodeling between ESUS and AFib patients in the absence of other potentially confounding variables. A related limitation is that patients with

stroke were excluded from the AFib cohort. This was because stroke etiology in the database from which AFib patients were drawn was not explicitly adjudicated to be cardioembolic, other ischemic such as atherosclerotic, or hemorrhagic. Therefore, we would not be able to draw reliable conclusions regarding the role of fibrosis in stroke in this population.

Finally, the mechanism of stroke in ESUS patients may be independent of AFib. Decreased atrial function due to atrial fibrosis may contribute to reduced hemodynamic efficacy and thrombus formation in the absence of AFib. Currently, secondary stroke prophylaxis is dependent on detecting AFib and predicting, through computational modeling, which atria are more prone to manifest AFib may be of clinical value. Another future research direction that could prove highly fruitful would be to create multi-scale, multi-physics image-based models of the fibrotic atria to assess each individual's risk of clot formation in a patient-specific manner (39).

3.10 Conclusions

Simulations suggest that the pro-arrhythmic properties of fibrotic substrate in ESUS and AFib patients are indistinguishable. Our results show that fibrotic remodeling in ESUS patients has the theoretical capacity to sustain reentry when subjected to common AFib triggers. Thus, we conclude that fibrotic substrate conducive to perpetuating reentry may exist in up to half of ESUS patients. As individuals studied in this cohort present with incident AFib over the next few years, we will be able to put this hypothesis to the test. Our findings also support the notion that the lack of AFib in this population may be attributable to a lack of suitable arrhythmic triggers, but further research is needed to fully justify this claim. While the existence of pre-clinical substrate is correlated with a higher global proportion of fibrotic tissue, many ESUS cases defied these expectations, suggesting that fibrosis burden alone is insufficient for predicting pre-clinical AFib substrate. This conclusion justifies the use of computational simulations to probe beyond the fibrosis as imaged. Overall, these results provide novel insights into the role of atrial

fibrotic remodeling as a critical nexus between the otherwise distinct manifestations of AFib and ESUS.

3.11 Methods and Data Availability

Patients were recruited to undergo cardiac LGE-MRI from the University of Washington (Seattle, WA) and Klinikum Coburg (Coburg, Germany) between July 2016 and June 2019. This study was approved by the Institutional Review Board (IRB) of the University of Washington (UW) and the Ethikkommission der Bayerischen Ländesärztekammer München, Bayern, Deutschland; all participants provided written informed consent. Patients with ESUS met published diagnostic criteria (137). Patients with paroxysmal (27/45, 60%) or persistent AFib and without stroke were recruited from the UW Cardiac Arrhythmia Data Repository, an IRB-approved database for arrhythmia patients. Exclusion criteria for AFib patients included those who had undergone LA catheter ablation before MRI and those with only atrial flutter. Patients with cardiac implantable electronic devices, severe claustrophobia, renal dysfunction, and other contraindications to MRI or gadolinium-based contrast were excluded.

Cardiac LGE-MRI was obtained on all participants to quantify the extent of LA fibrosis using previously described protocols (27). Scans were performed on Philips Ingenia and Siemens Avanto clinical scanners, 15–25 min after contrast injection, using a three-dimensional inversion-recovery, respiration-navigated, ECG-gated, gradient echo pulse sequence. Acquisition parameters included transverse imaging volume with a voxel size of 1.25 × 1.25 × 2.5 mm (reconstructed to 0.625 × 0.625 × 1.25 mm). Scan time was 5–10 min dependent on respiration and heart rate. Fat saturation sequences were used to suppress signal from fatty tissue.

Geometric models were reconstructed from LGE-MRI, and the relative extent of fibrosis in the LA was quantified via an adaptive histogram thresholding algorithm (138). Clinical-grade

meshes (i.e., coarse discretization) produced by Merisight Inc (Salt Lake City, UT) were resampled with a target resolution of 200 μm using an automated process based on gmsh (139). Each LA model was represented as a bilayer comprising of nested endocardial and epicardial shells (135), linked at every point by linear connections (σ = 0.8 S m^{-1}) (**Figure 3.1A**). LA bilayer models were generated by slightly inflating the single-surface mesh to form the epicardial surface (i.e., duplicating endocardial points then moving them outward by 100 μm along the surface normal vector), then connecting the nested shells by attaching linear elements between corresponding nodes. In each patient-derived model, realistic myocardial fiber orientations were mapped from an atlas geometry (135) using the universal atrial coordinates (UAC) approach. Briefly, this process assigned epicardial and endocardial fibers from a previously published bilayer model to the target atrial geometry (**Figure 3.1B**; (140, 141)). In all finite-element LA meshes, the average element edge length was ≈188 μm and the number of nodes ranged from ≈600,000 to ≈1.4 million, depending on LA size. This mesh resolution is consistent with previously established benchmarks for minimizing numerical error due to spatial discretization in simulations of cardiac wavefront propagation (71).

Our methodology for computational modeling at the cell and tissue scale of the fibrotic and non-fibrotic atrial electrophysiology can be found in previously published papers (40-42). Briefly, in non-fibrotic regions, a human atrial action potential model (56) (see 2.3 Cell-Scale Modeling) was used to represent membrane kinetics, including parameter modifications to fit clinical monophasic action potential recordings from AFib patients (I_{Kur}, I_{to}, and I_{CaL} decreased by 50%, 50%, and 70%, respectively) (40, 142). At the tissue scale, conductivity tensor values in non-fibrotic tissue (longitudinal: σ_L = 0.409 S m^{-1}; transverse: σ_T = 0.0820 S m^{-1}) were calibrated to obtain effective CV values of 71.49 cm s^{-1} and 37.14 cm s^{-1} (longitudinal and transverse). These conductivities were chosen as a compromise between CV values measured in patients induced AFib (61 ± 6 cm s^{-1}) (143), clinically mapped patients with AFib or atrial flutter (median:

60 cm s^{-1}; inter-quartile range: 22 cm s^{-1}) (144), and simulations calibrated to match intracardiac mapping data from an individual with paroxysmal AFib (median: 143 cm s^{-1} longitudinal, 94 cm s^{-1} transverse) (145). In fibrotic regions, modifications to the AFib-like action potential model (I_{CaL}, I_{Na}, and I_{K1} decreased by 50%, 40%, and 50%, respectively) were implemented as in prior studies (40, 124), resulting in a 15.4% increase in action potential duration and a 49.6% decrease in upstroke velocity. These changes represented the effect of elevated transforming growth factor-β1, a key component of the fibrogenic signaling pathway. As in previous studies (40-42), tissue-scale effects of interstitial fibrosis and gap junction remodeling were represented by reducing overall conductivity and exaggerating the anisotropy ratio (σ_L:σ_T) from 5:1 to 8:1 (σ_L = 0.177 S m^{-1}; σ_T = 0.0221 S m^{-1}).

Electrical propagation in bilayer LA models was simulated by solving the monodomain equation using the finite-element method (see section 2.4 Tissue-Scale Modeling). This system was coupled with ordinary differential and algebraic equations representing myocyte membrane dynamics at each node in the mesh, as described in the prior section. All simulations were executed on the Hyak supercomputer system at the University of Washington using the openCARP software package (146, 147), which is available for academic use (see https://openCarp.org). The compute time required to complete each unique simulation ranged from 1 to 10 hr. The total CPU time for all simulations conducted in all models was 13.4 years.

Simulations were performed to assess the pro-arrhythmic propensity of the fibrotic substrate in each patient-derived model. Arrhythmia induction via rapid pacing was attempted from 15 pacing sites derived from AFib trigger sites (**Figure 3.1C**, see caption for detailed anatomical site descriptions) (7). Clinically relevant AFib trigger sites were chosen over a random pacing schematic to specifically capture RDs that arise from locations demonstrated to induce AFib. As in previous publications, a clinically relevant pacing sequence of 12 electrical stimuli was

delivered at each of the 15 locations (40, 124). Individual cell-scale ionic models were paced to limit cycle at a rate basic cycle length of 500 ms. The electrical stimulus consisted of two initial pulses with a coupling interval of 300 ms, followed by pulses ramping down to 200 ms in 20 ms intervals. After the delivery of the final stimulus, simulations were monitored for self-sustaining electrical wavefront propagation. For all cases in which activity persisted for at least 5,000ms post-pacing, we applied further analysis to determine whether the cause was an induced RD or macroscopic re-entry (i.e., continuous repetitive, self-sustaining activation propagating around a non-conductive obstacle such as the mitral valve or pulmonary vein(s)), which we consider flutter-like reentry. Instances of macroscopic re-entry were excluded from further analysis.

For each AFib-inducible simulation, we documented whether each pacing site induced reentry and analyzed patterns of RD localization. Unique RD morphologies in each patient-derived model were classified as belonging to one of five anatomical regions (**Figure 3.1D**), which were delineated automatically in a process summarized in Chapter 3. First, the LA was subdivided into three broad anatomical areas (region 1: LA floor, 2: posterior wall; 3: anterior wall including LAA) using standardized cutoff values in the UAC space (140). Second, the left and right PV areas (regions 4 and 5, respectively) were established using a region-growing approach such that each accounted for 15% of the total LA surface area (**Figure 3.2**). We then defined region-wise inducibility scores (IdS) across all models in a particular group (ESUS or AFib) as the proportion of pacing sites within a given region from which rapid pacing resulted in initiation of an RD. For example, since the LPV region contains four pacing sites (anterior/posterior LSPV/LIPV), the corresponding ESUS IdS value would be derived by summing the number of instances in which pacing from those locations induced RD across inducible ESUS models then dividing by four. This ensured our ability to assess spatial heterogeneity of sensitivity to triggered activity in a manner that was unbiased to the relative abundance of pacing sites in some LA regions.

Fibrotic tissue areas with both high local fibrosis density (FD) and high local fibrosis entropy (FE) have increased propensity for RD localization, as shown in computational models (131) and intracardiac mapping of patients with persistent AFib (132). We used a constraint equation derived by support vector machine-based classification to delineate such pro-RD regions. As in prior studies (40, 99), the classification polynomial was as follows: $0.4096\ FD^2 + 3.28(FD)(FE) - 0.1036\ FE^2 - 0.7112(FD) - FE + 0.0429$. Maps of pro-RD tissue were subdivided into the five LA regions, as described above, and region-specific burdens of pro-RD fibrosis pattern were calculated.

In some situations, fibrosis itself can develop the capacity to generate ectopic triggers of arrhythmia (125, 126). Although the cell-scale models used in this study do not undergo early or delayed afterdepolarizations due to simplified intracellular calcium handling, fibrotic regions in our models do have a potentially pro-ectopic higher resting membrane voltage (V_m) compared to non-fibrotic regions due to reduced ion channel expression levels (I_{CaL}, I_{Na}, and I_{K1}). Thus, as a surrogate measure of potential intrinsic pro-trigger capacity in fibrotic tissue, we characterized the extent of tissue in ESUS and AFib models in which the fibrosis pattern resulted in abnormal depolarization. To do this, we allowed all 90 models to reach a quasi-equilibrium state (1000 ms in the absence of pacing). We aggregated resting V_m values across all models and identified the 95th percentile as the threshold for delineation of fibrosis-induced abnormal depolarization (–75.3 mV). Then, we calculated the proportion of tissue in each model with an equilibrium V_m above that threshold.

LA models for ESUS and AFib patients were divided into quartiles based on the extent of fibrotic remodeling as measured by LGE-MRI. Continuous variables were compared pairwise between groups using Wilcoxon rank-sum tests and were reported as mean ± standard deviation. Confidence intervals were calculated as the interval for the true difference in mean with 95% certainty. Categorical variables were compared using a χ^2 test. After classifying unique RDs and

number of pacing sites that induced reentry, correlation with fibrosis was assessed with logistic regression. Statistical significance was established at two-tailed $p \leq 0.05$. All statistical analysis was performed using R (148).

Where possible (**Figures 3.3, 3.4, 3.6, 3.7**), raw numerical data underlying figures are available via this permanennt figshare link: https://figshare.com/articles/dataset/Source_Data_for_Study_by_Bifulco_et_al_/14348042. Patient-derived data related to this article, including processed versions thereof, are not publicly available out of respect for the privacy of the patients involved. Interested parties wishing to obtain these data for non-commercial reuse should contact the author. Upon all reasonable requests for access to these data, the corresponding authors and I will work to pursue negotiation of a Data Transfer and Use Agreement with the requesting party; administrators at the requesting party's institution, the University of Washington, and Klinikum Coburg; and relevant Institutional Review Boards at all the latter institutions. Source files for a complete example of computational modeling and simulation of the fibrotic atria, using publicly available data sets and software tools only, can be found via the following permanent link: https://figshare.com/articles/dataset/Computational_Modeling_Simulation_of_Atria_with_Fibrotic_Remodeling_-_Example/14347979.

Documentation provided with this example includes instructions on the use of the openCARP cardiac electrophysiology simulator and the meshalyzer visualization software (both available via https://opencarp.org/) to precisely reproduce the computational protocol applied to patient-specific left atria models in this study.

Chapter 4. Explainable Machine Learning to Predict Anchored Reentry Substrate Created by Persistent Atrial Fibrillation Ablation in Computational Models

4.1 Abstract

Post-ablation arrhythmia recurrence occurs in ~40% of persistent atrial fibrillation (PsAF) patients. Fibrotic remodeling exacerbates arrhythmic activity in PsAF and can play a key role in reentrant arrhythmia, but emergent interaction between non-conductive ablation-induced scar and native fibrosis (i.e., residual fibrosis [ResF]) is poorly understood. We conducted computational simulations in pre- and post-ablation left atrial models reconstructed from LGE-MRI scans to test the hypothesis that ablation in PsAF patients creates new substrate conducive to recurrent arrhythmia mediated by anchored reentry (AR). We trained a random forest machine learning classifier to accurately pinpoint specific non-conductive tissue regions (i.e., areas of ablation-delivered scar or vein/valve boundaries) with the capacity to serve as substrate for AR-driven recurrent arrhythmia (area under the curve: 0.91±0.03). Our analysis suggests there is a distinctive non-conductive tissue pattern prone to serving as arrhythmogenic substrate in post-ablation models, defined by a specific size and proximity to ResF. Overall, this suggests PsAF ablation transforms substrate that favors functional reentry (i.e., rotors meandering in excitable tissue) into an arrhythmogenic milieu more conducive to AR. Our work also indicates that explainable machine learning and computational simulations can be combined to effectively probe mechanisms of recurrent arrhythmia.



4.2 Introduction

Atrial fibrillation (AFib) is a chronic, progressive arrhythmia associated with a twofold increased risk of cardiovascular mortality (149). Catheter ablation by pulmonary vein isolation (PVI) is an established rhythm control strategy, but recurrence rates are high (~40-50%) (150). The exact cause of recurrent AFib is unknown, but a potential factor is inter-individual variability in underlying electrical and anatomical substrate (151). Numerous supplemental ablation strategies that go beyond PVI to target this substrate have been suggested (152). However, in the recent DECAAF II study, which combined MRI-guided fibrosis ablation with conventional PVI catheter ablation, there was no reduction in arrhythmia recurrence in persistent AFib (PsAF) patients (153). Similarly, ablation of complex fractionated activity sites was not superior to

traditional PVI (154). A potential conclusion from these results is that while the role of left atrial (LA) fibrosis in AFib pathophysiology is well-recognized, we have little understanding of how atrial fibrosis interacts with ablation lesions to explain the high arrhythmia recurrence rate.

Cardiac late gadolinium enhanced (LGE)-magnetic resonance imaging (MRI) has been used to detect fibrosis based on differences between signal intensities in remodeled tissue and normal myocardium. Atrial LGE-MRI scans acquired pre-ablation have been used to construct patient-specific computational models of fibrotic atria; such models have been used to elucidate relationships between fibrosis and AFib perpetuation, prospectively identify ablation targets, and predict post-ablation arrhythmia recurrence (40, 101, 103). Prior attempts to use patient-specific models to assess post-ablation substrate were confined to assessment of fibrotic tissue in conjunction with ablation lesions as documented via peri-procedural electroanatomic mapping systems (99, 130). These studies found that recurrent AFib may be attributable to preserved functional reentries (FRs; i.e., rotors) that sustain AFib pre- and post-ablation, emergence of new FR locations, and post-ablation anchored reentry (AR). In post-ablation LGE-MRI, hyper-enhancement of ablation scar relative to fibrotic tissue facilitates detection and localization of gaps in ablation lines (155), which are not typically detected in procedural maps. In this respect, post-ablation MRIs offer a more comprehensive representation of the patient-specific distribution of ablation-induced scarring (156), which can be combined with the native fibrosis distribution in pre-ablation scans to yield detailed maps of each patient's post-ablation substrate.

In this study, we aim to assess pro-arrhythmic properties of post-ablation substrate by merging spatial patterns of native fibrosis and ablation-induced scarring, derived from pre- and post-treatment LGE-MRI scans, respectively. Computational simulations are used to analyze how these two components of post-ablation substrate (i.e., residual fibrosis [ResF] and scar) could influence the incidence of recurrent arrhythmia, either distinctly or synergistically. We characterize the unique spatial patterns of post-ablation arrhythmogenic substrate using a

machine learning classifier. The study thus provides mechanistic insight into links between ablation-induced scarring and ResF, providing new insight into why some PsAF patients have an arrhythmogenic post-ablation substrate.

4.3 Persistent AFib Patient Characteristics

Thirty-seven patients with clinically diagnosed PsAF (157) using standard Heart Rhythm Society consensus criteria were included in this study. Demographic information is provided in **Table 1**. Patients underwent catheter ablation via radiofrequency (RF) or cryoballoon catheter per standard protocol (except for one patient who had a surgical ablation). Some (19/37, 51.4%) patients who had RF ablation and one patient who had cryoballoon catheter ablation had additional substrate modification outside of the pulmonary veins.

	Pre-ablation	**Post-ablation**		
	All PsAF patients	**AF recurrence**	**AFL recurrence**	**No recurrence**
N (%)	37	15 (50.0%)	5 (21.1%)	16 (28.9%)
Age (years)	62.9±3.5	64.5±6.8	64.2±10.7	60.3±4.8
BMI	33.2±2.9	31.9±4.3	32.9±7.2	34.6±5.5
Male gender	56.8%	53.3%	40%	68.8%
Prior DC cardioversions	1.9±0.4	2.2±0.6	2.4±1.2	1.3±0.4
Hypertension	56.7%	46.7%	40%	68.8%
Hyperlipidemia	29.7%	26.7%	0%	37.5%
Coronary artery disease	16.2%	20%	40%	6.3%
Systolic CHF*	24.3%	13.3%	20%	31.3%
OSA (% on CPAP)	29.7% (18.9%)	33.3% (20%)	20% (0%)	31.2% (18.8%)
Stroke/TIA	5.4%	6.7%	20%	0%
Diabetes	13.5%	13.3%	0%	18.8%
COPD	5.4%	6.7%	12.5%	6.3%
Cigarette use (% active)	16.2% (10.8%)	6.7% (6.7%)	20% (20%)	25% (18.8%)

Thyroid disease	8.1%	13.3%	20%	0%
Hypertrophic/HOCM	5.4%	13.3%	0%	0%
Left atrial LGE (%)	18.1±2.4	18.1±5.4	21.0±17.5	17.3±3.8
AF ablation type:				
Cryocatheter PVI only	34.2%	26.7%	40%	25%
Cryocatheter PVI + RF SM	5.4%	6.7%	0%	6.3%
RF PVI only	15.8%	26.7%	0%	18.8%
RF PVI + SM	42.1%	40%	40%	50%
Surgical Cox-MAZE	2.6%	0%	20%	0%

Table 4.1. **Patient characteristics in PsAF cohort.** Continuous normally distributed variables were reported as mean ± 95%; continuous non-normally distributed variables include age, BMI, and prior DC cardioversions and are reported as median (IQR). For binary variables, proportions were reported. BMI, body mass index, CHF, congestive heart failure, COPD, chronic obstructive pulmonary disease, CPAP, continuous positive airway pressure, DC, direct current, HOCM, hypertrophic obstructive cardiomyopathy, LGE, late gadolinium enhancement, OSAH, obstructive sleep apnea, PVI, pulmonary vein isolation, RF, radiofrequency, SM, substrate modification, TIA, transient ischemic attack.

4.4 Arrhythmia Induction and Substrate Quantification

We show examples of pre-ablation and post- ablation models in **Figure 4.1A**. Fibrotic regions that were not rendered completely non-conductive by ablation scar were defined as ResF. Rapid electrical stimulation induced reentrant arrhythmias in 21/37 (57%) of pre-ablation models and 27/37 (73%) of post-ablation models (p=0.14). Examples of simulated FRs and ARs in pre-ablation and post-ablation models are shown in **Figures 4.1B** and **4.1C**, respectively.



Figure 4.1 Pre- and post-ablation models with examples of FR- and AR-perpetuated simulated arrhythmia. (A) Pre-ablation LA models derived from LGE-MRI and post-ablation models with LGE-MRI-derived scar. Post-ablation scar was overlaid upon pre-ablation fibrosis to achieve the final post-ablation model. (B) Examples of FRs in both pre- and post-ablation models. (C) Examples of ARs in pre- and post-ablation models.

To explore the independent propensities of ResF and ablation-induced scar for sustaining reentrant activity in post-ablation models, we analyzed these substrate properties with respect to model inducibility. ResF burden in post-ablation models was significantly higher in inducible vs. non-inducible models (**Figure 4.2A**, $p=8.376x10^{-5}$). However, the absolute burden of ablation scar did not differ between inducible and non-inducible post-ablation models (**Figure 4.2B**, p=1). We then investigated the associations of the different types of post-ablation substrate (i.e., either ResF or scar) in sustaining specific arrhythmia sub-types (ARs vs. FRs). As the amount of ResF increased, the number of unique AR and FR morphologies also significantly increased (**Figure 4.2C**; ARs: p=0.0003, R=0.56; FRs: p=<0.0001, R=0.65). However, there were no significant associations between total ablation scar burden and either ARs or FRs (**Figure 4.2D**; ARs: P=0.93, R=0.015; FRs: p=0.2, R=0.22).



Figure 4.2 Analysis of the effect substrate burden on model inducibility. (A) Boxplot of ResF percentage in post-ablation models with respect to model inducibility (Non-Inducible: N=10, median8.15±6.15; Inducible: N=27, median: 16.6±8.2; $p=8.376x10^{-5}$). (B) Boxplot of ablation-induced scar percentage with respect to model inducibility (Non-Inducible: 13.1±11.325; Inducible: 14.6±7.05; p=1). (C) Correlation plot of ResF vs. number of unique ARs and FRs (ARs: R=0.56, P=0.0003; FRs: R=0.65, P<0.0001). (D) Correlation plot of ablation-induced scar vs number of unique ARs and FRs (ARs: R=0.015, P=0.93; FRs: R=0.22, P=0.2).

When pre- and post-ablation models were compared, there was no significant difference in the combined number of FRs and ARs (**Figure 4.3A**, p=0.9569). By distinguishing between FR- and AR-mediated drivers, we uncovered potential differences in the capacity of substrate in pre- vs. post-ablation to preferentially sustain one type of arrhythmia driver. A significant difference was evident in both cases. Post-ablation models had significantly more ARs than pre-ablation models (**Figure 4.3B**, P=0.0003) and pre-ablation models had significantly more unique FR sites than post-ablation models (**Figure 4.3C**, P=0.0068).



Figure 4.3. Summary of pre- and post-ablation simulation outcomes. (A) Boxplot of the total number of combined unique ARs and FRs in pre- and post-ablation models (Pre-ablation median: 2±2; post-ablation median: 2±2; p=0.9569). (B) Boxplot of the number of unique ARs in pre- vs. post-ablation models (Pre-ablation: 1±1; post-ablation median 1±1: p=0.0003). (C) Boxplot of the number of unique FRs in pre- vs. post-ablation models (Pre-ablation: 1±1; post-ablation: 0±1; p=0.0068).

4.5 Explainable prediction of scar capable of sustaining reentrant arrhythmia drivers

We augmented the set of simulations discussed above by running additional post-ablation simulations with a wider range of conduction velocity values to account for potential inter-patient variability and potential ablation-induced effects on conduction velocity in non-ablated tissue. We observed more arrhythmogenic non-conductive tissue clusters when accounting for additional conduction velocity values (**Figure 4.4**).

Patient	80% CV		90% CV		Baseline CV		110% CV		120% CV	
	FRs	MRs	FRs	MRs	FRs	MRs	FRs	MRs	FRs	MRs
1	0	0	0	0	0	0	0	0	0	0
2	3	2	1	3	0	2	0	1	0	1
3	0	0	0	0	0	1	0	0	0	0
4	0	4	0	3	0	1	0	2	0	2
5	1	0	0	0	0	0	1	0	0	0
6	0	0	0	0	0	0	0	0	0	0
7	0	2	0	2	0	2	0	2	0	1
8	2	1	1	3	1	1	1	3	1	1
9	2	1	1	2	0	1	0	1	0	1
10	2	1	1	1	2	2	0	1	0	1
11	0	1	0	0	0	0	0	0	0	0
12	1	2	2	0	0	1	0	0	0	0
13	2	2	4	3	3	2	2	1	1	1
14	1	0	0	0	0	0	0	0	0	0
15	0	0	0	0	0	1	0	0	0	0
16	0	0	0	0	0	0	0	0	0	0
17	1	1	0	3	0	1	1	0	1	0
18	0	1	0	1	0	1	0	0	1	0
19	5	0	1	1	1	1	2	0	3	0
20	0	2	0	1	0	1	0	1	0	1
21	2	2	3	3	2	3	1	2	0	3
22	1	2	2	3	1	3	0	2	0	0
23	1	3	2	1	0	2	2	2	0	1
24	3	1	3	1	3	1	4	0	2	1
25	0	2	0	4	0	3	0	2	0	3
26	1	2	1	2	0	1	0	1	1	1
27	0	3	1	1	0	2	0	1	0	1
28	0	2	0	3	0	3	0	2	0	3
29	0	0	0	0	0	0	0	0	0	0
30	0	0	0	0	0	0	0	0	0	0
31	1	5	1	4	1	2	1	4	1	1
32	1	2	1	3	1	1	1	2	1	0
33	0	0	0	0	0	0	0	0	0	0
34	1	6	0	5	2	1	0	2	0	4
35	0	1	0	0	0	0	0	0	0	0
36	1	3	1	3	1	2	0	2	0	1
37	1	1	1	2	0	1	0	1	0	1

Indicates presence of unique FR or MR absent in baseline simulations

Figure 4.4. Overview of additional simulation sets. Each column of FRs and ARs corresponds to the number of unique driver morphologies for each simulation set in post-ablation models. CV, conduction velocity.

As such, our random forest (RdF) machine learning classifier was exposed to 633 non-conductive tissue morphologies. Of these 633 morphologies, 90 were labeled as arrhythmogenic since they sustained ARs in post-ablation simulations. We examined the spatial features of each non-conductive tissue morphology (area, perimeter, surrounding ResF percentage, and proximity index; see schematic illustrations in **Figure 4.5A**). For each non-conductive tissue morphology, the corresponding spatial features were inputted into an RdF algorithm. Our classifier was successful in predicting the likelihood of harboring an AR (**Figure 4.5B;** mean testing area under the curve (AUC): 0.91 ± 0.03). AUC values in each data partition (i.e., ROC fold) ranged from 0.83 to 0.95. **Figure 4.5C** shows the relative importance, extracted via the SHAP method, of learned spatial features in deciding to classify the tissue as

arrhythmogenic or non-arrhythmogenic. The most important feature was non-conductive tissue perimeter, while proximity index had the lowest predictive power.



Figure 4.5 Summary of non-conductive tissue arrhythmogenicity RdF prediction algorithm. (A) Feature extraction for a potentially arrhythmogenic non-conductive tissue region, including the area, perimeter, surrounding fibrosis, and proximity to nearest non-conductive tissue. (B) Receiver operating characteristic curve for 10-fold cross validation RdF prediction algorithm. (C) Bar graph of spatial feature importance.

Figure 4.6 shows the prediction breakdown for five different non-conductive tissue clusters with respect to each of the four spatial features. The arrow associated with each spatial feature points in the direction of its prediction (i.e., arrhythmogenic or non-arrhythmogenic) with arrow size indicating the strength of the feature's influence. **Figure 4.6A** shows a correct, non-arrhythmogenic prediction for a small scar region resulting from ablation (area: 0.16 cm^2;

perimeter: 3.35 cm) with 21.9% ResF. While the scar's associated proximity index provided a slight positive pressure, there was a net negative influence resulting from low area, perimeter, and surrounding ResF characteristics. **Figure 4.6B** shows an arrhythmogenic prediction for a mitral valve that promoted flutter-like activity in simulations. This prediction was primarily driven by large positive forces corresponding to the valve's size (area: 9.57 cm^2; perimeter: 17.54 cm). **Figure 4.6C** shows the prediction for a non-arrhythmogenic scar spanning the posterior wall. The scar's size (area: 21.94 cm^2; perimeter: 80.94 cm) was the leading driver in the algorithm's accurate prediction. For cases **4.6D** and **4.6E**, the algorithm's classification of arrhythmogenic was correct, yet the decision was borderline. **Figure 4.6D** shows a case where size promoted arrhythmic activity (area: 4.03cm^2; perimeter: 16.52cm), but low ResF (7.9%) resulted in two opposing predictive indicators. **Figure 4.6E** shows another uncertain decision where high surrounding ResF (59.16%) provided a considerable predictor of arrhythmogenicity, while smaller size (area: 0.48 cm^2; perimeter: 5.22 cm) resulted in non-arrhythmogenic predictors.



Figure 4.6. Explainability analysis of RdF for predicting arrhythmogenicity from scar spatial attributes. Grey outline indicates model prediction. (A) Explanation of a correct non-arrhythmogenic prediction for an ablation-delivered scar. SHAP values: Area: −0.0434; Perimeter: −0.0740; Surrounding ResF: −0.0147; Proximity Index: 0.0032. (B) Explanation of a correct prediction for an arrhythmogenic mitral valve. SHAP values: Area: 0.163; Perimeter: 0.260; Surrounding ResF: 0.113; Proximity Index: 0.002. (C) Explanation of a correct non-arrhythmogenic prediction for a large non-conductive tissue region. SHAP values: Area: −0.0462; Perimeter: −0.0119; Surrounding ResF: −0.0195; Proximity Index: −0.0122. (D) Explanation of a correct prediction for an arrhythmogenic ablation-delivered scar. SHAP values: Area: 0.081; Perimeter: 0.158; Surrounding ResF: −0.192; Proximity Index: −0.009. (E) Explanation of a correct arrhythmogenic prediction for an ablation-delivered scar. SHAP values: Area: −0.0913; Perimeter: −0.0582; Surrounding ResF: 0.144; Proximity Index: 0.0113.

To further probe each feature's influence, we plotted raw feature values against SHAP values corresponding to feature importance (**Figure 4.7**). We identified an intermediate range of the perimeter and area features (perimeter: ~15 to 60 cm and area: ~2 to 20 cm^2) for which the corresponding non-conductive tissue cluster was highly likely to be arrhythmogenic (**Figure 4.7A and 4.7B**). Non-conductive tissue with sizes below these ranges have a sharp falloff, with smaller cluster perimeter/area indicating decreasing likelihood of arrhythmogenicity. For larger non-conductive tissue regions, there was a gradual falloff culminating in SHAP values predictive of non-arrhythmogenicity. Furthermore, as the amount of fibrosis surrounding non-conductive tissue increased, the likelihood of potentially arrhythmogenic substrate also increased linearly (**Figure 4.7C**). There was no significant distinctive relationship identified relating scar proximity to arrhythmogenicity (**Figure 4.7D**). Overall, our analysis suggests that scars with a specific size (perimeter: ~15 to 60 cm and area: ~2 to 20 cm^2), and juxtaposition to ResF are key in harboring arrhythmic activity in post-ablation models of PsAF patients.



Figure 4.7. Dependence plots of SHAP importance value vs. raw feature value. (A) Dependence plot for perimeter. (B) Dependence plot for area. (C) Dependence plot of surrounding ResF percentage. Trendline equation: y=0.3304x-0.0759; R^2=0.6502. (D) Dependence plot for proximity index. Trendline equation: y=-0.000008x+0.0035; R^2=0.0.0349.

To highlight areas of potentially arrhythmogenic and non-arrhythmogenic non-conductive tissue, we show six unique models each with patient specific ResF and scar distributions. **Figure 4.8A** depicts a region of ablated tissue on the posterior wall with elevated surrounding ResF (69.4%) and within the susceptible size range (area: 4.34cm^2; perimeter: 19.59cm). This scar promoted AR in post-ablation simulations. **Figure 4.8B** depicts an ablation-delivered scar continuous with the right superior pulmonary vein, yielding tissue with sufficient perimeter and area to sustain reentry. In **Figure 4.8C**, we show a mitral valve that was arrhythmogenic in simulations. Despite

lower surrounding ResF (24.32%), the valve was within the ideal size range for arrhythmia susceptibility. None of the purple highlighted regions were capable of sustaining arrhythmias from a multitude of common AFib trigger locations (**Figure 4.8D-F**). **Figure 4.8D** depicts a right inferior pulmonary vein non-arrhythmogenic in simulations. **Figure 4.8E** shows a case of a small (area 0.22cm^2; perimeter: 2.6cm), isolated scar cluster. Finally, **Figure 4.8F** shows a large (area: 53.1cm^2; perimeter: 141.72cm) scar.



Figure 4.8. Scar patterns with and without post-ablation simulated recurrence sites. Green outlines indicate tissue that sustained an AR in post-ablation simulations. Purple outlines indicate tissue that did not sustain ARs in post-ablation simulations. (A) Scar on the posterior wall with an area of 4.34cm^2, a perimeter of 19.59cm, and 64.9% surrounding ResF. (B) Right superior pulmonary vein contiguous with scar yielding a total perimeter of 25.64cm, and area of 7.35cm^2 and 20.0% surrounding ResF (C) Reentrant activity around the mitral valve, with a perimeter of 18.00cm, area of 9.79cm^2 and 24.32% surrounding ResF. (D) Right inferior pulmonary vein with a perimeter of 7.56cm, area of 1.88cm^2 and 0.00% surrounding ResF (E) Non-arrhythmogenic ablation-delivered scar on the posterior wall with a perimeter of 2.6cm, area of 0.22cm^2 and 16.2% surrounding ResF. (F) Scar on the posterior LA with a perimeter of 141.72cm, area of 53.1cm^2 and surrounding ResF of 23.14% unable to sustain a simulated arrhythmia.

4.6 Further Discussion

This computational modeling study used a novel representation of post-ablation PsAF substrate, combining LGE-MRI derived pre-ablation native fibrosis with ablation-induced scar. In 37 PsAF LA models, we investigated the emergent effects of two post-ablation substrates (i.e., ResF and ablation-induced scar). We showed that PsAF ablation may transform substrate that favors FR perpetuation into one that is more conducive to ARs. We also demonstrated that spatial properties of non-conductive tissue areas, particularly area, perimeter, and proximity to fibrosis, are predictive of AR-prone substrate in post-ablation models. This study analyzes the combined effects of ResF and ablation-delivered scar quantified via LGE-MRI to provide insights on potential mechanisms of recurrent arrhythmia in PsAF patients.

4.4.1 Relationship between PsAF substrate characteristics and model inducibility

Given high recurrence rates of catheter ablation for PsAF (150), it is essential to elucidate potential recurrence mechanisms. Prior simulation-based work suggests post-ablation arrhythmia episodes may be perpetuated by emergent FRs, preserved FRs, or AR circuits around ablation-lesions (99, 130). Our work builds on these studies via incorporation of image-derived ablation lesions achieved by characterization of native fibrosis in pre-ablation scans, then superimposition of post-ablation enhanced tissue as non-conductive scar. This aspect of our study is key, as it allows us to investigate consequences of incomplete PVI ablation lesions and untargeted fibrosis (i.e., ResF) with respect to AR and FR perpetuation.

We first investigated the individual contribution of ResF and ablation-induced scar to the incidence of each reentry mechanism (i.e., AR and FR). In this study, total ablation scar burden did not influence the incidence of post-ablation ARs and FRs. This offers a potential explanation for failure of PVI with additional substrate modification to show superiority over stand-alone PVI (158), as our results show that additional scar has no correlative relationship with either post-ablation reentrant mechanism. In contrast, extent of ResF was a significant modulator of post-

ablation model inducibility. This finding is consistent with clinical data indicating that elevated pre- and post-procedural fibrosis is a strong predictor of recurrent arrhythmia (50, 159). The DECAAF-II trial assessed targeting MRI-identified fibrotic regions in addition to PVI in persistent AF patients and did not show an improvement in arrhythmia recurrence outcomes (153). While this approach is aimed at reducing residual fibrosis, further analysis is needed into whether reduction in residual fibrosis was actually achieved and how this impacted the observed results.

We then compared mechanisms of simulated arrhythmia in pre- and post-ablation models. Pre-ablation substrate consisting exclusively of native fibrosis was more likely to perpetuate FRs. Conversely, in post-ablation models, synergistic interaction between ResF and ablation lesions reduced the incidence of FRs and favored AR initiation. This suggests that ablation in PsAF patients might transform the substrate from one that perpetuates primarily FRs to one that favors ARs. Clinically, atypical flutters sustained by AR drivers can be common after PVI, affecting up to 10% of patients following RF ablation (160-163). Thus, our study provides reasonable explanation for the incidence of these tachyarrhythmias via anatomically AR around the mitral valve. The remaining 90% of recurrent AFib cases may be attributed to emergent or preserved FRs, as previously suggested (99). In this study, we observed both types of FR-driven arrhythmias in post-ablation simulations. However, another possibility stems from the remainder of ARs (i.e., ablation-delivered scar AR and anatomically AR around veins). The clinical manifestation of these types of simulated activity is not well-characterized. As such, some AR morphologies from our study may present clinically as AFib-like activity, particularly those with small reentrant path-lengths allowing for wave break and chaotic activity in the periphery (see Chapter 4). Nevertheless, there exists a pattern of arrhythmogenic post-ablation substrate that should be further characterized due to its potential role in recurrent arrhythmias.

4.4.2 Machine learning to identify pro-arrhythmic post-ablation substrate

We picked intuitive features based on prior knowledge to train an RdF machine learning model to identify arrhythmogenic regions in the post-ablation substrate. There is some evidence that using inductive features chosen by an algorithm (i.e., unsupervised machine learning) may increase predictive capability (103). However, rather than trying to optimize the predictive capability of our algorithm, our goal was to maximize its clinical usefulness and interpretability (164). We included size (i.e., area and perimeter) of a non-conductive tissue cluster as a feature since large, contiguous scars are associated with better clinical outcomes (165). We also examined the percentage of ResF surrounding a non-conductive tissue region, since ResF was a key factor in post-ablation model inducibility in this study and others (50). The concept of an isthmus as a complex structure with entrances and exits capable of sustaining arrhythmias has been explored through the lens of ventricular tachycardias (166, 167) and to some extent anatomically in the atria as having an important role in atrial flutter (168, 169). As such, the last feature we included in our predictive model was the distance to the nearest neighboring non-conductive tissue region, or proximity index score. Combining all of these features, we devised an RdF algorithm highly capable of predicting non-conductive tissue regions that would be arrhythmogenic in post-ablation simulations.

A key aspect of this work is the explainability of our algorithm, meaning the results of our prediction with respect to the contribution of each input feature are easily interpretable. Machine learning has a variety of applications, including in electrophysiology (170-172). Unfortunately, due to valid logistic concerns in hospital adoption and algorithmic biases, there are calls for improved interpretability of machine learning findings (173-175). By measuring the importance of each feature in our model and relating it to the original feature value, we can unveil the so-called “black box” and quantify our findings beyond merely characterizing predictive power. We

specifically chose RdF learning as it allows for greater algorithmic transparency, since raw feature values are not altered during the learning process.

4.4.3 Analysis of potentially arrhythmogenic non-conductive tissue regions

Application of SHAP analysis revealed non-conductive tissue perimeter as the most influential feature in predicting arrhythmogenicity, followed closely by tissue area and amount of surrounding ResF. The perimeter and area features are associated with a “Goldilocks principle”, whereby non-conductive areas with values that are too small or too large were much less likely to be associated with AR perpetuation. Mitral valve annuli commonly had values that fell in the arrhythmogenic perimeter and area ranges (64% of post-ablation models), providing a potential explanation for the prevalence of atypical flutter following catheter ablation (176). Our findings also suggest that higher surrounding ResF is predictive of non-conductive tissue regions prone to sustaining AR. We surmise that this increased propensity for reentry arises from reduced cardiac wavelength in fibrotic tissue, which has been shown to be associated with the presence of both AR and FR reentrant mechanisms (177). The distance to the nearest neighboring non-conductive tissue, our surrogate measurement for presence of an isthmus, was not a strong driver of RdF decision-making.

Thus, our algorithm suggests there are two key constituents for arrhythmogenic post-ablation substrate: ideal non-conductive tissue size and high surrounding ResF. Our algorithm suggests that if both components are present, a potent arrhythmogenic substrate exists. If only one of two components are present, there is still a possibility for arrhythmogenic substrate, albeit potentially only under certain conditions not assessed in this study. These findings implore caution during ablation procedures as lesions in proximity to native fibrosis and non-contiguous lesions may lead to adverse ablation outcomes. Our explainable machine learning classifier suggests that non-arrhythmogenic post-ablation substrate patterns are generally characterized by contiguous non-conductive regions free of surrounding ResF.

4.7 Clinical Perspective

The knowledge revealed by this study regarding links between the arrhythmogenicity of post-ablation substrate and spatial features of ablation lesions has implications for clinical strategies to treat PsAF in patients. Like previous computational work, which identified fibrotic spatial fibrosis patterns that favor FR localization (40), our work characterizes how AR localization is modulated by synergistic interaction between ablation lesion size/location, distribution of non-ablated native fibrosis, and left atrial geometry. Our work indicates that the most effective ablation-induced scars are ones which are small (area < 2 cm^2; perimeter < 15 cm) or large (area > 20 cm^2; perimeter > 60 cm). Regardless of size, ablation lesions or anatomical structures with minimal surrounding fibrosis are less likely to be arrhythmogenic. Many prior studies have suggested confirmation of durable, continuous ablation lesions as they lead to better outcomes in patients (165, 178-180) likely due to a reduction of potential arrhythmogenic trigger sites. We suspect that ablation success in the context of complete lesion formation may also be attributable to the presence of post-ablation substrate too large to sustain reentry. We also speculate that ablation procedures without suitable lesion formation may result in unintended, isolated scar clusters which may serve as substrate for recurrent arrhythmias. This is a potential mechanism for recurrent arrhythmia following PVI beyond inadequately isolated focal sources. It is also conceivable that these susceptible spatial locations could be a key target for repeat ablation, as identified by standardized fibrosis identification methods.

4.8 Limitations

We studied a homogenous cohort of PsAF patients, allowing us to retrospectively examine how ablation alters the substrate's propensity for AFib. As such, these findings may not apply to those with paroxysmal AFib. Several studies have also reported that other factors influence the dynamics of AFib, including heterogeneity of wall thickness (181, 182), endo-epicardial dissociation (183), and complex micro-structures (184). Our study is primarily concerned with

the relationship between the interplay of the macroscopic patient-specific distribution of fibrotic tissue and ablation-delivered lesions. We emphasize that the emergent arrhythmia dynamics may interact with other factors to give rise to the complex behavior of AFib, particularly in a post-ablation milieu. Additionally, limitations in the methodological dependency of fibrosis assessment by LGE-MRI implore caution during interpretation of fibrosis extent and spatial pattern (185).

We also recognize that a limitation of this study is the inability to include clinical electrocardiographic imaging or electroanatomical mapping as inputs to our machine learning algorithm to obtain a multi-faceted view of potential arrhythmogenic substrate. Future work could pursue using this technique to further investigate potentially pro-arrhythmic post-ablation substrate. Furthermore, with respect to ablation-delivered scar-anchored reentries, cardiac mapping tools are needed to characterize the clinical behavior of this reentry. Prior work in has shown reasonable correlation between predictions from pre-ablation computational modeling and measurements from intracardiac mapping or electrocardiographic imaging (41, 42). We expect that the addition of post-ablation scar to these models would not greatly diminish their predictive power. Nevertheless, future work should prioritize correlating the characteristics of post-ablation arrhythmogenic substrate with recurrent arrhythmias seen in PsAF patients.

4.9 Conclusions

Simulations suggest that ablation in PsAF patients can transform the left atrial fibrotic substrate from one that primarily harbors FRs into a milieu that heavily favors ARs. Our results show significantly more AR activity (i.e., activity sustained by a pulmonary vein, mitral valve, or ablation lesion) in post-ablation models, which is correlated with increased ResF and independent of total scar burden. Using an explainable RdF machine learning algorithm, we identified the spatial attributes of non-conductive regions that are most likely to perpetuate AR in post-ablation models (intermediate perimeter/area and surrounding ResF). Future work should

aim to clinically validate these findings by interrogating post-ablation mapping data for recurrent arrhythmias in regions of susceptible non-conductive tissue identified by LGE-MRI. Overall, these results provide important insights into the combined role of fibrosis and ablation-induced scar in post-ablation recurrent arrhythmias.

4.10 Methods and Data Availability

Patient Population and MRI Acquisition

The population considered in this study was drawn retrospectively from an established database of patients with clinically diagnosed PsAF (157) who were previously recruited to undergo cardiac LGE-MRI at the University of Washington (Seattle, WA). Institutional Review Board approval was secured (protocol #HSD 8763) as part of the UW Cardiac Arrhythmia Data Repository. Inclusion criteria were PsAF at time of initial visit and availability of pre- and post-ablation LGE-MRI. Patients with prior AFib ablation were excluded. All 37 patients underwent PVI, and some (19/37) had additional substrate modification outside of the pulmonary veins. Using previously described protocols (27), cardiac LGE-MRIs were obtained in all participants up to 2 months before ablation and again 3-6 months following ablation to quantify the extent of LA fibrosis and scar, respectively. MRI scans were performed in patients in sinus rhythm or AFib with controlled ventricular rate to reduce potential imaging artifacts (186). We excluded AFib patients who had previous catheter ablation, cardiac implantable electronic devices, severe claustrophobia, renal dysfunction, and other contraindications to MRI or gadolinium-based contrast. Scans were performed on Philips Ingenia clinical scanners, 15–25 min after contrast injection, using a 3D inversion-recovery, respiration-navigated, ECG-gated, gradient echo pulse sequence. Acquisition parameters included transverse imaging volume with a voxel size of 1.25 × 1.25 × 2.5 mm (reconstructed to 0.625 × 0.625 × 1.25 mm).

Reconstruction of patient-specific LA models

Geometric models were reconstructed by Merisight Inc (Salt Lake City, UT) from the pre-ablation LGE-MRI and the extent of fibrosis in the LA was quantified via an adaptive histogram thresholding algorithm (138). In post-ablation models, ablation scar geometry on post-ablation LGE-MRI was identified using previously established methods. Briefly, for both pre- and post-ablation scans, an enhancement intensity threshold typically ~2 standard deviations from the mean value was applied (86). This methodology accounts for the fact that hyperenhancement from ablation-induced scar is brighter than that from fibrosis. Thus, regions labeled as fibrotic pre-ablation fall below the hyperenhancement threshold in post-procedure scans. We used non-rigid registration to map LGE-derived post-ablation non-conductive scar patterns onto pre-ablation models including native fibrosis. Hyper-enhancement on post-ablation scans coinciding with regions labeled as fibrotic in the pre-ablation scan were considered non-conductive scar. Fibrosis percentage was calculated for each model by dividing the sum of the surface area of each fibrotic element by the total surface area of the myocardium of the LA (i.e., excluding vein/valve surface area). Each LA model was represented as a bilayer comprising of nested endocardial and epicardial shells, linked at every point by linear connections (135), as in previous work (119). Realistic myocardial fiber orientations were mapped from an atlas geometry using universal atrial coordinates (140).

Modeling of Atrial Electrophysiology

Our methodology for computational modeling at the cell and tissue scale of the fibrotic and non-fibrotic atrial electrophysiology can be found in previously published papers (40-42). Briefly, a human atrial action potential model (56) was used to represent membrane kinetics in non-fibrotic myocardium, with the addition of parameter modifications to fit clinical monophasic action potential recordings from AFib patients (40, 142) (I_{Kur}, Ito, I_{CaL} decreased by 50%, 50%, 70%, respectively). In fibrotic regions, further action potential modifications were implemented (I_{CaL}, I_{Na}, and I_{K1} decreased by 50%, 40%, 50%, respectively) to represent elevated transforming

growth factor-β (187), as in prior studies (40, 119, 130). At the tissue scale, we applied conductivity tensor values of $\sigma_L = 0.409\ S\ m^{-1}$ the longitudinal direction and $\sigma_T = 0.0820\ S\ m^{-1}$ in the transverse, as in our previous study (119). These conductivity tensor values correspond to physiologically realistic conduction velocity values of 71.49 and 37.14 cm s^{-1} (longitudinal and transverse) (143-145). In fibrotic tissue, the overall conductivity was reduced, and the anisotropy ratio was exaggerated from 5:1 to 8:1 ($\sigma_L = 0.177\ S\ m^{-1}$; $\sigma_T = 0.0221\ S\ m^{-1}$) to represent the effects of interstitial fibrosis and gap junction remodeling (33, 40, 188). Prior work has suggested that conduction velocity, fibrosis representation, and action potential duration can markedly affect driver localization dynamics (73, 104, 131). Thus, to ensure the set of potential driver sites produced by our analysis was fairly comprehensive in this manner, we repeated all simulations in post-ablation models with four additional conductivity sets, chosen to increase/decrease conduction velocity by ±10% or ±20% (**Figure 4.4**).

Simulation Protocol and Analysis

Propagation of electrical activity was simulated by solving the monodomain formulation using the finite element method. All simulations were performed on the University of Washington Hyak supercomputer system using the openCARP environment for cardiac electrophysiology modeling (76), which is freely available for academic use (see: https://openCarp.org).

In pre- and post-ablation versions of each model, virtual pacing was applied from fifteen LA sites representing common AFib trigger areas (7) to assess arrhythmia driver inducibility. The pacing protocol for AFib induction can be found in previous publications (40, 119). We ran a total of 555 (37 models x 15 sites) pre-ablation simulations and 2775 post-ablation simulations (37 models × 15 pacing sites × 5 conduction velocity settings), with a post-pacing interval of 5.5s. After pacing ceased, electrophysiologic activity was extinguished spontaneously unless a reentrant driver perpetuated conduction. Each induced episode of arrhythmia was manually sub-classified as either FR or AR (interobserver agreement >96%). FR was defined by an electrical wavefront

conducting in a spiral fashion, making at least two revolutions, and typically occurring at the border zone between fibrotic and non-fibrotic tissue. AR was defined by an electrical wavefront sustained in some measure by a non-conducting region (i.e., one or more pulmonary vein ostia; mitral valve annulus; area of ablation-induced scar). We infrequently observed "hybrid" arrhythmias involving reentrant paths with both functional and anchored components (see Chapter 4). We classified these as AR due to the dependency on non-conductive tissue. As in prior studies (40, 101, 119), in regions distal to the primary driver (FR or AR) we observed bystander conduction slowing and wavefront pivoting that was transient in nature (i.e., in the absence of the primary driver, the auxiliary activity might not sustain the arrhythmia). An example is shown in Chapter 4. Prior work has demonstrated that FR-sustained arrhythmias are more AFib-like because of their transient reentry, wave collisions, conduction blocks, and distal fibrillatory activity that resemble AFib in mapping studies (40). We classified anatomical AR around the mitral valve as mitral annular flutter. Yet, for other forms of AR (anatomically anchored around veins or ablation-induced scar-AR) the emergent clinical rhythm is unclear.



Figure 4.9. Edge cases for classification of simulated reentrant arrhythmias. (A) "Hybrid" reentrant activity, in which the wavefront includes both functional (purple; FR) and anchored (black; AR) components. Due to the essential involvement of non-conductive tissue, we classified examples like this

as AR. **(B)** Auxiliary FR-like activity (purple) in the periphery of an arrhythmia sustained by AR around the mitral valve (black).

Extraction of Non-Conductive Tissue Regions Spatial Features

Spatial features were extracted for all non-conductive tissue regions larger than 1mm^2 in area. Non-conductive tissues were defined as pulmonary vein ostia, mitral valve annuli, or ablation-derived scar. These non-conductive tissue clusters were designated as independent entities unless they shared a common edge with a neighboring scar, vein, or valve in which case the two entities were combined into one cluster.

The area of each non-conductive tissue cluster was defined as the surface area of all ablation-induced scar and vein/valve tissue in that cluster. To account for the arbitrary nature of pulmonary vein segmentation, in which some veins are truncated further down the ostium than others, we eliminated the pulmonary vein ostia altogether and replaced it with a flat cap (**Figure 4.10**) for spatial feature calculations. Perimeter was determined by adding up the lengths of the outer edges of each non-conductive tissue cluster. The extent of fibrosis surrounding each non-conductive cluster was determined by iteratively adding layers of finite elements (average edge length: 188μm) at the periphery; 50 iterations of region growing resulted in a ~1 cm-wide neighborhood. Within this periphery, we calculated the percentage of total excitable tissue that was fibrotic (i.e., non-conductive tissue was not factored into the calculation). We used a similar approach to compute proximity index, defined as the number of element layers added to each cluster before encountering a distinct non-conductive region. We opted for this approach because it was more computationally efficient than calculating geodesic distance.



Figure 4.10. Example of flattened pulmonary vein ostia and mitral valve for area of non-conductive tissue calculation. Anterior (left) and posterior view (right).

Evaluation of Machine Learning Classifier

From the entire population of post-ablation simulations conducted, we selected the subset in which AR was induced and designated the corresponding non-conductive tissue region as pro-arrhythmic. All remaining non-conductive areas were labeled as non-arrhythmogenic. These data were used to train a supervised RdF classifier to recognize combinations of spatial features associated with the arrhythmogenic subset of non-conductive tissue morphologies. We used 10-fold stratified cross validation to minimize the possibility of predictive power being overestimated due to lucky initialization (189); this approach also ensured an equal distribution of arrhythmogenic and non-arrhythmogenic sites in the training and test sets. We used SHapley Additive exPlanations (SHAP) to probe feature importance in the RdF classifier; SHAP is a framework for interpreting algorithmic predictions that calculates the marginal contribution of every feature for each prediction (116, 117).

Statistical Analysis

Continuous variables were compared pairwise between groups using Wilcoxon rank-sum tests and were reported as median ± interquartile range (IQR). After classifying FRs and ARs,

correlation with fibrosis and scar burden was assessed with logistic regression. Statistical significance was established at two-tailed P≤0.05. All statistical analysis was performed using R (148).

Data availability

Where possible (Figures 3.2, 3.3, 3.4, 3.5, and 3.6), raw numerical data underlying figures are available via this figshare link**:** https://doi.org/10.6084/m9.figshare.23605671.v1. Patient-derived data in this article, including processed versions thereof, are not publicly available out of respect for the privacy of the patients involved. Interested parties wishing to obtain these data for non-commercial reuse should contact the author. Upon all reasonable requests for access to these data, the corresponding authors and I will work to pursue negotiation of a Data Transfer and Use Agreement with the requesting party, administrators at the requesting party's institution, the University of Washington, and relevant Institutional Review Boards. Source files for a complete example of computational modeling and simulation of the fibrotic atria, using publicly available data sets and software tools only, can be found via the following permanent link: https://figshare.com/articles/dataset/Computational_Modeling_Simulation_of_Atria_with_Fibrotic_Remodeling_-_Example/14347979. Documentation provided with this example includes instructions on the use of the openCARP cardiac electrophysiology simulator and the meshalyzer visualization software (both available via https://opencarp.org/) to precisely reproduce the computational protocol applied to patient-specific left atria models in this study. Code to reproduce the random forest machine learning and the associated SHAP explainability can be found at github: https://github.com/Sfbifulco/CardSSRFxML.

Chapter 5. Explainable Machine Learning for Cardiac Catheter Ablations: Identifying Risk Factors and Predicting Post-Ablation Recurrence

5.1 Abstract

It is challenging to distinguish patients at risk for recurrent arrhythmias from those who will remain arrhythmia free following ablation. New explainable machine learning (xML) techniques allow for systematic assessment of known risk factors for catheter ablation recurrence on population and patient specific strata. Our aim is to develop an xML algorithm that predicts arrhythmia recurrence and reveals key risk factors influencing model predictions to facilitate better treatment planning in ablation candidates. We reconstructed pre-and post-ablation models of LA from clinical LGE-MRI scans. Patient-specific features (LGE-MRI-based measurements of pre/post-ablation arrhythmogenic substrate, LA geometry metrics, and clinical risk factors from each patient's electronic health record) were extracted and used to train a random forest classifier to predict recurrent arrhythmia. We reported each risk factor's marginal contribution using SHapley Additive exPlanations (SHAP). Across 67 patients, the classifier was able to predict post-ablation arrhythmia recurrence (mean ROC AUC: 0.84 ± 0.08; mean PR AUC: 0.89 ± 0.08). SHAP analysis revealed that of 55 features tested, the key population risk factors for post-ablation recurrence were large LA volume, clinical characterization of persistent atrial fibrillation, and low lesion number assessed by post-ablation LGE-MRI. We also examined the predictions of recurrence for each patient. The explainable aspect of our approach allows us to understand why a particular patient can have large prediction weights for some categories without tipping the balance towards an incorrect prediction. We also validated our model in a retrospective internal testing cohort (12/15 [80%] correct predictions). This work presents a

comprehensive clinical tool to explain patient recurrence risk by combining patient-specific clinical profiles and LA LGE-MRI-derived data via an explainable classifier.



5.2 Introduction

Atrial fibrillation (AFib) is the most common cardiac arrhythmia, affecting 1-2% of the world's population and significantly contributing to morbidity and mortality (120). Catheter ablation by pulmonary vein isolation is an established rhythm control strategy and is the cornerstone of AFib ablation. However, this one-for-all method results in recurrent rhythms in ~20-40% of patients (150, 161). Differentiating patients at risk for recurrent rhythm from those who will remain arrhythmia-free following ablation poses a challenge. However, the development of a methodology that predicts recurrent arrhythmia following ablation in an explainable manner (i.e., explainable ML; xML), could provide valuable insights for ablation planning and decision-making, leading to improved outcomes in AFib patients.

Prior work has investigated potential mechanisms and risk factors associated with recurrent arrhythmia. These studies have considered clinical features such as hypertension (190), diabetes (191), cardiomyopathy (192), and smoking status (193). Left atrial (LA) models derived from late gadolinium enhanced magnetic resonance imaging (LGE-MRI) also offer a means to characterize potential arrhythmogenic substrate. These models have been leveraged to investigate fibrosis (40), ablation-delivered scar (99, 130), and LA shape characteristics (194, 195) as risk factors for recurrent arrhythmia. Integrating this rich multi-modal risk factor data for prediction of post-ablation recurrence is a potential avenue for generating a robust classifier and furthering our scientific understanding of recurrent arrhythmia.

Existing machine learning algorithms have leveraged various features such as pre-ablation LGE-MRI imaging data, patient-specific simulations, and electronic health record data to predict recurrent AFib (103, 104, 196, 197). Each study has found varying measures of success; however, these algorithms often lack robust explainability metrics to elucidate how input features influence the final decision, which can potentially hinder their clinical implementation (198). Moreover, the assessment of ablation-delivered scar, despite its significant impact on procedural outcomes (199, 200), has not yet been included in these algorithms.

In this proof-of-concept study, we aim to develop an xML recurrent arrhythmia prediction algorithm by combining risk factors of patient-specific fibrotic tissue, ablation-delivered scar, LA geometry metrics, and clinically relevant electronic health record data. The algorithm's output will report the likelihood of recurrence and the specific risk factors which are most influential in the algorithm's decision. These risk factors can be analyzed on a cohort-wide or patient-specific scale, offering important contextualization to the machine learning findings which can be further tested in randomized trials.

5.3 Results

In the training and validation cohort, 40/67 (59.7%) patients experienced recurrence of either AF (29/40; 72.5%) or atrial flutter (11/40; 27.5%) in the 2-year follow-up. 36/67 (53.7%) of patients underwent circumferential linear radiofrequency or cryoballoon ablation around the left and right pulmonary veins without additional substrate modification. The remaining 31/67 (46.3%) of patients had additional substrate modification via radiofrequency ablation. The median time to reported recurrence was 153 days. Mean follow-up time was two years.

	Recurrence	**No Recurrence**	**p-value**
N (%)	40	27	
Age (years)	65 (53-77)	59 (46-72)	0.4896
BMI	31.2 (20.4-42.0)	29.9(22.5-37.5)	0.9747
Sex (male)	60.0%	55.6%	0.7251
Hypertension	57.5%	59.3%	0.8929
Hyperlipidemia	37.5%	40.7%	0.7968
Coronary artery disease	20%	14.8%	0.5966
OSA	32.5%	33.3%	0.7091
Stroke/TIA	10.0%	3.7%	0.3469
Diabetes	10.0%	7.4%	0.7272
COPD	10.0%	0%	0.09566
Cigarette use	17.5%	18.5%	0.9233
Thyroid disease	15.0%	7.4%	0.6570
CHF	32.5%	22.2%	0.3679
Pre-Ablation left atrial LGE (%)	15.6% (11.48%-21.9%)	17.6% (8.95%-20.25%)	0.9033
AF ablation type:			
Cryo PVI only	35.0%	44.4%	0.4444
Cryo PVI + RF SM	5.0%	3.7%	0.8166
RF PVI only	17.5%	11.1%	0.4814
RF PVI + SM	42.5%	40.7%	0.8929

Table 5.1. Patient characteristics in training and testing cohort. Variables are reported as median (IQR). For binary variables, proportions were reported. BMI, body mass index, CHF, congestive heart failure, COPD, chronic obstructive pulmonary disease, LGE, late gadolinium enhancement, OSA, obstructive sleep apnea, PVI, pulmonary vein isolation, RF, radiofrequency, SM, substrate modification, TIA, transient ischemic attack.

A table of 57 features with sub-classifications of (1) clinical attributes, (2) left atrial geometry, (3) patient-specific fibrosis patterns and (4) patient-specific ablation-delivered scar patterns is provided **Table 5.2**. Simulation-derived features collected are outlined in **Table 5.3,** but due to a lack of improvement in prediction capability (AUC with simulation features: 0.82±0.08 [**Figure 5.1**] vs AUC without simulation features 0.84±0.08 [**Figure 5.3**], p=0.4116 (201)) coupled with a lack of clinical accessibility we opted to exclude these features to retain clinical usefulness.

Clinical Features	**Geometry Features**	**LGE-MRI Derived Fibrosis Features**	**LGE-MRI Derived Ablation-delivered Scar Features**
Ablation type (Cryoballoon/Radiofrequency)	Pre-Ablation LA Surface Area	Pre-ablation fibrosis SA	Post-ablation scar SA
Additional Ablation Lines	Pre-Ablation LA Volume	Pre-ablation fibrosis as a percentage of LA	Post-ablation scar as a percentage of LA
Age	Pre-Ablation LA Volume Index	Post-ablation fibrosis SA	Number of LGE-derived scar lesions
BMI	Post-Ablation LA Surface Area	Post-ablation fibrosis as a percentage of LA	Number of LGE-derived scar lesions with arrhythmogenic perimeters
Sex	Post-Ablation LA Volume	Pre-Ablation Average Fibrosis Density	Number of LGE-derived scar areas with high surrounding fibrosis
Symptom Class *(Range 1-4, depending on severity of symptoms)*	Post-Ablation LA Volume Index	Pre-Ablation Average Fibrosis Entropy	Post-Ablation Scar in each of the following regions: Atrial Floor; Anterior Wall; LPVs; RPVs; Posterior Wall.
Number of Direct Cardioversions		Post-Ablation Average Fibrosis Density	
Cardiomyopathy		Post-Ablation Average Fibrosis Entropy	
Coronary Artery Disease		Pre-Ablation Tissue % with high FE/FD	
Hypertension		Post-Ablation Tissue % with high FE/FD	
Congestive Heart Failure		Pre-Ablation Fibrosis in each of the following regions: Atrial Floor; Anterior Wall; LPVs;	

		RPVs; Posterior Wall	
Obstructive Sleep Apnea		Post-Ablation Fibrosis in each of the following regions: Atrial Floor; Anterior Wall; LPVs; RPVs; Posterior Wall.	
Stroke / Transient Ischemic Attack			
Diabetes			
Chronic Obstructive Pulmonary Disease			
Smoking			
Thyroid Disease			
Class I AAD usage			
Class II AAD usage			
Class III AAD usage			
Class IV AAD usage			

Table 5.2. List of all features prior to feature selection process. Features are grouped into three sections: clinical variables, geometry features, LGE-MRI derived fibrosis and ablation-delivered scar features.

Simulation Features
Number of macro-reentrant tachycardias in post-ablation simulations
Number of macro-reentrant tachycardias in pre-ablation simulations
Number of reentrant drivers in pre-ablation simulations
Number of reentrant drivers in post-ablation simulations
Number of inducible trigger sites in pre-ablation simulations
Number of inducible trigger sites in post-ablation simulations
Pre-ablation number of phase singularities
Post-ablation number of phase singularities
Pre-ablation number of unique phase singularities
Post-ablation number of unique phase singularities

Table 5.3. List of simulation features excluded from study.



Figure 5.1. ROC curve including simulation data.

Features were inputted into a least absolute shrinking and selection operator (LASSO) feature selection algorithm to both minimize the feature to outcome variable ratio and remove observed confounders (**Figure 5.2A).** At this step, we reduced the number of risk factors to 20. We then performed hierarchical SHAP-based cluster analysis to quantitatively assess variable confounding. When working with SHAP, direct assessment feature redundancy is possible through model loss comparisons rather than compute correlation matrices or other types of traditional clustering methods. In **Figure 5.2B**, we show a dendrogram which depicts the relationships between the features. We implemented a variable cutoff scheme to determine the

optimal set of features which maximized model performance and minimized potential variable confounding. Our optimal threshold removed features which share more than 70% of their explanation power (**Figure 5.2B**).



Figure 5.2. Feature selection process. (A) Five-fold cross validation of regularization to determine the optimal alpha parameter to use in LASSO feature selection algorithm. (B) Cluster analysis of features selected by LASSO. Red line indicates optimal cutoff value for which one of two features below this line were removed to account for observed confounders. The feature removed was chosen based on the lower SHAP importance value. Features in red were removed.

Our final list of features was inputted into a random forest algorithm with stratified 5-fold cross validation. The random forest algorithm was exposed to 40 recurrent AFib or atrial flutter cases, and 27 non-recurrent cases. Our classifier was successful in predicting the likelihood of recurrent arrhythmia (**Figure 5.3A**; mean receiver operating characteristic (ROC) testing area under the curve (AUC): 0.86 ± 0.08). AUC values in each data partition (i.e., ROC fold) ranged from 0.74 to 0.94. Our classifier had a balanced precision-recall score (**Figure 5.3B**; mean precision-recall (PR) AUC: 0.89 ± 0.08) with fold values ranging from 0.79 to 0.96.



Figure 5.3. Summarization of random forest prediction algorithm effectiveness in testing sets across five folds. (A) ROC for testing set (AUC: 0.84 ± 0.08). (B) Precision-Recall curve for testing set. (AUC: 0.89 ± 0.08).

Figure 5.4 shows the relative importance, extracted via the SHAP method, of the features in deciding to classify a patient as recurrent or non-recurrent. Features are sorted in decreasing order of importance. Each point on each feature row represents an individual patient, for which

we color-coded their feature value. Post-ablation left atrial volume index was the most important feature. Patients with a high post-ablation LA volume index were at risk for recurrent arrhythmia, while patients with low post-ablation LA volume indices were more likely to be arrhythmia free according to our algorithm. Furthermore, variables associated with the number of LGE-derived scar areas (i.e., contiguous, independent units of ablation-delivered scar) suggest that patients with a high number of these scar areas may be less likely to recur. **Figure 5.4** also suggests that patients with increased fibrosis in the left pulmonary vein region following ablation and high fibrosis in the posterior wall region prior to their ablation are more likely to experience a recurrent arrhythmia. There are many clinical variables which indicate higher risk of recurrent arrhythmias, including persistent AFib, a high number of prior direct current cardioversions (DCCVs), and cardiomyopathy. Age as a risk factor exhibits an interesting relationship with arrhythmia recurrence, which is explored further in the Discussion section. Finally, our algorithm suggests that patients with many clinical risk factors (i.e., have Cardiomyopathy, Stroke / TIA, COPD) are at risk for recurrent atrial fibrillation, yet patients without these characteristics have minimal pressure from that feature for the algorithm to suggest arrhythmia freedom. In other words, patients lacking these risk factors have SHAP values for these features very close to zero, thus exerting little influence on the model.



Figure 5.4. Summary of feature importance. Features are organized in descending feature importance order. Features are classified as either left atrial geometry (black), clinical attributes (blue), fibrosis (green), or ablation-delivered scar (orange). Red dots indicate patients with a high feature value for continuous variables, or presence of variable in binary cases. For other cases color meaning is indicated. The center line represents no impact on model outcome, while right-shifted data is indicative of recurrence and left-shifted data indicates non-recurrence. LPV, left pulmonary veins, DCCV, direct current cardioversion, AAD, anti-arrhythmic drug.

We can further characterize the relationship between feature value and impact on model output (i.e., SHAP value) by plotting these two variables against each other. We have chosen the top four continuous risk factors to highlight in **Figure 5.5**. The full range of features can be found in **Figure 5.6**. **Figure 5.5A** shows the S-shaped relationship between SHAP value and post-ablation left atrial volume index. The maximal change in slope occurs at ~51, with patients above this threshold having a high likelihood of recurrence. We fit an exponential decay model for the relationship between the number of LGE-derived scar areas and the model pressure (**Figure 5.5B**). Most patients received approximately 10-20 scar areas during their ablation.

Those who received more were more likely to have a favorable outcome, while those with less had a severe risk of recurrence according to our model. For the number of DCCVs, we identified a positive, linear relationship with increasing number of prior DCCVs pressuring our model to suggest recurrent arrhythmia (**Figure 5.5C**). Finally, we plotted a moving average filter to posterior wall fibrosis. In general, the model suggests that patients who have >3cm^2 residual fibrotic area in their left pulmonary veins have a marginal increased risk in our model (**Figure 5.5D**).



Figure 5.5. **Dependence plots of SHAP importance vs. raw feature value. (A)** Dependence plot for post-ablation LA volume index. y=0.305/(1+e^(-0.47*(x-50.786))-0.15. **(B)** Dependence plot for the number of scar clusters. Y=0.41*e^(-0.14x) – 0.06. **(C)** Dependence plot for DCCV number. y = 0.236x - 0.0337; R^2 = 0.7153. **(D)** Dependence plot for post-ablation fibrosis in the LPV region with moving average trendline.



Figure 5.6. Dependence plots for all features. (A) Dependence plot for AFib Type (Paroxysmal vs. Persistent AFib). (B) Dependence plot for pre-ablation fibrosis in the posterior wall region. (C) Dependence plot for post-ablation scar in the right pulmonary vein (RPV) region. (D) Dependence plot for Age. (E) Dependence plot for post-ablation scar in the anterior wall region. (F) Dependence plot for pre-ablation Class III anti-arrhythmic drugs (AADs). (G) Dependence plot for any cardiomyopathy. (H)

Dependence plot for discrete symptom severity (1-4). (I) Dependence plot for sex (male vs. female). (J) Dependence plot for pre-ablation class III AADs. (K) Dependence plot for stroke or transient ischemic attack (TIA). (L) Dependence plot for thyroid disease. (M) Dependence plot for smoking. (N) Dependence plot for chronic obstructive pulmonary disease (COPD).

By summing each SHAP value for each feature for each patient, we can achieve a patient specific arrhythmia recurrence prediction profile. **Figure 5.7** shows such a profile for three different patients, each correctly predicted by our algorithm. The arrow associated with each risk factor points in the direction of its prediction (i.e., recurrence or no recurrence) with arrow size indicating the strength of the feature's influence. **Figure 5.7A** shows a patient with a high probability of recurrence according to our model. The most important risk factors contributing to this decision were elevated post-ablation left atrial volume index and elevated fibrosis on the posterior wall. The use of class III anti-arrhythmic drugs acted as a predictor for non-recurrence for this patient. In this case, the classifier correctly assigned this patient who recurred with atrial flutter. **Figure 5.7B** shows a patient with a high likelihood of arrhythmia freedom following their procedure. This patient experienced no recurrence after 2 years of follow-up, and our xML algorithm correctly classified this patient based on decreased left atrial volume index and no prior direct current cardioversions. Finally, despite having an elevated left atrial volume index indicative of recurrence, our model suggested that the patient depicted in **Figure 5.7C** would not have a recurrent arrhythmia based off of features pertaining to the patient's substrate profile (low post ablation fibrosis in the left pulmonary vein region and a high amount of scar in the right pulmonary vein region). Indeed, this patient has not experienced a recurrent rhythm within the follow-up time.



Figure 5.7. Explanation of individual patient prediction scores. Grey outline indicates model prediction. (A) Visualization of pre- and post-ablation models and explanation of a correct recurrent arrhythmia prediction driven by geometry and substrate features. (B) Pre- and post-ablation models of patient and explanation of a correct non-recurrent arrhythmia prediction driven by geometry and clinical features. (C) Visualization of pre- and post-ablation patient-specific models and explanation of a correct non-recurrent arrhythmia prediction driven by pre- and post-ablation substrate features.

We performed a retrospective internal validation study with 15 patients to quantify model performance on previously unseen data. Patient characteristics of the internal testing cohort did not significantly differ from the training and validation cohort except in BMI (**Table 5.4**). The

recurrence rate between the two groups was similar (59.7% vs 53.3%) and the proportion of patients receiving each type of sub-classification of ablation type was similar. The median time to reported recurrence was 305 days; mean follow-up time was two years.

	Training and Validation Cohort	Internal Testing Cohort	p-value
N (%)	67	15	
Recurrence	59.7%	53.3%	0.658
Age (years)	62 (56-70)	70 (62-76)	0.1215
BMI	30.6 (26.4-35.8)	26.3 (23.1-31.7)	**0.0353**
Sex (male)	58.2%	40.0%	0.2054
Hypertension	58.2%	46.6%	0.4224
Hyperlipidemia	38.8%	60.0%	0.1378
Coronary artery disease	17.9%	13.3%	0.6788
OSA	34.3%	40.0%	0.6851
Stroke/TIA	7.5%	6.7%	0.9259
Diabetes	9.0%	6.7%	0.7852
COPD	6.0%	0%	0.343
Cigarette use	17.9%	6.7%	0.2884
Thyroid disease	13.4%	0%	0.1378
CHF	28.4%	6.7%	0.08021
Pre-Ablation left atrial LGE (%)	16.7% (10.95%-21.35%)	15.9% (10.6%-20.6%)	0.6229
AF ablation type:			
Cryo PVI only	38.8%	40.0%	0.9378
Cryo PVI + RF SM	4.5%	6.7%	0.7357
RF PVI only	14.9%	26.7%	0.2817
RF PVI + SM	41.8%	26.7%	0.2838

Table 5.4. Patient characteristics in training and testing cohort and internal validation cohort. Variables are reported as median (IQR). For binary variables, proportions were reported.

We applied the finalized model outlined in **Figures 5.3** to the new dataset. Only data corresponding to the 19 selected features was collected for assessment of ablation outcome for these patients. As such, no further parameter tuning occurred at this step. **Figure 5.8A** shows the breakdown of model performance for each of the 15 patients. 13/15 (80%) patients were

correctly predicted with 1/15 false positives (6.7%) and 2/15 false negatives (13.3%). A patient-specific prediction breakdown is shown in **Figure 5.8B** outlining a correct prediction driven by a high number of prior DCCVs and a low post-ablation left atrial volume index. On the other hand, a false positive prediction is shown in **Figure 5.8C**. There were primarily two features driving the model's prediction of recurrence: elevated left atrial volume index and low number of LGE-derived scar areas. On the other hand, there were three features indicative of non-recurrence: low number of prior direct current cardioversions, high post-ablation scar in the right pulmonary veins, and being of average age.



Figure 5.8. Summary of model performance on internal validation cohort. (A) Chart of each patient outcome and model prediction in the internal validation cohort. Gradient indicates confidences, wherein 0 indicates 100% confidence of non-recurrence and 1 indicates 100% confidence in recurrence. (B) Example of correct prediction with post-ablation patient-specific model and prediction breakdown via SHAP analysis. (C) Example of incorrect positive prediction with patient specific post-ablation model and prediction breakdown.

5.4 Discussion

Our algorithm is designed to integrate multi-modal data to proactively predict recurrent arrhythmias following catheter ablation. Based on literature comparisons (103, 104, 197, 202) our model achieves similar or better performance when predicting recurrent arrhythmia risk but with the added benefit of interpretable explanations. This combination of accuracy and interpretability allows electrophysiologists to receive optimized prediction scores while also gaining scientific insight into why those predictions were made. We present three distinct data perspectives: population-based (**Figure 5.4**), risk factor-based (**Figure 5.5**), and patient-specific based **(Figure 5.7**). We further validate these findings in an internal testing cohort comprised of patients not seen by the algorithm during the training and validation phase.

To minimize the influence of confounders in our algorithm, we implemented a rigorous feature selection process. Observed confounders refer to highly correlated features, while unobserved confounders are features that are unmeasurable or not accounted for in the model (203). To mitigate the presence of observed confounders, we used a combination of LASSO feature selection algorithm and cluster analysis (**Figure 5.2**). These feature selection steps ensure independence of the feature information, as redundant variables can impact model generalizability. Unobserved confounders are a central barrier to drawing causal inferences from observational data and are biases that are difficult to avoid. We prioritized features that have been previously examined in the literature for their potential impact on procedure outcome (**Table 5.2**), thus reducing the impact of potential unobserved confounding variables. Due to the limited additional predictive power of the simulation features (**Figure 5.1**) and the lack of clinical access to computational simulations, we opted to exclude them from this study.

Random forest learning is a versatile algorithm and was specifically chosen for this problem since features values are not altered during the learning process. If alternative machine learning methods, such as support vector machines, were used we would not be able to reliably and

confidently observe how a specific feature value impacts model outcome. This aspect of our algorithm is key, as quantifiable risk factor measurements like those presented in **Figure 5.5** would be difficult to obtain otherwise.

5.4.1 Population-based risk factors

When applying SHAP analysis to understand feature importance from a population perspective, we identified post-ablation left-atrial volume index as the most important feature that influenced determination of recurrent arrhythmia freedom. While this finding alone in the context of this study is not necessarily causative in nature, the role of left atrial dilation has been known to play a role in recurrence (204) and has been an independent factor associated with arrhythmia-free survival (205). Previous machine learning models achieved an AUC of 0.67 when predicting AFib recurrent and non-recurrent patients using left atrial shape metrics identified using pre-procedure CT scans (206). Studies have also shown that enlarged atria post-ablation is strongly associated with long-term outcomes of catheter ablation independent of left ventricular function (207). Mechanistically, left atrial enlargement has been known to promote AFib via additional area available for rotor formation (25) or by indirectly affecting tissue properties such as atrial stretch (26). These results suggest that there is a strong relationship between post-ablation LA volume index and recurrence. In our study, this relationship followed an S-shaped curve where post-ablation volume indices above 51 were predictive of recurrence and values below were indicative of arrhythmia freedom.

Decreased number of ablation lesions yielding high risk for recurrent arrhythmia may suggest that a patient received a low amount of scar during their procedure. Indeed, poor scar formation is associated with atrial fibrillation recurrence (199). However, it is worth noting that surface area of ablation-delivered scar and percentage of scar as a function of left atrial size were variables included in the study but not selected during our feature selection process. We validated via additional testing that there is, indeed, a positive correlation in our training and validation cohort

between scar amount and the associated SHAP value for arrhythmia recurrence. Yet, our results may indicate that the number of LGE-derived ablation lesions might be a more suitable predictor. These findings suggest future research to investigate if many independent lesions might yield favorable outcomes and follow-up studies to validate the number of LGE-derived scar areas as an appropriate indicator for arrhythmia recurrence.

The relationship between age and catheter ablation outcome is unclear. Results from the CABANA trial indicate that there were no differences in the relative effectiveness of catheter ablation with respect to age in preventing recurrent atrial arrhythmias (208). However, age has been found to significantly impact outcomes when analyzed with 5-year follow-up (209). In our study, there is no clear relationship between age and SHAP value (**Figure 5.6D**), but our model considers the variable to be an important indicator of ablation outcome, nonetheless. We believe this effect is due to a high amount of interaction between age and other features in our model. Although, we hesitate to quantify these interaction terms due to low sample size and lack of power to reliably assess these relationships. Further research with a larger dataset should prioritize assessing how these interaction terms affect model predictions of recurrent arrhythmia, especially with respect to age.

A primary asset to this explainable technology is that we can easily tune our model following validation to remove unintended sources of overfitting in our small cohort. For example, in our study, some patients who smoke have a slight SHAP value indicating arrhythmia freedom. Research consistently indicates that smoking worsens ablation outcomes (193, 210). However, due to a relatively low number of smokers in our cohort (17.9%), our model might be over fit with respect to this variable. Fault diagnosis and identification of improperly weighted variables is a key advantage to using xML over black box algorithms (211). Thus, following further validation, we can reassess this feature to improve model accuracy with minimal time spent problem-solving.

5.4.2 Patient-specific risk-factors

Precision medicine is an emerging approach to clinical research and patient care that focuses on understanding and treating disease by integrating multi-modal data from an individual to make patient-tailored decisions. Machine learning analysis of precision medicine data enables us to identify specific patients who may benefit from a specific treatment. Using SHAP analysis, we can generate both a recurrence prediction and a breakdown of the feature importances that contribute to the prediction. For some cases, the features work together in a constructive manner to produce a prediction with high confidence. Although, for most patients, the model identifies multiple key features that contribute for or against a particular prediction, resulting in a multi-faceted decision that weighs many features against one another. Since these feature relationships shown in this study are not inherently causative, it is important to clarify that adjustment of these features may not result in changes in outcome. Nonetheless, they provide a useful platform for further research and validation which may be able to guide patient selection for ablation procedures or indicate optimal treatment plans moving forward.

An important finding that highlights the importance of patient-specific feature analysis is that the key decision-making features for a specific patient can differ from the most important population-based features. An example of this is shown in **Figure 5.7C**, where the most important population-based feature (high post-ablation left atrial volume index) indicated an incorrect prediction for this patient. Thus, even using a relatively simple machine learning algorithm, we are able to make multi-faceted decisions and assess risk factors depending on the patient's overall profile rather than the trends of a population. We believe this patient-specific prediction breakdown provides a comprehensive tool for medical professionals that allows them to assess the overall impact of each risk factor and make their own well-informed decision for a particular patient, without relying on population trends which may not be applicable.

5.4.3 Application of Model on New Clinical Data

Our internal test set aims to simulate how our prospective model may function in a clinical environment and assess internal generalizability. We used the model described in **Figure 5.3** on a new set of unseen clinical data for further validation. Our random forest machine learning model exhibited appropriate testing accuracy based on results from the validation set (validation AUC: 0.86 ± 0.08; testing accuracy: 0.80). Furthermore, we show how SHAP explainability analysis can still be applied, providing insight into how and why our model is deciding on the outcome. In **Figure 5.8C**, we highlighted a false positive prediction in which we can visually troubleshoot the model's incorrect decision. We believe the model may have over-weighted the influence of a low number of scar clusters and elevated post-ablation left atrial volume index *or* under-weighted the influence of low number of prior direct current cardioversions, high post-ablation scar in the RPV region, and age. Additionally, there may be features unaccounted for which could have swayed the decision. Overall, we expect these model-agnostic explanations of feature weights to increase physician understanding and overall confidence in our model (198).

5.5 Clinical Applications

Due to the nature of "black box" algorithms, it has been difficult to understand how known physiological mechanisms of recurrent arrhythmia impact an algorithm's output. Significant danger exists with the application of these complex models in the clinic, where predictions are difficult to interpret and hence less actionable. These models are difficult for physicians to trust and provide little insight on how one should respond to a given prediction. Our model demonstrates a solution that avoids obscurity and favors model interpretation, transforming the current ML paradigm into a model that also explains *why*.

We believe our proof-of-concept algorithm has significant clinical applications following catheter ablation: (1) re-ablation planning, (2) post-ablation care, (3) patient-clinician communication, and (4) future informed hypothesis-driven research. Based on key fibrosis and ablation-delivered

scar features identified for each patient, we believe improved patient selection for re-ablation procedures and pre-identification of sites for targeted re-ablation may be possible. Following an ablation procedure, depending on the prediction outcome and associated confidence, healthcare professionals could use our algorithm to make informed decisions about monitoring for recurrent rhythms or medication adjustment. We also predict this explainable algorithm to foster patient-clinician communication facilitating a better understanding of risk factors and their effect on ablation outcome in an easily digestible format. Finally, we have emphasized that relationships between feature values and outcomes depicted in this study do not indicate a direct causal relationship. However, we have identified potential key features of ablation recurrence that promote hypothesis-driven validation studies of these features.

5.6 Limitations

It should be clarified that our endeavor, although promising, should still be considered an initial and preliminary venture into xML for catheter ablation recurrence. Our study has a limited sample size, and while extensive measures were taken to ensure proper feature selection and model design to limit overfitting in this model, a larger sample size is needed to further validate these findings. To that end, an external testing cohort is needed to ensure that our model is generalizable to data from other institutions. Furthermore, other accessible forms of clinical data such as ECG or electroanatomical mapping data could be used to enrich this xML algorithm, thus potentially leading to more accurate predictions. Prospective trials of this classifier as well as additional randomized trials assessing the ML-identified features are needed before deployment to verify causal relationships.

Other research has suggested that simulations provide a significant benefit to predictive capability of recurrent arrhythmias (103, 104). In our study, we did not see this same benefit. We believe that this result may be attributed to the increased rigor in our analysis of LGE-MRI, which included a larger gamut of fibrosis-derived and ablation-scar derived features.

Furthermore, these studies performed a more comprehensive set of simulations including alterations in fibrosis representation, a larger absolute set of simulation features, and deductive algorithm-chosen simulation features. With the overarching goal of this study being to provide a proof-of-concept method to predict recurrent rhythms in a clinically feasible manner, we are satisfied with our predictive capability without the inclusion of these features as they come at a significant computational cost currently infeasible in existing clinical paradigms.

5.7 Conclusion

In this study, we developed an xML classifier capable of accurately predicting arrhythmia recurrence following an ablation procedure. The classifier uses input features extracted from each patient's electronic health record, pre- and post- ablation LA LGE-MRI, and LA geometry. Our vision for the use of the classifier is to provide a guide for clinicians to decide the optimal treatment plan for a patient following an initial ablation procedure. An important characteristic of our classifier is that it only considers clinically available data with features based on existing mechanistic research of recurrent arrhythmias. We believe our model demonstrates a predictive solution that avoids obscurity and favors model interpretation, giving clinicians a tool for well-informed decision making following a procedure. We implore future work to explore larger datasets that include external data to improve model accuracy and validate our findings.

5.8 Methods and Data Availability

Patient Cohort and Image Acquisition

This study included patients from University of Washington Medical Center with documented persistent AFib or paroxysmal AFib who received pre- and post-procedural LGE-MRI scans and underwent either a cryoballoon or radiofrequency ablation. Paroxysmal AFib was defined as an episode of AFib that terminated spontaneously or within intervention within 7 days (157). Persistent AFib was defined as AFib that persists for a minimum of 7 days (157). Cardiac LGE-MRIs were obtained on all participants before ablation and again 3-6 months following ablation

to quantify the extent of LA fibrosis and LA scar respectively, using previously described protocols (212). Exclusion criteria for AFib patients included those who had a previous catheter ablation, patients with cardiac implantable electronic devices, severe claustrophobia, renal dysfunction and other contraindications to MRI or gadolinium-based contrast. Scans were performed on Philips Ingenia and Siemens Avanto clinical scanners, 15–25 min after contrast injection, using a three-dimensional inversion-recovery, respiration-navigated, ECG-gated, gradient echo pulse sequence. Acquisition parameters included transverse imaging volume with a voxel size of 1.25 × 1.25 × 2.5 mm (reconstructed to 0.625 × 0.625 × 1.25 mm). Scan time was 5–10 minutes dependent on respiration and heart rate.

Patients had clinical assessment and catheter ablation at the University of Washington (UW) AFib program. All patients underwent pulmonary vein isolation, and some had additional substrate modification. As such, all feature data originating from the clinical attributes subsection in **Table 5.2** such as persistent vs. paroxysmal AFib status (213), comorbidities, and medications were determined at time of initial visit. Patients underwent ablation and were followed longitudinally at UW with 7-day ambulatory electrocardiogram monitoring at 3, 6, and 12 months after ablation. Recurrence was defined by at least 30 seconds of documented atrial arrhythmia after a 90-day blanking period (213). Recurrence was classified as either AFib or AFL. In some patients with recurrence, follow-up procedures were used to confirm mechanisms of recurrence. Loss-to-follow-up bias was limited as all patients completed at least 2 years of prespecified follow-up. There was no missing data for any patient.

Model Reconstruction

Geometric models were reconstructed from both pre- and post- ablation LGE-MRI scans by Merisight Inc. to assess LA volume and surface area. Geometric models were reconstructed from the pre-ablation scans and the relative extent of fibrosis in the LA was quantified via an adaptive histogram thresholding algorithm (138) to determine pre-ablation LGE-MRI derived

fibrosis. For post-ablation models, ablation scar was quantified on post-ablation LGE-MRI using previously established methods (86). Then, non-rigid registration was used to map LGE-derived post-ablation scar patterns onto existing LA pre-ablation fibrotic models. Hyper-enhancement on post-ablation scans coinciding with regions labeled as fibrotic in the pre-ablation scan were considered ablation-induced scar. Overall, our approach accounts for the fact that ablation-induced scar hyperenhancement is at a higher level relative to hyperenhancement of fibrosis. Consequently, regions labeled as fibrotic pre-ablation fall below the hyperenhancement threshold in post-procedure scans.

Extraction of LGE-MRI derived fibrosis and ablation-delivered scar features

In pre- and post-ablation models, we characterized regional fibrosis and ablation-delivered scar area with respect to LA landmarks. We defined five different LA regions: LPVs, RPVs, posterior wall, anterior wall, and atrial floor, as in our prior work (119). First, the LA was subdivided into three broad anatomical areas LA floor, posterior wall, and anterior wall including left atrial appendage using standardized cutoff values in the UAC space (140). Then, the left and right pulmonary vein areas were established using a region-growing approach such that each accounted for 15% of the total LA surface area.

Average fibrosis entropy and density were also calculated for pre- and post-ablation models. Prior work showed that regions which promote reentrant driver activity are characterized by fibrosis boundary zones with high fibrosis entropy (FE) and high fibrosis density (FD). As such, we also calculated the surface area of such regions for each patient following the equation: $0.4096FD^2 + 3.28(FD)(FE)-0.1036FE^2 – 0.7112(FD) – FE + 0.0429$.

Prior computational work also suggests that ablation lesions and non-conductive anatomical landmarks (i.e., mitral valve annuli or pulmonary vein ostia) may contribute to recurrent arrhythmias. We counted the total number of contiguous scar units with an area > $1cm^2$. Within

this set we also counted the number of LGE-derived scar areas of specific size ($20cm^2$ > area > 2 cm^2; 60cm > perimeter > 15cm) and in proximity to fibrosis (>30% fibrosis in the surrounding 1cm area), as these may be indicative of potentially arrhythmogenic substrate.

Extraction of features from personalized atrial computational modeling

Each LA model was represented as a bilayer comprising of nested endocardial and epicardial shells, linked by linear connections (135), as in previous work (119). Realistic myocardial fiber orientations were mapped from an atlas geometry using universal atrial coordinates (140). Our methodology for computational modeling at the cell and tissue scale of the fibrotic and non-fibrotic atrial electrophysiology can be found in previously published papers (40-42). A human atrial action potential model (56) was used to represent membrane kinetics in non-fibrotic myocardium, with the addition of parameter modifications to fit clinical monophasic action potential recordings from AF patients (40, 142) (I_{Kur}, I_{to}, I_{CaL} decreased by 50%, 50%, 70%, respectively). In fibrotic regions, further action potential modifications were implemented (I_{CaL}, I_{Na}, and I_{K1} decreased by 50%, 40%, 50%, respectively; as in previously modeling studies (40, 119, 130). We applied conductivity tensor values of $\sigma_L = 0.409\ S\ m^{-1}$ in the longitudinal direction and $\sigma_T = 0.0820\ S\ m^{-1}$ in the transverse at the tissue scale, as in our previous study (119). These conductivity tensor values correspond to physiologically realistic conduction velocity values of 71.49 cm^{-1} and 37.14 cm^{-1} (longitudinal and transverse). In fibrotic tissue, the overall conductivity was reduced and the anisotropy ratio between longitudinal and transverse conductivities was exaggerated ($\sigma_L = 0.177\ S\ m^{-1}$; $\sigma_T = 0.0221\ S\ m^{-1}$). Propagation of electrical activity was simulated by solving the monodomain formulation using the finite element method. All simulations were performed on the Hyak supercomputer system at the University of Washington using the openCARP simulation environment for cardiac electrophysiology (76), which is available for academic use (see: https://openCarp.org).

In each patient-specific model, virtual pacing was applied from fifteen LA sites representing common AFib trigger sites (7). The rapid pacing protocol and locations for virtual pacing can be found in our previous publication (119). After pacing ceased, electrophysiological activity terminated spontaneously unless a driver perpetuated conduction. Each induced episode of induced arrhythmia was manually classified either as either rotor-like (i.e., RDs; rotational sources localized to compact areas of fibrotic substrate) or macro-reentrant in nature. Rotor-like was defined by an electrical wavefront conducted in a spiral fashion making at least two revolutions, and typically occurring at the border zone between fibrotic and non-fibrotic tissue. An instance of macro-reentry was defined by an electrical wavefront traveling around, or partially sustained by, a non-conducting block of tissue (i.e., pulmonary vein ostia, mitral valve annuli, or ablation-induced scar).

We also automatically characterized the presence of RDs within the left atrium using implicit detection of phase singularities (PS), defined as points at which continuous connection of the excitation phase in myocardial tissue is undefined, indicating reentrant activity and wave break. Explicit detection of PSs is computationally unfeasible for organ-scale meshes with the current technology. Therefore, we performed implicit identification of phase singularities via filament detection. Filaments are defined as lines of wavebreak that indicate the path of a 3D RD. More information on phase singularities, filaments, and detection strategies can be found here (214). Briefly, to detect filaments, we represented simulated cardiac tissue in phase space and identifying intersecting activation isolines (215). Using this method, we obtained a quantifiable metric of PSs. PSs were deemed unique if they shared <10% of points (i.e., if two filaments share only 9% of their makeup, they are deemed unique).

Design and Evaluation of Random Forest Machine Learning Classifier

LASSO feature selection was used to reduce the overall number of features. This type of feature selection algorithm was chosen because it performs well when the number of

observations is low, and the number of features is high. LASSO attempts to eliminate all irrelevant variables (i.e., variables not related to the outcome) and removing highly collinear variables. Five-fold cross validation was used to determine the optimal parameterization. (**Figure 5.2A**). We then performed hierarchical clustering analysis via Shapley values. Shapley Additive exPlanations (SHAP) is a framework for interpreting algorithmic predictions that calculates the marginal contribution of each risk factor for each prediction (i.e., a Shapley value). By using SHAP values which all have the same unit (i.e., the unit of prediction space), we can perform clustering analysis in a reliable way to assess feature redundancy. Features that are highly dependent merge together at the lefthand side of the dendrogram, while independent features merge on the righthand side. We implemented a varying cutoff scheme from 0-0.90 in which the feature with the lowest average Shapley value below the cutoff was iteratively removed. We then reassessed model performance to determine an optimal threshold value of 0.70, resulting in removal of pre-ablation LA volume index and pre-ablation fibrosis in the anterior wall region.

The final set of features was then used to train a random forest machine learning classifier to recognize risk factors associated with patients with recurrent AFib. We used 5-fold stratified cross validation to minimize the possibility of predictive power being overestimated due to lucky initialization; this approach also ensured an equal distribution of recurrent and non-recurrent AFib patients in the training and testing sets. We used SHAP to probe feature importance in the random forest classifier (116, 117). We also applied the trained and validated random forest classifier to a new training set of patients previously unseen by the classifier. Only pertinent features (i.e., features used in the final classifier) were extracted for this set of patients. We applied SHAP to this dataset to similarly explain feature importance for each patient.

Data Availability

Patient-derived data in this article, including processed versions thereof, are not publicly available out of respect for the privacy of the patients involved. Code to reproduce Figures 5.1-5.4 (i.e., the feature selection process, 5-fold stratified cross validation random forest machine learning, associated SHAP explainability, and data visualization tools) can be found at github: https://github.com/Sfbifulco/CardSSRFxML.

Chapter 6. Conclusion and Future Directions

Understanding how heterogeneity in atrial tissue leads to arrhythmias is an important step in mitigating patient arrhythmia risk. This knowledge can inform procedures like catheter ablation and aid in the development of new tools for predicting and selecting patients who would benefit from these procedures. The above work used two primary methods to better understand potentially arrhythmogenic tissue: patient-specific computational simulations and explainable machine learning. In Chapter 3, patient-specific computational modeling was used to determine that there was no significant difference in the theoretical capacity for fibrotic substrate in ESUS and AFib patients to sustain arrhythmias. This led us to conclude that there may exist a discrepancy in the likelihood of triggered activity between these two populations. In Chapter 4, we used a combination of simulations and explainable machine learning to define a set of potentially arrhythmogenic ablation lesions, veins, and values, characterized by proximity to fibrosis and intermediate size. In Chapter 5, we combined electronic health record data with patterns of potentially arrhythmogenic tissue derived from LGE-MRI to predict post-ablation recurrence in a clinically-feasible manner. In combination, this collection of work advances our understanding of potentially arrhythmogenic substrate and its relationship to clinical phenomena, like ESUS and recurrent AFib/AFL.

Future advances in cardiac computational modeling hold significant potential for enhancing our understanding and management of arrhythmias. At the cell-scale level, there is evidence that intracellular Ca^{2+} handling and altered excitation contraction coupling play pivotal roles in AFib pathophysiology (216), emphasizing the need for implementation of more detailed cell-scale models in organ-scale simulations. Furthermore, exploring the contribution of adipocytes to AFib pathophysiology and understanding electrophysiological alterations induced by the comingling of fatty and fibrotic tissue in atrial tissues are important areas for future investigation (217, 218). Optimization approaches that combine stochastic and deterministic processes (219) can be

developed to enhance cardiac electrophysiology models and assess ectopy in the pulmonary vein sleeves, unraveling the relationship between patient-specific predisposition to atrial ectopy, substrate characteristics, and AFib onset and maintenance. The integration of patient-specific measurements, including action potential duration, conduction velocity, fiber orientation, and genomic/transcriptomic data, can facilitate the development of models that capture individualized atrial electrophysiology.

In the realm of ML and AI, there is immense potential for transforming diagnostic tools and treatment plans in clinical practice. xML that allows users to understand why a system has produced a given output. Currently, there is a steep tradeoff between explainability vs. performance in complex models. Future developments in xML/xAI should prioritize striking an optimal balance between these aspects. Furthermore, additional metrics to evaluate the performance of xML/xAI should be prioritized, since the majority of studies focus on subjective measurements such as user satisfaction, trust, and explanation effectiveness. Moreover, studies are needed to understand how users interpret model explanations and guard against potential over-reliance on the results. Finally, studies considering the impact of these technologies from a patient's perspective are essential for their successful integration into healthcare practices.

The combination of computational simulations and ML/AI holds promise as a potential future avenue of research. Machine learning can be leveraged to generate personalized human heart models from population-based libraries in a high-throughput manner (220). Overall, the integration of robust and explainable ML with multi-scale modeling approaches can propel us beyond the "whole-organ" scale and towards the "whole-patient" scale, allowing for incorporation and assessment of mechanistic links between clinical factors beyond the heart. With the continued growth of mechanistic and diagnostic insights derived from computational modeling, simulations, and ML/AI, this research will pave the way for precision medicine and significantly improve our understanding and management of arrhythmias.

Acknowledgements

I cannot pinpoint the exact moment my journey toward becoming a scientist began. Like many others, it often felt like a meandering path where the destination was never clear from the start. In that regard, my journey mirrors Alice's trip to wonderland

"Would you tell me, please, which way I ought to go from here?"

"That depends a good deal on where you want to get to," said the Cat.

"I don't much care where—" said Alice.

"Then it doesn't matter which way you go," said the Cat.

"—so long as I get somewhere*," Alice added as an explanation.*

"Oh, you're sure to do that," said the Cat, "if you only walk long enough."

I suppose I have arrived at a point that can be called "somewhere". And much like Alice, I was not alone in my journey. I owe a profound debt of gratitude to my remarkable supervisor, Dr. Pat Boyle. His unwavering guidance and support have been invaluable. Pat always seemed to possess a seemingly incomprehensible understanding surrounding modeling and electrophysiology that I can only hope to attain one day. He offered valuable insight, guidance, and challenged my assumptions, urging me to explore beyond the constraints of my own scientific imagination. I can't fathom just how different my graduate experience would have been without his personal and professional mentorship. I owe the scientist I am today to his mentorship.

Beyond my supervisor, I must acknowledge the profound influence of my academic committee. Each member has recognized potential in me beyond my own comprehension. To Dr. Mike Regnier, I want to thank you for being one of the first individuals to recognize my potential beyond my background. You saw something more in me and provided me with the opportunity to shine. To Dr. Nazem Akoum, you helped me understand the sheer impact science can have

on day-to-day life. Through your mentorship, you have empowered me with a mindset to translate how scientific knowledge shapes and transforms clinical practice. To Dr. Herbert Sauro, you challenged me to broaden my understanding more than I thought possible. Your dedication to teaching and your commitment to fostering a culture of reproducibility have significantly shaped my academic journey. And finally, to Dr. Megan Streur, who endlessly offered assistance throughout the arduous process of applying for countless awards, supporting me every step of the way, especially during moments of disappointment when I didn't receive them.

My lab mates, Alex Ochs, Chelsea Gibbs, Yaacoub Chahine, Fima Macheret, Izzy Kim, Griffin Scott and most recently Åshild Telle and Matt Magoon, added a dash of vibrancy to my wonderland. Through our tea-filled antics and stimulating conversations, our small lab community overflowed with camaraderie, intellectual exploration, and a shared passion for scientific discovery. Each lab member has played a crucial role in formulating the questions answered in this dissertation and has greatly contributed to my mental well-being throughout the entire process. Specifically, I am grateful to Alex, Chelsea and Åshild for their indispensable support in Chapters 1 and 2, Griffin for his assistance in model reconstruction in Chapter 3, Fima for his diligent analysis of over 7000 simulations in Chapter 4, Yaacoub for his meticulous work with acquiring patient data in Chapter 5, and the immense contributions of the remarkable co-authors who have collaborated with us.

My wonderful partner, Chase, has supported the creation of this dissertation in more ways than I can count. I am truly thankful to have had him by my side, celebrating my accomplishments and encouraging me to "just quit" whenever I felt like giving up (he knew, as well as I did, that I never would). He serves as a reminder to me that amid all the seriousness and unpredictability of science, to embrace the joy and playfulness of life. I love you and I look forward to our shared future together.

Finally, I would like to express my deepest gratitude and appreciation to my parents for their love, support, and encouragement throughout my journey. I am forever grateful for the sacrifices my parents have made to ensure my education and well-being. I dedicate this achievement to them. Thank you for shaping me into the person I am today and for standing by my side every step of the way. I am forever grateful and blessed to have you as my parents.

At the end of it all, the only thing I can say for certain is

“I wish I hadn’t cried so much!” said Alice.

Nevertheless, I found resilience, growth, and a determination to overcome challenges and reach "somewhere." My journey as a scientist, like Alice's adventure in wonderland, has been enriched by the incredible individuals who have guided and supported me along the way. As I stand at this gigantic milestone, I embark on the next chapter of my scientific exploration with a heart full of gratitude, a mind filled with curiosity, and a deep sense of purpose that I owe to those I met along the way.

References

1. Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, et al. Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association. *Circulation.* 2019;139(10):e56-e528.
2. Sidhu S, and Marine JE. Evaluating and managing bradycardia. *Trends in Cardiovascular Medicine.* 2020;30(5):265-72.
3. Nayyar S, Ganesan AN, Brooks AG, Sullivan T, Roberts-Thomson KC, and Sanders P. Venturing into ventricular arrhythmia storm: a systematic review and meta-analysis†. *European Heart Journal.* 2013;34(8):560-71.
4. Kotadia ID, Williams SE, and O'Neill M. Supraventricular tachycardia: An overview of diagnosis and management. *Clin Med (Lond).* 2020;20(1):43-7.
5. Sanchez-Quintana D, Lopez-Minguez JR, Pizarro G, Murillo M, and Cabrera JA. Triggers and anatomical substrates in the genesis and perpetuation of atrial fibrillation. *Curr Cardiol Rev.* 2012;8(4):310-26.
6. Iwasaki YK, Nishida K, Kato T, and Nattel S. Atrial fibrillation pathophysiology: implications for management. *Circulation.* 2011;124(20):2264-74.
7. Santangeli P, and Marchlinski FE. Techniques for the provocation, localization, and ablation of non-pulmonary vein triggers for atrial fibrillation. *Heart Rhythm.* 2017;14(7):1087-96.
8. Wijffels MC, Kirchhof CJ, Dorland R, and Allessie MA. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. *Circulation.* 1995;92(7):1954-68.
9. Allessie MA, Bonke FI, and Schopman FJ. Circus movement in rabbit atrial muscle as a mechanism of tachycardia. III. The "leading circle" concept: a new model of circus movement in cardiac tissue without the involvement of an anatomical obstacle. *Circ Res.* 1977;41(1):9-18.
10. Pandit SV, and Jalife J. Rotors and the dynamics of cardiac fibrillation. *Circ Res.* 2013;112(5):849-62.
11. Comtois P, Kneller J, and Nattel S. Of circles and spirals: bridging the gap between the leading circle and spiral wave concepts of cardiac reentry. *Europace.* 2005;7 Suppl 2:10-20.
12. Mann I, Sandler B, Linton N, and Kanagaratnam P. Drivers of Atrial Fibrillation: Theoretical Considerations and Practical Concerns. *Arrhythm Electrophysiol Rev.* 2018;7(1):49-54.
13. Hansen BJ, Zhao J, Helfrich KM, Li N, Iancau A, Zolotarev AM, et al. Unmasking Arrhythmogenic Hubs of Reentry Driving Persistent Atrial Fibrillation for Patient-Specific Treatment. *J Am Heart Assoc.* 2020;9(19):e017789.
14. Berenfeld O, Zaitsev AV, Mironov SF, Pertsov AM, and Jalife J. Frequency-dependent breakdown of wave propagation into fibrillatory conduction across the pectinate muscle network in the isolated sheep right atrium. *Circ Res.* 2002;90(11):1173-80.
15. Moe GK, and Abildskov JA. Atrial fibrillation as a self-sustaining arrhythmia independent of focal discharge. *Am Heart J.* 1959;58(1):59-70.
16. Markowitz SM, Thomas G, Liu CF, Cheung JW, Ip JE, and Lerman BB. Atrial Tachycardias and Atypical Atrial Flutters: Mechanisms and Approaches to Ablation. *Arrhythm Electrophysiol Rev.* 2019;8(2):131-7.
17. Waks JW, and Josephson ME. Mechanisms of Atrial Fibrillation - Reentry, Rotors and Reality. *Arrhythm Electrophysiol Rev.* 2014;3(2):90-100.
18. de Bakker JM, and Wittkampf FH. The pathophysiologic basis of fractionated and complex electrograms and the impact of recording techniques on their detection and interpretation. *Circ Arrhythm Electrophysiol.* 2010;3(2):204-13.

19. Sohal M, Choudhury R, Taghji P, Louw R, Wolf M, Fedida J, et al. Is Mapping of Complex Fractionated Electrograms Obsolete? *Arrhythm Electrophysiol Rev.* 2015;4(2):109-15.
20. van der Velden J, de Jong JW, Owen VJ, Burton PB, and Stienen GJ. Effect of protein kinase A on calcium sensitivity of force and its sarcomere length dependence in human cardiomyocytes. *Cardiovasc Res.* 2000;46(3):487-95.
21. Landstrom AP, Dobrev D, and Wehrens XHT. Calcium Signaling and Cardiac Arrhythmias. *Circ Res.* 2017;120(12):1969-93.
22. Dobrev D, Friedrich A, Voigt N, Jost N, Wettwer E, Christ T, et al. The G protein-gated potassium current I(K,ACh) is constitutively active in patients with chronic atrial fibrillation. *Circulation.* 2005;112(24):3697-706.
23. Girmatsion Z, Biliczki P, Bonauer A, Wimmer-Greinecker G, Scherer M, Moritz A, et al. Changes in microRNA-1 expression and IK1 up-regulation in human atrial fibrillation. *Heart Rhythm.* 2009;6(12):1802-9.
24. Kim KB, Rodefeld MD, Schuessler RB, Cox JL, and Boineau JP. Relationship between local atrial fibrillation interval and refractory period in the isolated canine atrium. *Circulation.* 1996;94(11):2961-7.
25. Zou R, Kneller J, Leon LJ, and Nattel S. Substrate size as a determinant of fibrillatory activity maintenance in a mathematical model of canine atrium. *Am J Physiol Heart Circ Physiol.* 2005;289(3):H1002-12.
26. Kalifa J, Jalife J, Zaitsev AV, Bagwe S, Warren M, Moreno J, et al. Intra-atrial pressure increases rate and organization of waves emanating from the superior pulmonary veins during atrial fibrillation. *Circulation.* 2003;108(6):668-71.
27. Marrouche NF, Wilber D, Hindricks G, Jais P, Akoum N, Marchlinski F, et al. Association of atrial tissue fibrosis identified by delayed enhancement MRI and atrial fibrillation catheter ablation: the DECAAF study. *JAMA.* 2014;311(5):498-506.
28. Ehrlich JR, Hohnloser SH, and Nattel S. Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence. *Eur Heart J.* 2006;27(5):512-8.
29. Reil JC, Hohl M, Selejan S, Lipp P, Drautz F, Kazakow A, et al. Aldosterone promotes atrial fibrillation. *Eur Heart J.* 2012;33(16):2098-108.
30. Gramley F, Lorenzen J, Koellensperger E, Kettering K, Weiss C, and Munzel T. Atrial fibrosis and atrial fibrillation: the role of the TGF-beta1 signaling pathway. *Int J Cardiol.* 2010;143(3):405-13.
31. Zhou G, Kandala JC, Tyagi SC, Katwa LC, and Weber KT. Effects of angiotensin II and aldosterone on collagen gene expression and protein turnover in cardiac fibroblasts. *Molecular and Cellular Biochemistry.* 1996;154(2):171-8.
32. Li X, Ma C, Dong J, Liu X, Long D, Tian Y, et al. The fibrosis and atrial fibrillation: is the transforming growth factor-beta 1 a candidate etiology of atrial fibrillation. *Med Hypotheses.* 2008;70(2):317-9.
33. Burstein B, Comtois P, Michael G, Nishida K, Villeneuve L, Yeh YH, et al. Changes in connexin expression and the atrial fibrillation substrate in congestive heart failure. *Circ Res.* 2009;105(12):1213-22.
34. Duffy HS. The molecular mechanisms of gap junction remodeling. *Heart Rhythm.* 2012;9(8):1331-4.
35. Nguyen TP, Qu Z, and Weiss JN. Cardiac fibrosis and arrhythmogenesis: the road to repair is paved with perils. *J Mol Cell Cardiol.* 2014;70:83-91.
36. Verheule S, and Schotten U. *Cells*. 2021.
37. Zhou X, and Dudley SC. Evidence for Inflammation as a Driver of Atrial Fibrillation. *Frontiers in Cardiovascular Medicine.* 2020;7.
38. Wells RG. Tissue mechanics and fibrosis. *Biochim Biophys Acta.* 2013;1832(7):884-90.

39. Boyle PM, Del Alamo JC, and Akoum N. Fibrosis, atrial fibrillation and stroke: clinical updates and emerging mechanistic models. *Heart.* 2021;107(2):99-105.
40. Zahid S, Cochet H, Boyle PM, Schwarz EL, Whyte KN, Vigmond EJ, et al. Patient-derived models link re-entrant driver localization in atrial fibrillation to fibrosis spatial pattern. *Cardiovasc Res.* 2016;110(3):443-54.
41. Boyle PM, Hakim JB, Zahid S, Franceschi WH, Murphy MJ, Prakosa A, et al. The Fibrotic Substrate in Persistent Atrial Fibrillation Patients: Comparison Between Predictions From Computational Modeling and Measurements From Focal Impulse and Rotor Mapping. *Front Physiol.* 2018;9:1151.
42. Boyle PM, Hakim JB, Zahid S, Franceschi WH, Murphy MJ, Vigmond EJ, et al. Comparing Reentrant Drivers Predicted by Image-Based Computational Modeling and Mapped by Electrocardiographic Imaging in Persistent Atrial Fibrillation. *Front Physiol.* 2018;9:414.
43. Roney CH, Bayer JD, Cochet H, Meo M, Dubois R, Jais P, et al. Variability in pulmonary vein electrophysiology and fibrosis determines arrhythmia susceptibility and dynamics. *PLoS Comput Biol.* 2018;14(5):e1006166.
44. Aronis KN, Ali RL, Liang JA, Zhou S, and Trayanova NA. Understanding AF Mechanisms Through Computational Modelling and Simulations. *Arrhythm Electrophysiol Rev.* 2019;8(3):210-9.
45. Li J, Gao M, Zhang M, Liu D, Li Z, Du J, et al. Treatment of atrial fibrillation: a comprehensive review and practice guide. *Cardiovasc J Afr.* 2020;31(3):153-8.
46. Law SWY, Lau WCY, Wong ICK, Lip GYH, Mok MT, Siu CW, et al. Sex-Based Differences in Outcomes of Oral Anticoagulation in Patients With Atrial Fibrillation. *J Am Coll Cardiol.* 2018;72(3):271-82.
47. Osmanagic A, Moller S, Osmanagic A, Sheta HM, Vinther KH, and Egstrup K. Effect of early direct current cardioversion on the recurrence of atrial fibrillation in patients with persistent atrial fibrillation. *Am J Cardiol.* 2015;116(2):225-9.
48. Khan MA, Raja S, Ibrahim MS, and Hammersely C. Prevalence and management of atrial fibrillation in primary care: a case study. *Prim Health Care Res Dev.* 2014;15(4):355-61.
49. Morillo CA, Verma A, Connolly SJ, Kuck KH, Nair GM, Champagne J, et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of paroxysmal atrial fibrillation (RAAFT-2): a randomized trial. *JAMA.* 2014;311(7):692-700.
50. Akoum N, Morris A, Perry D, Cates J, Burgon N, Kholmovski E, et al. Substrate Modification Is a Better Predictor of Catheter Ablation Success in Atrial Fibrillation Than Pulmonary Vein Isolation: An LGE-MRI Study. *Clin Med Insights Cardiol.* 2015;9:25-31.
51. Peigh G, Wasserlauf J, Kaplan RM, Amaral AP, Trivedi A, Chicos AB, et al. Repeat pulmonary vein isolation with or without FIRM-guided ablation for recurrent atrial fibrillation with pulmonary vein reconnection. *J Cardiovasc Electrophysiol.* 2020;31(5):1031-7.
52. La Rosa G, Quintanilla JG, Salgado R, Gonzalez-Ferrer JJ, Canadas-Godoy V, Perez-Villacastin J, et al. Anatomical targets and expected outcomes of catheter-based ablation of atrial fibrillation in 2020. *Pacing Clin Electrophysiol.* 2021;44(2):341-59.
53. Savelieva I, Kakouros N, Kourliouros A, and Camm AJ. Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part II: secondary prevention. *Europace.* 2011;13(5):610-25.
54. Pellman J, and Sheikh F. Atrial fibrillation: mechanisms, therapeutics, and future directions. *Compr Physiol.* 2015;5(2):649-65.
55. Bifulco SF, Akoum N, and Boyle PM. Translational applications of computational modelling for patients with cardiac arrhythmias. *Heart.* 2020.
56. Courtemanche M, Ramirez RJ, and Nattel S. Ionic mechanisms underlying human atrial action potential properties: insights from a mathematical model. *Am J Physiol.* 1998;275(1):H301-21.

57. Maleckar MM, Greenstein JL, Trayanova NA, and Giles WR. Mathematical simulations of ligand-gated and cell-type specific effects on the action potential of human atrium. *Prog Biophys Mol Biol.* 2008;98(2-3):161-70.
58. Grandi E, Pandit SV, Voigt N, Workman AJ, Dobrev D, Jalife J, et al. Human atrial action potential and Ca2+ model: sinus rhythm and chronic atrial fibrillation. *Circ Res.* 2011;109(9):1055-66.
59. Wilhelms M, Hettmann H, Maleckar MM, Koivumaki JT, Dossel O, and Seemann G. Benchmarking electrophysiological models of human atrial myocytes. *Front Physiol.* 2012;3:487.
60. Blanc O, Virag N, Vesin JM, and Kappenberger L. A computer model of human atria with reasonable computation load and realistic anatomical properties. *IEEE Trans Biomed Eng.* 2001;48(11):1229-37.
61. Seemann G, Hoper C, Sachse FB, Dossel O, Holden AV, and Zhang H. Heterogeneous three-dimensional anatomical and electrophysiological model of human atria. *Philos Trans A Math Phys Eng Sci.* 2006;364(1843):1465-81.
62. Nattel S. Molecular and Cellular Mechanisms of Atrial Fibrosis in Atrial Fibrillation. *JACC Clin Electrophysiol.* 2017;3(5):425-35.
63. Morita N, Mandel WJ, Kobayashi Y, and Karagueuzian HS. Cardiac fibrosis as a determinant of ventricular tachyarrhythmias. *J Arrhythm.* 2014;30(6):389-94.
64. Kapa S, and Asirvatham SJ. Atrial fibrillation: focal or reentrant or both?: a new autonomic lens to examine an old riddle. *Circ Arrhythm Electrophysiol.* 2009;2(4):345-8.
65. Zaman J, Baykaner T, and Narayan SM. Mapping and Ablation of Rotational and Focal Drivers in Atrial Fibrillation. *Card Electrophysiol Clin.* 2019;11(4):583-95.
66. Hansen BJ, Zhao J, and Fedorov VV. Fibrosis and Atrial Fibrillation: Computerized and Optical Mapping; A View into the Human Atria at Submillimeter Resolution. *JACC Clin Electrophysiol.* 2017;3(6):531-46.
67. Dewan S, McCabe KJ, Regnier M, and McCulloch AD. Insights and Challenges of Multi-Scale Modeling of Sarcomere Mechanics in cTn and Tm DCM Mutants—Genotype to Cellular Phenotype. *Frontiers in Physiology.* 2017;8.
68. Luo CH, and Rudy Y. A dynamic model of the cardiac ventricular action potential. II. Afterdepolarizations, triggered activity, and potentiation. *Circ Res.* 1994;74(6):1097-113.
69. Paci M, Hyttinen J, Rodriguez B, and Severi S. Human induced pluripotent stem cell-derived versus adult cardiomyocytes: an in silico electrophysiological study on effects of ionic current block. *Br J Pharmacol.* 2015;172(21):5147-60.
70. Kernik DC, Morotti S, Wu H, Garg P, Duff HJ, Kurokawa J, et al. A computational model of induced pluripotent stem-cell derived cardiomyocytes incorporating experimental variability from multiple data sources. *J Physiol.* 2019;597(17):4533-64.
71. Niederer SA, Kerfoot E, Benson AP, Bernabeu MO, Bernus O, Bradley C, et al. Verification of cardiac tissue electrophysiology simulators using an N-version benchmark. *Philos Trans A Math Phys Eng Sci.* 2011;369(1954):4331-51.
72. Saha M, Roney CH, Bayer JD, Meo M, Cochet H, Dubois R, et al. Wavelength and Fibrosis Affect Phase Singularity Locations During Atrial Fibrillation. *Front Physiol.* 2018;9:1207.
73. Deng D, Murphy MJ, Hakim JB, Franceschi WH, Zahid S, Pashakhanloo F, et al. Sensitivity of reentrant driver localization to electrophysiological parameter variability in image-based computational models of persistent atrial fibrillation sustained by a fibrotic substrate. *Chaos.* 2017;27(9):093932.
74. Tung, Leslie. *Electrical Engineering and Computer Science*. Massachusetts Institute of Technology; 1978.
75. Keener JaS, James. *Mathematical Physiology.* Springer Link

1998.
76. Plank G, Loewe A, Neic A, Augustin C, Huang YL, Gsell MAF, et al. The openCARP simulation environment for cardiac electrophysiology. *Comput Methods Programs Biomed.* 2021;208:106223.
77. Hoermann JM, Pfaller MR, Avena L, Bertoglio C, and Wall WA. Automatic mapping of atrial fiber orientations for patient-specific modeling of cardiac electromechanics using image registration. *Int J Numer Method Biomed Eng.* 2019;35(6):e3190.
78. Roney CH, Bendikas R, Pashakhanloo F, Corrado C, Vigmond EJ, McVeigh ER, et al. Constructing a Human Atrial Fibre Atlas. *Ann Biomed Eng.* 2020; In press, doi: 10.1007/s10439-020-02525-w.
79. Corrado C, Williams S, Karim R, Plank G, O'Neill M, and Niederer S. A work flow to build and validate patient specific left atrium electrophysiology models from catheter measurements. *Med Image Anal.* 2018;47:153-63.
80. Clayton RH, Aboelkassem Y, Cantwell CD, Corrado C, Delhaas T, Huberts W, et al. An audit of uncertainty in multi-scale cardiac electrophysiology models. *Philos Trans A Math Phys Eng Sci.* 2020;378(2173):20190335.
81. Boyle PM, Zahid S, and Trayanova NA. Towards personalized computational modelling of the fibrotic substrate for atrial arrhythmia. *Europace.* 2016;18(suppl 4):iv136-iv45.
82. Xiong Z, Fedorov VV, Fu X, Cheng E, Macleod R, and Zhao J. Fully Automatic Left Atrium Segmentation From Late Gadolinium Enhanced Magnetic Resonance Imaging Using a Dual Fully Convolutional Neural Network. *IEEE Trans Med Imaging.* 2019;38(2):515-24.
83. Corrado C, Razeghi O, Roney C, Coveney S, Williams S, Sim I, et al. Quantifying atrial anatomy uncertainty from clinical data and its impact on electro-physiology simulation predictions. *Med Image Anal.* 2020;61:101626.
84. Simonetti OP, Kim RJ, Fieno DS, Hillenbrand HB, Wu E, Bundy JM, et al. An improved MR imaging technique for the visualization of myocardial infarction. *Radiology.* 2001;218(1):215-23.
85. Kim RJ, Fieno DS, Parrish TB, Harris K, Chen EL, Simonetti O, et al. Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. *Circulation.* 1999;100(19):1992-2002.
86. Akoum N, Wilber D, Hindricks G, Jais P, Cates J, Marchlinski F, et al. MRI Assessment of Ablation-Induced Scarring in Atrial Fibrillation: Analysis from the DECAAF Study. *J Cardiovasc Electrophysiol.* 2015;26(5):473-80.
87. Kelly D, Mackenzie L, Hunter P, Smaill B, and Saint DA. Gene expression of stretch-activated channels and mechanoelectric feedback in the heart. *Clin Exp Pharmacol Physiol.* 2006;33(7):642-8.
88. Usyk TP, and McCulloch AD. Relationship between regional shortening and asynchronous electrical activation in a three-dimensional model of ventricular electromechanics. *J Cardiovasc Electrophysiol.* 2003;14(10 Suppl):S196-202.
89. Campbell SG, Howard E, Aguado-Sierra J, Coppola BA, Omens JH, Mulligan LJ, et al. Effect of transmurally heterogeneous myocyte excitation-contraction coupling on canine left ventricular electromechanics. *Exp Physiol.* 2009;94(5):541-52.
90. Adeniran I, MacIver DH, Garratt CJ, Ye J, Hancox JC, and Zhang H. Effects of Persistent Atrial Fibrillation-Induced Electrical Remodeling on Atrial Electro-Mechanics – Insights from a 3D Model of the Human Atria. *PLOS ONE.* 2015;10(11):e0142397.
91. Ahmad Bakir A, Al Abed A, Stevens MC, Lovell NH, and Dokos S. A Multiphysics Biventricular Cardiac Model: Simulations With a Left-Ventricular Assist Device. *Front Physiol.* 2018;9:1259.
92. Ellinor PT, Lunetta KL, Albert CM, Glazer NL, Ritchie MD, Smith AV, et al. Meta-analysis identifies six new susceptibility loci for atrial fibrillation. *Nat Genet.* 2012;44(6):670-5.

93. Bai J, Lo A, Gladding PA, Stiles MK, Fedorov VV, and Zhao J. In silico investigation of the mechanisms underlying atrial fibrillation due to impaired Pitx2. *PLoS Comput Biol.* 2020;16(2):e1007678.
94. Bai J, Lu Y, and Zhang H. In silico study of the effects of anti-arrhythmic drug treatment on sinoatrial node function for patients with atrial fibrillation. *Sci Rep.* 2020;10(1):305.
95. Saliani A, Irakoze E, and Jacquemet V. Simulation of diffuse and stringy fibrosis in a bilayer interconnected cable model of the left atrium. *Europace.* 2021;23(23 Suppl 2):i169-i77.
96. Gharaviri A, Verheule S, Eckstein J, Potse M, Kuklik P, Kuijpers NH, et al. How disruption of endo-epicardial electrical connections enhances endo-epicardial conduction during atrial fibrillation. *Europace.* 2017;19(2):308-18.
97. Gharaviri A, Bidar E, Potse M, Zeemering S, Verheule S, Pezzuto S, et al. Epicardial Fibrosis Explains Increased Endo-Epicardial Dissociation and Epicardial Breakthroughs in Human Atrial Fibrillation. *Front Physiol.* 2020;11:68.
98. Scherr D, Khairy P, Miyazaki S, Aurillac-Lavignolle V, Pascale P, Wilton SB, et al. Five-year outcome of catheter ablation of persistent atrial fibrillation using termination of atrial fibrillation as a procedural endpoint. *Circ Arrhythm Electrophysiol.* 2015;8(1):18-24.
99. Ali RL, Hakim JB, Boyle PM, Zahid S, Sivasambu B, Marine JE, et al. Arrhythmogenic propensity of the fibrotic substrate after atrial fibrillation ablation: a longitudinal study using magnetic resonance imaging-based atrial models. *Cardiovasc Res.* 2019;115(12):1757-65.
100. Bayer JD, Roney CH, Pashaei A, Jais P, and Vigmond EJ. Novel Radiofrequency Ablation Strategies for Terminating Atrial Fibrillation in the Left Atrium: A Simulation Study. *Front Physiol.* 2016;7:108.
101. Boyle PM, Zghaib T, Zahid S, Ali RL, Deng D, Franceschi WH, et al. Computationally guided personalized targeted ablation of persistent atrial fibrillation. *Nat Biomed Eng.* 2019;3(11):870-9.
102. Kim IS, Lim B, Shim J, Hwang M, Yu HT, Kim TH, et al. Clinical Usefulness of Computational Modeling-Guided Persistent Atrial Fibrillation Ablation: Updated Outcome of Multicenter Randomized Study. *Front Physiol.* 2019;10:1512.
103. Shade JK, Ali RL, Basile D, Popescu D, Akhtar T, Marine JE, et al. Preprocedure Application of Machine Learning and Mechanistic Simulations Predicts Likelihood of Paroxysmal Atrial Fibrillation Recurrence Following Pulmonary Vein Isolation. *Circ Arrhythm Electrophysiol.* 2020;13(7):e008213.
104. Roney CH, Sim I, Yu J, Beach M, Mehta A, Alonso Solis-Lemus J, et al. Predicting Atrial Fibrillation Recurrence by Combining Population Data and Virtual Cohorts of Patient-Specific Left Atrial Models. *Circ Arrhythm Electrophysiol.* 2022;15(2):e010253.
105. Attia ZI, Kapa S, Lopez-Jimenez F, McKie PM, Ladewig DJ, Satam G, et al. Screening for cardiac contractile dysfunction using an artificial intelligence-enabled electrocardiogram. *Nat Med.* 2019;25(1):70-4.
106. Feeny AK, Chung MK, Madabhushi A, Attia ZI, Cikes M, Firouznia M, et al. Artificial Intelligence and Machine Learning in Arrhythmias and Cardiac Electrophysiology. *Circ Arrhythm Electrophysiol.* 2020;13(8):e007952.
107. Hannun AY, Rajpurkar P, Haghpanahi M, Tison GH, Bourn C, Turakhia MP, et al. Cardiologist-level arrhythmia detection and classification in ambulatory electrocardiograms using a deep neural network. *Nat Med.* 2019;25(1):65-9.
108. Charilaou P, and Battat R. Machine learning models and over-fitting considerations. *World J Gastroenterol.* 2022;28(5):605-7.
109. Ma Y, and Zhu L. A Review on Dimension Reduction. *Int Stat Rev.* 2013;81(1):134-50.

110. Suri JS, Bhagawati M, Paul S, Protogeron A, Sfikakis PP, Kitas GD, et al. Understanding the bias in machine learning systems for cardiovascular disease risk assessment: The first of its kind review. *Comput Biol Med.* 2022;142:105204.
111. Linardatos P, Papastefanopoulos V, and Kotsiantis S. Explainable AI: A Review of Machine Learning Interpretability Methods. *Entropy.* 2021;23(1):18.
112. Adadi A, and Berrada M. Peeking Inside the Black-Box: A Survey on Explainable Artificial Intelligence (XAI). *IEEE Access.* 2018;6:52138-60.
113. Barredo Arrieta A, Díaz-Rodríguez N, Del Ser J, Bennetot A, Tabik S, Barbado A, et al. Explainable Artificial Intelligence (XAI): Concepts, taxonomies, opportunities and challenges toward responsible AI. *Information Fusion.* 2020;58:82-115.
114. Garreau D, and Luxburg U. In: Silvia C, and Roberto C eds. *Proceedings of the Twenty Third International Conference on Artificial Intelligence and Statistics*. Proceedings of Machine Learning Research: PMLR; 2020:1287--96.
115. Muhammad RNK. DLIME: A Deterministic Local Interpretable Model Agnostic Explanations Approach for Computer-Aided Diagnosis Systems. *arXIV:190610263.* 2019.
116. Scott LS-IL. A Unified Approach to Interpreting Model Predictions. *arXiv:170507874.* 2017.
117. Lundberg SM, Erion G, Chen H, DeGrave A, Prutkin JM, Nair B, et al. From Local Explanations to Global Understanding with Explainable AI for Trees. *Nat Mach Intell.* 2020;2(1):56-67.
118. Fujimoto K, Kojadinovic I, and Marichal J-L. Axiomatic characterizations of probabilistic and cardinal-probabilistic interaction indices. *Games and Economic Behavior.* 2006;55(1):72-99.
119. Bifulco SF, Scott GD, Sarairah S, Birjandian Z, Roney CH, Niederer SA, et al. Computational modeling identifies embolic stroke of undetermined source patients with potential arrhythmic substrate. *Elife.* 2021;10.
120. Andrade J, Khairy P, Dobrev D, and Nattel S. The clinical profile and pathophysiology of atrial fibrillation: relationships among clinical features, epidemiology, and mechanisms. *Circ Res.* 2014;114(9):1453-68.
121. Arbel-Ganon L, Behar JA, Gomez AM, and Yaniv Y. Distinct mechanisms mediate pacemaker dysfunction associated with catecholaminergic polymorphic ventricular tachycardia mutations: Insights from computational modeling. *J Mol Cell Cardiol.* 2020;143:85-95.
122. Brachmann J, Morillo CA, Sanna T, Di Lazzaro V, Diener HC, Bernstein RA, et al. Uncovering Atrial Fibrillation Beyond Short-Term Monitoring in Cryptogenic Stroke Patients: Three-Year Results From the Cryptogenic Stroke and Underlying Atrial Fibrillation Trial. *Circ Arrhythm Electrophysiol.* 2016;9(1):e003333.
123. Tandon K, Tirschwell D, Longstreth WT, Jr., Smith B, and Akoum N. Embolic stroke of undetermined source correlates to atrial fibrosis without atrial fibrillation. *Neurology.* 2019;93(4):e381-e7.
124. Zahid S, Whyte KN, Schwarz EL, Blake RC, 3rd, Boyle PM, Chrispin J, et al. Feasibility of using patient-specific models and the "minimum cut" algorithm to predict optimal ablation targets for left atrial flutter. *Heart Rhythm.* 2016;13(8):1687-98.
125. Gouvea de Barros B, Weber dos Santos R, Lobosco M, and Alonso S. Simulation of Ectopic Pacemakers in the Heart: Multiple Ectopic Beats Generated by Reentry inside Fibrotic Regions. *Biomed Res Int.* 2015;2015:713058.
126. Alonso S, Dos Santos RW, and Bar M. Reentry and Ectopic Pacemakers Emerge in a Three-Dimensional Model for a Slab of Cardiac Tissue with Diffuse Microfibrosis near the Percolation Threshold. *PLoS One.* 2016;11(11):e0166972.
127. Caroline H. Roney MLB, Arihant Mehta, Iain Sim, Cesare Corrado, Rokas Bendikas, Jose A. Solis-Lemus, Orod Razeghi, John Whitaker, Louisa O'neill, Gernot Plank, Edward Vigmond, Steven E. Williams, Mark D. O'neill and Steven A. Niederer. In silico comparison of left atrial ablation

techniques that target the anatomical, structural and electrical substrates of atrial fibrillation. *Fronteirs Physiology.* 2020.

128. Xia Y, Hertervig E, Kongstad O, Ljungstrom E, Platonov P, Holm M, et al. Deterioration of interatrial conduction in patients with paroxysmal atrial fibrillation: electroanatomic mapping of the right atrium and coronary sinus. *Heart Rhythm.* 2004;1(5):548-53.
129. Litchenberg WH, Norman LW, Holwell AK, Martin KL, Hewett KW, and Gourdie RG. The rate and anisotropy of impulse propagation in the postnatal terminal crest are correlated with remodeling of Cx43 gap junction pattern. *Cardiovasc Res.* 2000;45(2):379-87.
130. Hakim JB, Murphy MJ, Trayanova NA, and Boyle PM. Arrhythmia dynamics in computational models of the atria following virtual ablation of re-entrant drivers. *Europace.* 2018;20(suppl_3):iii45-iii54.
131. Roney CH, Bayer JD, Zahid S, Meo M, Boyle PM, Trayanova NA, et al. Modelling methodology of atrial fibrosis affects rotor dynamics and electrograms. *Europace.* 2016;18(suppl 4):iv146-iv55.
132. Cochet H, Dubois R, Yamashita S, Al Jefairi N, Berte B, Sellal JM, et al. Relationship Between Fibrosis Detected on Late Gadolinium-Enhanced Cardiac Magnetic Resonance and Re-Entrant Activity Assessed With Electrocardiographic Imaging in Human Persistent Atrial Fibrillation. *JACC Clin Electrophysiol.* 2018;4(1):17-29.
133. Haissaguerre M, Hocini M, Denis A, Shah AJ, Komatsu Y, Yamashita S, et al. Driver domains in persistent atrial fibrillation. *Circulation.* 2014;130(7):530-8.
134. Tanaka K, Zlochiver S, Vikstrom KL, Yamazaki M, Moreno J, Klos M, et al. Spatial distribution of fibrosis governs fibrillation wave dynamics in the posterior left atrium during heart failure. *Circ Res.* 2007;101(8):839-47.
135. Labarthe S, Bayer J, Coudière Y, Henry J, Cochet H, Jaïs P, et al. A bilayer model of human atria: mathematical background, construction, and assessment. *Europace.* 2014;16 Suppl 4:iv21-iv9.
136. Hansen BJ, Zhao J, Li N, Zolotarev A, Zakharkin S, Wang Y, et al. Human Atrial Fibrillation Drivers Resolved With Integrated Functional and Structural Imaging to Benefit Clinical Mapping. *JACC Clin Electrophysiol.* 2018;4(12):1501-15.
137. Hart RG, Catanese L, Perera KS, Ntaios G, and Connolly SJ. Embolic Stroke of Undetermined Source: A Systematic Review and Clinical Update. *Stroke.* 2017;48(4):867-72.
138. Jadidi AS, Cochet H, Shah AJ, Kim SJ, Duncan E, Miyazaki S, et al. Inverse relationship between fractionated electrograms and atrial fibrosis in persistent atrial fibrillation: combined magnetic resonance imaging and high-density mapping. *J Am Coll Cardiol.* 2013;62(9):802-12.
139. Geuzaine C, and Remacle J-F. Gmsh: A 3-D finite element mesh generator with built-in pre- and post-processing facilities. *International Journal for Numerical Methods in Engineering.* 2009;79(11):1309-31.
140. Roney CH, Pashaei A, Meo M, Dubois R, Boyle PM, Trayanova NA, et al. Universal atrial coordinates applied to visualisation, registration and construction of patient specific meshes. *Med Image Anal.* 2019;55:65-75.
141. Roney CH, Bendikas R, Pashakhanloo F, Corrado C, Vigmond EJ, McVeigh ER, et al. Constructing a Human Atrial Fibre Atlas. *Ann Biomed Eng.* 2020.
142. Krummen DE, Bayer JD, Ho J, Ho G, Smetak MR, Clopton P, et al. Mechanisms of human atrial fibrillation initiation: clinical and computational studies of repolarization restitution and activation latency. *Circ Arrhythm Electrophysiol.* 2012;5(6):1149-59.
143. Konings KT, Kirchhof CJ, Smeets JR, Wellens HJ, Penn OC, and Allessie MA. High-density mapping of electrically induced atrial fibrillation in humans. *Circulation.* 1994;89(4):1665-80.
144. Verma B, Oesterlein T, Loewe A, Luik A, Schmitt C, and Dossel O. Regional conduction velocity calculation from clinical multichannel electrograms in human atria. *Comput Biol Med.* 2018;92:188-96.

145. Roney CH, Whitaker J, Sim I, O'Neill L, Mukherjee RK, Razeghi O, et al. A technique for measuring anisotropy in atrial conduction to estimate conduction velocity and atrial fibre direction. *Computers in Biology and Medicine.* 2019;104:278-90.
146. Vigmond EJ, Hughes M, Plank G, and Leon LJ. Computational tools for modeling electrical activity in cardiac tissue. *J Electrocardiol.* 2003;36 Suppl:69-74.
147. Vigmond EJ, Weber dos Santos R, Prassl AJ, Deo M, and Plank G. Solvers for the cardiac bidomain equations. *Prog Biophys Mol Biol.* 2008;96(1-3):3-18.
148. R Development Core Team. Vienna, Austria: R Fonudation for Statistical Computing; 2019.
149. Odutayo A, Wong CX, Hsiao AJ, Hopewell S, Altman DG, and Emdin CA. Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta-analysis. *BMJ.* 2016;354:i4482.
150. Vizzardi E, Curnis A, Latini MG, Salghetti F, Rocco E, Lupi L, et al. Risk factors for atrial fibrillation recurrence: a literature review. *J Cardiovasc Med (Hagerstown).* 2014;15(3):235-53.
151. Johner N, Namdar M, and Shah DC. Individualised Approaches for Catheter Ablation of AF: Patient Selection and Procedural Endpoints. *Arrhythm Electrophysiol Rev.* 2019;8(3):184-90.
152. Hong KL, Borges J, and Glover B. Catheter ablation for the management of atrial fibrillation: current technical perspectives. *Open Heart.* 2020;7(1).
153. Marrouche NF, Wazni O, McGann C, Greene T, Dean JM, Dagher L, et al. Effect of MRI-Guided Fibrosis Ablation vs Conventional Catheter Ablation on Atrial Arrhythmia Recurrence in Patients With Persistent Atrial Fibrillation: The DECAAF II Randomized Clinical Trial. *JAMA.* 2022;327(23):2296-305.
154. Hayward RM, Upadhyay GA, Mela T, Ellinor PT, Barrett CD, Heist EK, et al. Pulmonary vein isolation with complex fractionated atrial electrogram ablation for paroxysmal and nonparoxysmal atrial fibrillation: A meta-analysis. *Heart Rhythm.* 2011;8(7):994-1000.
155. Bisbal F, Guiu E, Cabanas-Grandio P, Berruezo A, Prat-Gonzalez S, Vidal B, et al. CMR-guided approach to localize and ablate gaps in repeat AF ablation procedure. *JACC Cardiovasc Imaging.* 2014;7(7):653-63.
156. Peters DC, Wylie JV, Hauser TH, Kissinger KV, Botnar RM, Essebag V, et al. Detection of pulmonary vein and left atrial scar after catheter ablation with three-dimensional navigator-gated delayed enhancement MR imaging: initial experience. *Radiology.* 2007;243(3):690-5.
157. Calkins H, Hindricks G, Cappato R, Kim YH, Saad EB, Aguinaga L, et al. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. *Heart Rhythm.* 2017;14(10):e275-e444.
158. Fink T, Schluter M, Heeger CH, Lemes C, Maurer T, Reissmann B, et al. Stand-Alone Pulmonary Vein Isolation Versus Pulmonary Vein Isolation With Additional Substrate Modification as Index Ablation Procedures in Patients With Persistent and Long-Standing Persistent Atrial Fibrillation: The Randomized Alster-Lost-AF Trial (Ablation at St. Georg Hospital for Long-Standing Persistent Atrial Fibrillation). *Circ Arrhythm Electrophysiol.* 2017;10(7).
159. Chelu MG, King JB, Kholmovski EG, Ma J, Gal P, Marashly Q, et al. Atrial Fibrosis by Late Gadolinium Enhancement Magnetic Resonance Imaging and Catheter Ablation of Atrial Fibrillation: 5-Year Follow-Up Data. *J Am Heart Assoc.* 2018;7(23):e006313.
160. Ferreira R, Primo J, Adao L, Gonzaga A, Goncalves H, Santos R, et al. Late atypical atrial flutter after ablation of atrial fibrillation. *Rev Port Cardiol.* 2016;35(10):539 e1-6.
161. Kobza R, Hindricks G, Tanner H, Schirdewahn P, Dorszewski A, Piorkowski C, et al. Late recurrent arrhythmias after ablation of atrial fibrillation: incidence, mechanisms, and treatment. *Heart Rhythm.* 2004;1(6):676-83.

162. Haissaguerre M, Hocini M, Sanders P, Sacher F, Rotter M, Takahashi Y, et al. Catheter ablation of long-lasting persistent atrial fibrillation: clinical outcome and mechanisms of subsequent arrhythmias. *J Cardiovasc Electrophysiol.* 2005;16(11):1138-47.
163. Akhtar T, Daimee UA, Sivasambhu B, Boyle TA, Arbab-Zadeh A, Marine JE, et al. Ablation outcomes for atypical atrial flutter versus recurrent atrial fibrillation following index pulmonary vein isolation. *J Cardiovasc Electrophysiol.* 2021;32(6):1631-9.
164. Lundberg SM, Nair B, Vavilala MS, Horibe M, Eisses MJ, Adams T, et al. Explainable machine-learning predictions for the prevention of hypoxaemia during surgery. *Nat Biomed Eng.* 2018;2(10):749-60.
165. Badger TJ, Daccarett M, Akoum NW, Adjei-Poku YA, Burgon NS, Haslam TS, et al. Evaluation of left atrial lesions after initial and repeat atrial fibrillation ablation: lessons learned from delayed-enhancement MRI in repeat ablation procedures. *Circ Arrhythm Electrophysiol.* 2010;3(3):249-59.
166. Martin R, Hocini M, Haisaguerre M, Jais P, and Sacher F. Ventricular Tachycardia Isthmus Characteristics: Insights from High-density Mapping. *Arrhythm Electrophysiol Rev.* 2019;8(1):54-9.
167. Brunckhorst CB, Delacretaz E, Soejima K, Maisel WH, Friedman PL, and Stevenson WG. Identification of the ventricular tachycardia isthmus after infarction by pace mapping. *Circulation.* 2004;110(6):652-9.
168. Scaglione M, Caponi D, Di Donna P, Riccardi R, Bocchiardo M, Azzaro G, et al. Typical atrial flutter ablation outcome: correlation with isthmus anatomy using intracardiac echo 3D reconstruction. *Europace.* 2004;6(5):407-17.
169. Becker AE. Left atrial isthmus: anatomic aspects relevant for linear catheter ablation procedures in humans. *J Cardiovasc Electrophysiol.* 2004;15(7):809-12.
170. Trayanova NA, Popescu DM, and Shade JK. Machine Learning in Arrhythmia and Electrophysiology. *Circ Res.* 2021;128(4):544-66.
171. Ng B, Nayyar S, and Chauhan VS. The Role of Artificial Intelligence and Machine Learning in Clinical Cardiac Electrophysiology. *Can J Cardiol.* 2022;38(2):246-58.
172. Sridhar AR, Chen Amber ZH, Mayfield JJ, Fohner AE, Arvanitis P, Atkinson S, et al. Identifying risk of adverse outcomes in COVID-19 patients via artificial intelligence-powered analysis of 12-lead intake electrocardiogram. *Cardiovasc Digit Health J.* 2022;3(2):62-74.
173. Verma AA, Murray J, Greiner R, Cohen JP, Shojania KG, Ghassemi M, et al. Implementing machine learning in medicine. *CMAJ.* 2021;193(34):E1351-E7.
174. Gianfrancesco MA, Tamang S, Yazdany J, and Schmajuk G. Potential Biases in Machine Learning Algorithms Using Electronic Health Record Data. *JAMA Intern Med.* 2018;178(11):1544-7.
175. Kelly CJ, Karthikesalingam A, Suleyman M, Corrado G, and King D. Key challenges for delivering clinical impact with artificial intelligence. *BMC Med.* 2019;17(1):195.
176. Chae S, Oral H, Good E, Dey S, Wimmer A, Crawford T, et al. Atrial tachycardia after circumferential pulmonary vein ablation of atrial fibrillation: mechanistic insights, results of catheter ablation, and risk factors for recurrence. *J Am Coll Cardiol.* 2007;50(18):1781-7.
177. Rensma PL, Allessie MA, Lammers WJ, Bonke FI, and Schalij MJ. Length of excitation wave and susceptibility to reentrant atrial arrhythmias in normal conscious dogs. *Circ Res.* 1988;62(2):395-410.
178. Nakagawa H. Creation of Continuous and Transmural Radiofrequency Lesions. *Circ Arrhythm Electrophysiol.* 2018;11(4):e006378.
179. Han S, and Hwang C. How to Achieve Complete and Permanent Pulmonary Vein Isolation without Complications. *Korean Circ J.* 2014;44(5):291-300.

180. Chen CC, Lee PT, Van Ba V, Chuang CM, Lin YJ, Lo LW, et al. Comparison of lesion characteristics between conventional and high-power short-duration ablation using contact force-sensing catheter in patients with paroxysmal atrial fibrillation. *BMC Cardiovasc Disord.* 2021;21(1):387.
181. Whitaker J, Rajani R, Chubb H, Gabrawi M, Varela M, Wright M, et al. The role of myocardial wall thickness in atrial arrhythmogenesis. *Europace.* 2016;18(12):1758-72.
182. Zuo K, Li K, Liu M, Li J, Liu X, Liu X, et al. Correlation of left atrial wall thickness and atrial remodeling in atrial fibrillation: Study based on low-dose-ibutilide-facilitated catheter ablation. *Medicine (Baltimore).* 2019;98(15):e15170.
183. Verheule S, Eckstein J, Linz D, Maesen B, Bidar E, Gharaviri A, et al. Role of endo-epicardial dissociation of electrical activity and transmural conduction in the development of persistent atrial fibrillation. *Prog Biophys Mol Biol.* 2014;115(2-3):173-85.
184. Chen R, Wen C, Fu R, Li J, and Wu J. The effect of complex intramural microstructure caused by structural remodeling on the stability of atrial fibrillation: Insights from a three-dimensional multi-layer modeling study. *PLoS One.* 2018;13(11):e0208029.
185. Boyle PM, Sarairah S, Kwan KT, Scott GD, Mohamedali F, Anderson CA, et al. Elevated fibrosis burden as assessed by MRI predicts cryoballoon ablation failure. *J Cardiovasc Electrophysiol.* 2023;34(2):302-12.
186. McGann C, Akoum N, Patel A, Kholmovski E, Revelo P, Damal K, et al. Atrial fibrillation ablation outcome is predicted by left atrial remodeling on MRI. *Circ Arrhythm Electrophysiol.* 2014;7(1):23-30.
187. Ramos-Mondragon R, Vega AV, and Avila G. Long-term modulation of Na+ and K+ channels by TGF-beta1 in neonatal rat cardiac myocytes. *Pflugers Arch.* 2011;461(2):235-47.
188. Li D, Fareh S, Leung TK, and Nattel S. Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort. *Circulation.* 1999;100(1):87-95.
189. Johnathan Frankle MC. The Lottery Ticket Hypothesis: Finding Sparse, Trainable, Neural Networks. *arXiv:180303635.* 2019.
190. Santoro F, Di Biase L, Trivedi C, Burkhardt JD, Paoletti Perini A, Sanchez J, et al. Impact of Uncontrolled Hypertension on Atrial Fibrillation Ablation Outcome. *JACC Clin Electrophysiol.* 2015;1(3):164-73.
191. Guckel D, Isgandarova K, Bergau L, Piran M, El Hamriti M, Imnadze G, et al. The Effect of Diabetes Mellitus on the Recurrence of Atrial Fibrillation after Ablation. *J Clin Med.* 2021;10(21).
192. Buckley BJR, Harrison SL, Gupta D, Fazio-Eynullayeva E, Underhill P, and Lip GYH. Atrial Fibrillation in Patients With Cardiomyopathy: Prevalence and Clinical Outcomes From Real-World Data. *J Am Heart Assoc.* 2021;10(23):e021970.
193. Cheng WH, Lo LW, Lin YJ, Chang SL, Hu YF, Hung Y, et al. Cigarette smoking causes a worse long-term outcome in persistent atrial fibrillation following catheter ablation. *J Cardiovasc Electrophysiol.* 2018;29(5):699-706.
194. Bieging ET, Morris A, Wilson BD, McGann CJ, Marrouche NF, and Cates J. Left atrial shape predicts recurrence after atrial fibrillation catheter ablation. *J Cardiovasc Electrophysiol.* 2018;29(7):966-72.
195. Jia S, Nivet H, Harrison J, Pennec X, Camaioni C, Jais P, et al. Left atrial shape is independent predictor of arrhythmia recurrence after catheter ablation for atrial fibrillation: A shape statistics study. *Heart Rhythm O2.* 2021;2(6Part A):622-32.
196. Ju Youn Kim YK, Gil-Hwan Oh, Sun Hwa Kim, Young Choi, Youmi Hwang, Tae-Seok Kim, Sung-Hwan Kim, Ji-Hoon Kim, Sung-Won Jang, Yong-Seog Oh & Man Young Lee A deep learning model to predict recurrence of atrial fibrillation after pulmonary vein isolation. *International Journal of Arrhythmia.* 2020;21(19).

197. Razeghi O, Kapoor R, Alhusseini MI, Fazal M, Tang S, Roney CH, et al. Atrial fibrillation ablation outcome prediction with a machine learning fusion framework incorporating cardiac computed tomography. *J Cardiovasc Electrophysiol.* 2023;34(5):1164-74.
198. Diprose WK, Buist N, Hua N, Thurier Q, Shand G, and Robinson R. Physician understanding, explainability, and trust in a hypothetical machine learning risk calculator. *J Am Med Inform Assoc.* 2020;27(4):592-600.
199. Parmar BR, Jarrett TR, Kholmovski EG, Hu N, Parker D, MacLeod RS, et al. Poor scar formation after ablation is associated with atrial fibrillation recurrence. *J Interv Card Electrophysiol.* 2015;44(3):247-56.
200. Tutuianu C, Szilagy J, Pap R, and Saghy L. Very Long-Term Results Of Atrial Fibrillation Ablation Confirm That This Therapy Is Really Effective. *J Atr Fibrillation.* 2015;8(2):1226.
201. Hanley JA, and McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. *Radiology.* 1982;143(1):29-36.
202. Ma Y, Zhang D, Xu J, Pang H, Hu M, Li J, et al. Explainable machine learning model reveals its decision-making process in identifying patients with paroxysmal atrial fibrillation at high risk for recurrence after catheter ablation. *BMC Cardiovasc Disord.* 2023;23(1):91.
203. Eleanor Dillon JL, Scott Lundberg, Jonathan Roth, and Vasilis Syrgkanis. Be careful when interpreting predictive models in search of causal insights. Accessed 4/28/2023.
204. Zhuang J, Wang Y, Tang K, Li X, Peng W, Liang C, et al. Association between left atrial size and atrial fibrillation recurrence after single circumferential pulmonary vein isolation: a systematic review and meta-analysis of observational studies. *Europace.* 2012;14(5):638-45.
205. Benali K, Barre V, Hermida A, Galand V, Milhem A, Philibert S, et al. Recurrences of Atrial Fibrillation Despite Durable Pulmonary Vein Isolation: The PARTY-PVI Study. *Circ Arrhythm Electrophysiol.* 2023;16(3):e011354.
206. Atta-Fosu T, LaBarbera M, Ghose S, Schoenhagen P, Saliba W, Tchou PJ, et al. A new machine learning approach for predicting likelihood of recurrence following ablation for atrial fibrillation from CT. *BMC Med Imaging.* 2021;21(1):45.
207. Wen S, Pislaru SV, Lin G, Scott CG, Lee AT, Asirvatham SJ, et al. Association of Postprocedural Left Atrial Volume and Reservoir Function with Outcomes in Patients with Atrial Fibrillation Undergoing Catheter Ablation. *J Am Soc Echocardiogr.* 2022;35(8):818-28 e3.
208. Bahnson TD, Giczewska A, Mark DB, Russo AM, Monahan KH, Al-Khalidi HR, et al. Association Between Age and Outcomes of Catheter Ablation Versus Medical Therapy for Atrial Fibrillation: Results From the CABANA Trial. *Circulation.* 2022;145(11):796-804.
209. Bunch TJ, May HT, Bair TL, Jacobs V, Crandall BG, Cutler M, et al. The Impact of Age on 5-Year Outcomes After Atrial Fibrillation Catheter Ablation. *J Cardiovasc Electrophysiol.* 2016;27(2):141-6.
210. Kinoshita M, Herges RM, Hodge DO, Friedman L, Ammash NM, Bruce CJ, et al. Role of smoking in the recurrence of atrial arrhythmias after cardioversion. *Am J Cardiol.* 2009;104(5):678-82.
211. Brusa E, Cibrario L, Delprete C, and Di Maggio LG. Explainable AI for Machine Fault Diagnosis: Understanding Features’ Contribution in Machine Learning Models for Industrial Condition Monitoring. *Applied Sciences.* 2023;13(4):2038.
212. Siebermair J, Kholmovski EG, and Marrouche N. Assessment of Left Atrial Fibrosis by Late Gadolinium Enhancement Magnetic Resonance Imaging: Methodology and Clinical Implications. *JACC Clin Electrophysiol.* 2017;3(8):791-802.
213. January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC, Jr., et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association

Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. *J Am Coll Cardiol.* 2019;74(1):104-32.
214. Clayton RH, Zhuchkova EA, and Panfilov AV. Phase singularities and filaments: simplifying complexity in computational models of ventricular fibrillation. *Prog Biophys Mol Biol.* 2006;90(1-3):378-98.
215. Boyle PM, Masse S, Nanthakumar K, and Vigmond EJ. Transmural IK(ATP) heterogeneity as a determinant of activation rate gradient during early ventricular fibrillation: mechanistic insights from rabbit ventricular models. *Heart Rhythm.* 2013;10(11):1710-7.
216. Heijman J, Zhou X, Morotti S, Molina CE, Abu-Taha IH, Tekook M, et al. Enhanced Ca(2+)-Dependent SK-Channel Gating and Membrane Trafficking in Human Atrial Fibrillation. *Circ Res.* 2023;132(9):e116-e33.
217. Chahine Y, Askari-Atapour B, Kwan KT, Anderson CA, Macheret F, Afroze T, et al. Epicardial adipose tissue is associated with left atrial volume and fibrosis in patients with atrial fibrillation. *Front Cardiovasc Med.* 2022;9:1045730.
218. Nattel S, and Aguilar M. Electrophysiological Effects of Atrial Epicardial Adipose Tissue: Keep Your Friends Close and Your Enemies Closer. *J Am Coll Cardiol.* 2020;76(10):1212-4.
219. Loewe A, Wilhelms M, Schmid J, Krause MJ, Fischer F, Thomas D, et al. Parameter Estimation of Ion Current Formulations Requires Hybrid Optimization Approach to Be Both Accurate and Reliable. *Front Bioeng Biotechnol.* 2015;3:209.
220. Peirlinck M, Costabal FS, Yao J, Guccione JM, Tripathy S, Wang Y, et al. Precision medicine in human heart modeling. *Biomechanics and Modeling in Mechanobiology.* 2021;20(3):803-31.